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Abstract 
 
The discovery of genes essential for normal T cell numbers and T cell-mediated 
immune responses provides valuable insights into the adaptive immune system 
and targets for modulating disorders of immunity in cancer, transplantation, 
infection and autoimmunity. The studies presented in this thesis investigate two 
novel gene mutations that diminish the number of circulating T cells. The 
mutations were discovered by genome-wide ENU-mutagenesis in mice by flow 
cytometric screening of lymphocyte subsets in splenocytes and in peripheral 
blood. Genetic mapping and sequencing identified the two mutations. The first 
was a premature stop-gain mutation in Dock2, encoding a GTP exchange factor 
for the Rac family of cytoplasmic small G proteins, which has previously been 
found to be critical for T cells and immunity in mice and humans. The second 
mutation was a synonymous exonic nucleotide substitution in Senp2, encoding a 
specific protease for cleaving the ubiquitin-like SUMO protein from its 
conjugates with other proteins, whose critical role in T cells had not previously 
been shown.  
 
Mice homozygous for the ‘dockland’ E775X mutation in DOCK2 (doc/doc) had 
80% fewer naïve (CD44low) CD8 and CD4 T cells, 70% fewer NKT cells, 50% 
fewer B cells in the blood and 80% fewer B cells in the spleen, and absence of 
splenic marginal zone B cells. Mutant T cells nevertheless divided normally to 
anti-CD3 in vitro, consistent with intact TCR signaling, and peripheral CD44high 
activated memory T cells were present in normal or increased numbers consistent 
with homeostatic proliferation. Thymocytes showed evidence of developmental 
defects, including 50% decreased CD4+CD8+ double positive (DP) cells with 
lower CD5 expression and greatly decreased NKT cells. The percentage of CD4+ 
or CD8+ single positive (SP) thymocytes lacking CD69 was increased, consistent 
with delayed egress of fully mature cells. In competitive bone marrow 
transplantation experiments, mutant hematopoietic stem cells engrafted efficiently 
based on their contribution to granulocytes, but failed to contribute to peripheral T 
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cells due to progressive under-representation at the DP and SP thymocyte stages 
of development. Mutant B cells contributed poorly to the follicular and germinal 
centre subsets, and were completely absent from the marginal zone subset. These 
results establish that DOCK2 is essential within T and B lymphocytes. 
 
Despite decreased circulating naïve T cells, Dock2 mutant doc/doc mice exposed 
sequentially to H3N2 and H1N1 influenza viruses formed normal numbers of 
memory CD8 T cells binding H2-Db MHC tetramers bearing the dominant 
influenza NP peptide epitope, NP366-374 (NP+), in contrast to Dock8 mutant 
mice analysed in parallel which had greatly diminished memory T cells. Dock2 
mutant mice nevertheless formed fewer NP-binding effector CD8 cells than wild-
type at the peak of the primary and recall response. During acute lung infection 
with PR8-strain H1N1 influenza virus, Dock2 mutant mice were protected from 
weight loss and morbidity occurring between days 5 and 7 in wild-type mice. 
Mice with combined homozygous mutations in Dock2 and Dock8 tended to have 
fewer circulating naïve T cells and NKT cells than either single mutant, although 
this did not achieve statistical significance in the cohort available. Collectively, 
these results extend earlier published findings in Dock2 knockout mice, and 
provide new insights into the effects of DOCK2 deficiency on the anti-viral 
immune response that are relevant to the fatal infections and T cell lymphopenia 
in DOCK2-deficient children.    
 
In the second mutant strain, duan, a 70% decrease selectively in circulating naïve 
CD8 T cells mapped as a recessive trait to a synonymous A>G substitution at 
Ch16:22,036,478 in exon 11 of Senp2. The mutation was +9 nucleotides from the 
exon 11 splice acceptor and diminished splicing of exon 10 to this acceptor. Of 
spliced mRNA that was produced, 55% skipped exon 11 to create an in-frame 
deletion of 15 amino acids. Upon expression of GFP-tagged SENP2, the internally 
deleted protein nevertheless exhibited normal intracellular localization to the 
nuclear membrane. While Senp2-/- null mutation in mice is homozygous lethal 
prior to blastocyst implantation, a complementation cross with the duan point 
mutant revealed that compound heterozygous Senp2dua/- mice were viable and 
	 ix	
recapitulated the CD8 T cell deficiency of Senp2dua/dua homozygotes, confirming 
that partial deficiency of SENP2 causes a selective T cell deficit.    
 
Thymic T cells subsets were unaffected in Senp2dua/dua mice, and the basis for the 
decreased number of naïve CD8 T cells was shown to be diminished survival in 
the periphery. This was most clearly shown by comparing the persistence of 
ovalbumin-specific OT-I CD8 T cells with normal or mutant Senp2 after the T 
cells were “parked” in wild-type mice without antigenic stimulation. In this 
setting, mutant OT-I T cells transduced with a retroviral vector expressing wild-
type SENP2 preferentially survived, further confirming that SENP2 deficiency 
was responsible. Competitive bone marrow transplantation also showed a cell 
autonomous requirement for normal splicing of Senp2 to maintain peripheral CD8 
T cell numbers but not for CD4 T cells or B cells. Upon sequential exposure to 
recombinant H3N2 and H1N1 influenza viruses expressing ovalbumin peptide, 
OT-I T cells bearing the Senp2dua/dua mutation formed an equally large population 
of effector CD8 T cells 7 days after primary or recall challenge, but persistence of 
memory CD8 T cells was decreased more than 90%. Senp2 mutant CD8 T cells 
responded normally to CD3 stimulation in vitro as measured by cell division. 
They also responded normally to IL-7 in vitro as measured by STAT5 
phosphorylation, despite a cell autonomous 25% decrease in IL7Ra/CD127 on 
their cell surface. Collectively, these results define a key role for controlling 
SUMO conjugation by SENP2 in the survival of naïve and memory CD8 T cells, 
apparently involving a pathway independent of the established TCR and IL-7 
signalling mechanisms.  
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Chapter 1: Introduction 
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Background 
 
The immune system is important for eliminating pathogens and preventing 
diseases. The immune system consists of two arms: immunity and adaptive 
immunity. Innate immunity provides the first line of defense against infection and 
a hierarchy of support mechanisms for the acquired immune response. 
Macrophages, neutrophils, dendritic cells and NK cells all play important roles in 
this system. The adaptive immune system can induce antigen-specific immune 
response by recognizing antigens through specific receptors on lymphocytes. In 
addition, it also exhibits a ‘memory’ function enabling a rapid response when re-
exposed to a previous encountered antigen. Lymphocytes are the cells involved in 
adaptive immunity they can be classified into T lymphocytes that express T cell 
receptors (TCRs) and B lymphocytes that express B cell receptors (BCRs).  Both 
T and B lymphocytes arise in bone marrow, but unlike B cells which mature in 
the bone marrow and spleen, T cells migrate to the thymus gland to mature. T 
cells can be further divided to two subpopulations - T helper (Th) and T cytotoxic 
(Tc) cells, which can be distinguished from each other by the presence of either 
CD4 (Th cells) or CD8 (Tc cells) co-receptors on the cell surface. Th cells can be 
further delineated based on their cytokine profile (for example, Th1, Th2, Th17) 
and regulatory T cells (Treg’s). This thesis focuses on T cells, mostly CD8 T 
cells, which have an astounding capacity to react to pathogens by differentiation 
into effector cells to clear the infection in the host.  
 
 
T cell development 
 
The immunological function of the thymus was first demonstrated in early 1960’s, 
when skin grafts were not rejected in mice thymectomized at birth (Miller, 1961, 
1962). Like other haematopoietic cells, T cells originate from haematopoietic 
stem cells (HSC) in bone marrow. Although T and B cells arise from the common 
lymphoid progenitors (CLPs), they have different maturation processes and 
develop in distinct locations. Unlike B cells that can mature in the bone marrow, T 
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cell progenitors are required to migrate to the thymus gland to undergo further 
maturation (Wu et al., 1991; Godfrey et al., 1993) 
 
The thymus has two main regions: cortex and medulla. Immature cells mostly 
develop in the cortex and migrate to medulla when they become mature single-
positive thymocytes. Thymic progenitors, after migrating to the thymus from the 
bone marrow, undergo differentiation to express a unique T-cell receptor (TCR). 
The TCR is a disulfide-bonded heterodimer of either TCRa (alpha) and TCRb 
(beta) or TCR d (delta) and TCR g (gamma) chains expressed on the cell surface 
and noncovalently associated with the CD3 protein complex (Davis and 
Bjorkman, 1988). The T cells studied in this thesis are TCRab cells. 
 
When progenitor cells enter the thymus, they don’t express TCR, CD3, CD4 or 
CD8. The immature T cells start from the CD4-CD8- double negative (DN) stage, 
progress to the CD4+CD8+ double positive (DP) stage and finally mature into 
CD4+CD8- or CD4-CD8+ single positive (SP) T cells (Godfrey et al., 1993; 
Godfrey and Zlotnik, 1993; Shortman and Wu, 1996). The DN stage can be 
further divided to 4 different stages based on the expression of CD44 and CD25: 
DN1 (CD25-CD44+), DN2 (CD25+CD44+), DN3 (CD25+CD44-) and DN4 (CD25-
CD44-) (Godfrey et al., 1993). The DN1 thymocytes (or early thymic precursor 
(ETP)) seed in thymus and lose their pluripotency to generate other cell lineages. 
In mouse, the DN1 population shows heterogeneity for Thy-1, HSA and c-kit 
expression. The cells in DN2 stage become physically larger (based upon forward 
scatter) and are Thy-1+, HSA+ and c-kithi and start their Dβ to Jβ rearrangement in 
the T cell receptor β–chain locus (Godfrey et al., 1993). DN3 thymocytes are 
smaller than DN2 and become c-kitlo and continue Vβ to DJβ rearrangement. In 
DN4 stage, cells express the β-chain and have high expression in Thy-1, HSA but 
down-regulate c-kit. Notch-mediated signals delivered by binding of Delta ligands 
have been shown to promote both commitment to the T cell lineage and the early 
development of thymocytes (Radtke et al., 1999). IL-7 and the signals derived 
from cortical thymic epithelial cells (cTECs) are also indispensable to support the 
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initial thymocytes development (Peschon et al., 1994; Von Freeden-Jeffry et al., 
1995). 
 
The cells now enter CD4 and CD8 double-positive stage. These cells are required 
to go through positive and negative selection to become mature T cell. Only the 
DP thymocytes that can recognize self peptide-MHC molecule receive survival 
signal in a process named ‘positive selection’. To allow self-tolerance, these cells 
also undergo negative selection to eliminate cells that have strong affinity for self 
antigens. Transcription factor Helios, an Ikaros family member, is preferentially 
expressed in regulatory T cells (Treg’s). Its expression has been first suggested to 
discriminate thymic-derived from peripherally induced Foxp3+ T regulatory cells 
(Thornton et al., 2010). Soon after, a study showed that Helios can also be 
peripherally induced in Foxp3+ T cells (Gottschalk et al., 2012). Recently, Helios 
has been discovered to be a unique molecular marker to be induced in strongly 
self-reactive thymocytes and can qualitatively measure the thymocytes bearing 
strongly self-reactive TCR at two waves of thymic negative selection (Daley et 
al., 2013). Helios enhances induced Treg cell function in cooperation with FoxP3 
(Takatori et al., 2015). Helios can control Treg-suppressive function, 
differentiation and survival in certain aspects (Sebastian et al., 2015). Thymocytes 
down-modulate CD4 or CD8 co-receptor molecules to commit to either the 
mature cytotoxic CD8SP or helper CD4SP T-cell lineages respectively. Zinc-
finger transcription factor gene Th-POK (T helper inducing POZ/Kruppel factor 
or Zbhtb7) specific induced in developing class II-restricted thymocytes is a 
crucial regulator of CD4 lineage commitment (He et al., 2005; Kappes et al., 
2006). RUNX (runt-related transcription factor) protein, particularly Runx3, is 
essential for the generation of cytotoxic T cell lineage. Runx3 and Th-POK forms 
a negative regulatory loop that regulate T-cell lineage commitment (Egawa, 2009; 
Collins et al., 2009). Only a small fraction of DP cells successfully proceed 
through positive and negative selection to become mature single-positive 
thymocytes ready to emigrate from the thymus and enter the circulation. 
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The maturation of thymic T cells also requires the expression of a CD4 or CD8 
co-receptor. CD4 is a single-chain molecule consisting of four immunoglobulin-
like extracellular domains, binding with low affinity to a nonpolymorphic part of 
MHC II molecules. CD8 is a disulfide linked α and β chain each consisting of a 
single immunoglobulin-like domain, binding with low affinity to a 
nonpolymorphic part of MHC I molecules (Babbitt et al., 1985). When a mature T 
cell binds to its specific peptide-MHC, the coreceptor CD4 or CD8 interacts with 
the lymphocyte-specific protein tyrosine kinase (Lck) through their cytoplasmic 
domain to initiate TCR signaling (Zamoyska et al., 2003; Salmond et al., 2009). 
 
Adaptive immunity requires mature T-cells to exit from the thymus and travel 
between secondary lymphoid organs to survey for foreign antigens. Sphingosine-
1-phosphate (S1P) and its receptor sphingosine 1-phosphate receptor-1 (S1P1), a 
widely distributed G protein-coupled receptor, has been shown as the central 
mediator of lymphocyte egress from the thymus (Matloubian et al., 2004). 
Starting with studies using FTY720, an agonist ligand for S1P1, S1P3, S1P4 and 
S1P5 receptor (Brinkmann et al., 2002), the S1P1 receptor has been shown to 
mediate and regulate lymphocyte recirculation and egress from the thymus and 
from secondary lymphoid organs (Matloubian et al., 2004). With T-cell specific 
deletion of S1P1 receptor, the egress of mature T cell from thymus into periphery 
was blocked (Allende et al., 2004). 
 
In transgenic overexpression studies, the cell surface activation marker CD69 has 
been shown to inhibit T cell egress from the thymus (Feng et al., 2002; Nakayama 
et al., 2002) Later, endogenous CD69 has been shown to inhibit the cell surface 
display and function of S1P1 receptors in T and B cells (Shiow et al., 2006). By 
chemical agonism of S1P1 receptor, CD69 was down-modulated and thymic 
egress was inhibited (Alfonso et al., 2006). 
 
By the end of their thymic development, newly mature CD4SP and CD8SP 
thymocytes need to lose the thymic putative retention signal CD69 and gain 
expression of the S1P1 receptors, and respond to blood-borne chemotactic S1P to 
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promote them to exit the thymus and enter the periphery to encounter foreign 
antigens (Weinreich et al., 2009). 
 
 
Peripheral survival of naïve CD8 T cells  
 
It is important for an immunocompetent adult to maintain a constant number of T 
cells. Circulating T cell numbers remain remarkably fixed despite large changes 
of naïve T cell input from the thymus. In young animals, recent thymic emigrants 
make up a large proportion of the peripheral T cell population (Scollay et al., 
1980). The T cell pool in adults is dependent on the division of mature T cells in 
the periphery. In an intact animal, the generation of new lymphocytes and the loss 
of cells are well balanced as the overall number of mature T cells is tightly 
regulated (Freitas and Rocha, 1993; Bell and Sparshott, 1997; Freitas and Rocha, 
2000; Surh and Sprent, 2000; Sprent et al., 2008) 
 
The newly matured CD8 T cells exiting the thymus are maintained in cell cycle 
interphase in the periphery for weeks or months (Jameson, 2002; Almeida et al., 
2005; Surh and Sprent, 2008; Takada and Jameson, 2009). This long-lived pool of 
naïve CD8 T cells is regulated by a homeostatic mechanism governing their 
survival and proliferation depending upon the total number of peripheral T cells 
(Freitas and Rocha, 1993; Surh and Sprent, 2000). Survival of naïve CD8+ T cells 
when there is a full complement of peripheral T cells, and proliferation of naïve 
cells in states of T-lymphopenia, depend upon signaling from the interaction of T-
cell receptor (TCR) and self-peptide major histocompatibility complex (self-
pMHC) as well as interleukin-7 (IL-7) binding to the IL-7 receptor (IL-7R), as 
summarized in more detail below.  
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TCR:MHC-peptide recognition in T cell survival  
 
T cells recognize foreign antigen presented by MHC molecules during an immune 
response. Naive CD4 T cells require constitutive signalling from transient contact 
between TCRs and self-pMHC-II molecules (Takeda et al., 1996). Similarly, the 
adoptive transfer of naïve CD8 T cell into recipients with different or no MHC 
class I molecules caused the reduction in the number of donor cells. Naïve CD8 T 
cells were then shown to require interaction with host MHC molecule for long-
term survival in periphery (Tanchot et al., 1997). More studies suggested that 
recognition of self-pMHC complex was required for naive T cells survival and 
homeostasis. (Kirberg, et al., 1997; Beutner and MacDonald, 1998; Kieper and 
Jameson, 1999; Nesic and Vukmanovic, 1998; Murali-krishna et al., 1999). 
However, comparable studies were more complicated for naïve CD4 T cells. As 
lymphopenic hosts were used in most of above studies, arguments were raised 
about the requirement of MHC complex in naïve T cell survival in lymphoreplete 
hosts. Some groups failed to found a role of MHC in naïve CD4 T cell survival 
(Dorfman et al., 2000; Grandjean et al., 2003; Clarke and Rudensky, 2000). More 
evidence has strongly supported the requirement of TCR signalling for naïve T 
cells survival. Abrogation of TCR expression or downstream molecules Fyn and 
Lck expression cause a survival defect in both CD4 and CD8 T cells (Labrecque 
et al., 2001; Polic et al., 2001; Seddon and Zamoyska, 2002). Unlike the 
polyclonal naïve T cell repertoire, there is no observation of competition for 
survival between TCR transgenic T cells (Kieper et al., 2004; Moses et al., 2003). 
The failure of survival when there was a high precursor frequency of one TCR 
clone further confirmed that the naïve T cell survival requires contacting self-
pMHC ligands that are limiting (Hataye et al., 2006; Moon et al., 2007; Obar et 
al., 2008)  
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IL-7 signalling 
  
IL-7 was originally discovered as a novel growth factor that stimulated 
proliferation of murine B cell progenitors in vitro (Namen et al., 1988). The 
murine IL-7 gene encodes a secreted protein of 154 amino acids produced by 
stromal cells in lymphoid organs. IL-7 was then shown to induce dramatic 
increases in the total number of T and B cells when administered to mice 
(Morrissey et al., 1991). In IL-7 transgenic mice, increased number of thymocytes 
and peripheral T lymphocytes were observed (Samaridis et al., 1991). IL-7 was 
first shown to be indispensible for murine B and T lymphopoiesis by injection of 
anti-IL-7 antibody (Grabstein et al., 1993) which was further affirmed by the 
severe peripheral and lymphoid organ lymphopenia phenotype in IL-7 knockout (-
/-) mice (Von Freeden-jeffry et al., 1995). IL-7 was reported as a key factor for 
survival and persistence of naïve T cells in the periphery and the availability of 
IL-7 in the periphery determines the size of the naïve T cell pool (Boise et al., 
1995; Vella et al., 1997; Rathmell et al., 2001, Schluns et al., 2000). IL-7 has also 
been shown to induce homeostatic expansion and restore the T cell homeostasis in 
a lymphopaenic environment by lymphopenia-induced proliferation (LIP) (Fry, 
T., et al., 2001; Tan et al., 2001; Surh and Sprent, 2008). In normal animals, naive 
T cells do not expand or proliferate due to restriction of cytokine and space. 
However, in T-cell-depleted hosts, increased availability of IL-7 could induce 
expansion of naïve T cells and restore the T cell homeostasis.    
 
The IL-7 receptor consists of two subunits: the IL-7Rα chain (CD127) and the 
common γ chain (γc) (CD132) (Park et al., 1990; Noguchi et al., 1993). The 
common γ chain is also shared by receptors for IL-2, IL-4, IL-9, IL-15 and IL-21 
(Takeshita et al., 1992; Kondo et al., 1993; Russell et al., 1993; Giri et al., 1994; 
Asao et al., 2001). Mice deficient in either IL-7Rα or γc chain displayed similar 
phenotypes of diminished total number of T cell and impaired lymphocyte 
development (Peschon et al., 1994; He and Malek, 1996; Cao et al., 1995; Di 
Santo and Rodewald, 1998). In humans, γc chain mutations result in X-linked 
severe combined immunodeficiency (SCID) with very few circulating T cells 
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(Noguchi et al., 1993). A similar T cell deficiency occurs in rare individuals with 
inactivating mutations in IL7RA (Puel, et al., 1998). In contrast to relatively 
constant level of IL-7, IL-7Rα expression is up and down during the development 
of both T and B cells. During thymopoiesis, IL-7Rα is highly expressed on DN 
stage, absent for DP stage but up again on thymocytes undergoing positive 
selection (Munitic et al., 2004; Mazzucchelli and Durum, 2007). 
 
IL-7 signalling is transmitted through the intracellular portion of its cognate 
receptor IL-7R by inducing the tyrosine phosphorylation of downstream tyrosine 
kinases Janus kinase1 (JAK1) and JAK3 which are associated with CD127 and γc 
chain, respectively (Foxwell et al., 1995; Suzuki et al., 2000). The activated JAK 
proteins phosphorylate the cytoplasmic protein, Signal Transducer and Activator 
of Transcription 5 (STAT5), and the phosphorylated STAT5 forms heterodimers 
(STAT5a and STAT5b) and translocate into the nucleus to activate transcription 
(reviewed in Jiang et al., 2005).  Mice deficient for both STAT5a and STAT5b 
have defective lymphoid development similar to IL-7R or Jak3 deficiency (Yao et 
al., 2006). JAK3 deficiency in humans also results in T-lymphopenia and SCID 
(Russell et al., 1995; Macchi et al., 1995) T cell specific deletion of STAT5 
demonstrated that STAT5 was indispensible for naïve CD4 and CD8 T cell 
survival (Yao et al., 2006; Seki et al., 2007). Through these downstream 
signalling molecules and transcriptional factors, IL-7 maintains T cell survival by 
promoting the expression of anti-apoptotic B-cell lymphoma 2 (Bcl-2) family 
members BCL-2 and myeloid-cell leukaemia sequence 1 (MCL1) and 
redistributing the cell-death protein BCL-2-associated X (BAX) and BCL-2-
antagonist of cell death (BAD) to inhibit the mitochondrial apoptotic pathway 
(Boise et al., 1995; Vella et al., 1997). 
 
Combined blocking of IL-7R and TCR signalling results in more dramatic decline 
of T cell number than either single deficiency (Seddon and Zamoyska, 2002) 
raising the question whether they are distinct signals or additively to the same 
pathway. Recent studies have shown that there is co-operation between IL-7 and 
TCR signal in naïve CD8 T cells (Park et al., 2007). Signals from both IL-7 
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signalling pathway and self-peptide-MHC complex negatively feed back on their 
own receptor but promote the other receptor’s expression (Park et al., 2007). In 
addition to inhibiting transcription of IL-7Ra, IL-7 signalling can transcriptionally 
enhance CD8α coreceptor expression and TCR-CD8 encounter with self-peptide-
MHC complexes (Park et al., 2007). On the other hand, TCR signalling impairs 
IL-7 signalling and promotes the increase of Il7ra transcription (Park et al., 2007). 
 
 
 
 
Figure 1. Cross-talk between TCR and IL-7 signaling. Survival of naïve 
CD8 T cells in the periphery requires signals from the interaction between 
TCR and self-peptide-MHC complex and IL-7 (Reprinted from Carrette 
and Surh, 2012). Transcription factors down streams of TCR that control 
CD127 expression: transcription factors inducing CD127 transcription (in 
green) and transcription factors repressing CD127 transcription (in red). 
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T cell activation  
 
When naïve T cells encounter specific foreign antigen (Ag) presented by self-
MHC on antigen presenting cells (APC), they are activated and start to proliferate. 
The first signal of cell activation comes from the binding of the TCR to its 
cognate peptide:MHC complex, Ag must be presented as short peptide fragments 
bound to MHC molecules on the surface of APC for T cell recognition (Townsend 
et al., 1985; Townsend et al., 1986). Cytotoxic CD8 T cells recognize peptides 
derived from protein in the cytosol and fragments of viral proteins on the surface 
by MHC-I molecules (human leukocyte antigen (HLA) in human) (Bjorkman et 
al., 1987a; Bjorkman et al., 1987b). CD4 T cells can recognize peptides derived 
from exogenous proteins processed within intracellular vesicles of macrophages 
and B cells presented by MHC-II molecules (Babbitt et al., 1985; reviewed by 
Unanue, 2002).  
 
Proliferation is additively enhanced by costimulatory signals mediated by CD28 
and CD86/CD80 and many other costimulatory receptors to prevent self attacking 
for a full activation (Gonzalo et al., 2001). Upon receiving TCR and co-
stimulatory signals, a clone of progeny cells with same antigen specificity is 
generated and many of these differentiate into effector T cells. A memory 
commitment theory of sequential differentiation from naïve T cells to memory T 
cells was suggested in 1999 (Opferman et al., 1999). Opferman et al. proposed 
that naïve T cells activated by Ag stimulation differentiate into effectors and clear 
pathogens through clonal expansion. After clearance of Ag, most effector cells die 
(contraction phase) and only a tiny proportion of Ag specific cells survive to 
become long-lived memory T cells (Summarized in Figure 2).  
 
Recent studies have reported that T cells require a third signal-inflammatory 
cytokines such as IL-2, IL-12, type I IFNs or IFN-γ for their optimal activation 
(Curtsinger et al., 1999; Kolumam et al., 2005; Cui et al., 2009). Therefore, 
signals from TCR, costimulation, and cytokines are critical for T cell activation 
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(Curtsinger et al., 1999; Zehn et al., 1999; Bertram, et al., 2004) and they can sum 
linearly to amplify the T cell response (Marchingo et al., 2014). 
 
 
 
 
Figure 2: Kinetics of a CD8 T cell response. 1) Expansion phase: 
antigen specific CD8 T cells proliferation. 2) Contraction phase: most of 
effector CD8 T cells die after the elimination of pathogen. 3) Memory 
phase: a small population survive and differentiate to memory CD8 T cells. 
 
 
Characteristics of T cell memory formation 
 
 After pathogen has been cleared, most of antigen-specific effector cells are 
eliminated by apoptosis. Only a tiny proportion of cells can survive and mature 
into long-term memory CD8 T cells (Lau et al., 1994; reviewed by Sprent and 
Surh, 2002). There are a number of different models to explain how effector T 
cells are selected to give rise to memory T cells. Effector CD8 T cells with 
increased expression of CD127, CD27 and Bcl-2 and decreased expression of 
killer cell lectin-like receptor G1 (KLRG1) were identified as early memory 
precursor cells in lymphocytic choriomeningitis virus (LCMV) infection 
experiments (Murali-Krishna, K. et al., 1998; Kaech, et al., 2003; Joshi et al., 
2007; Joshi et al., 2008; Sarkar et al., 2008). However, these phenotypic markers 
	
   
	
virus CD8
+
 T cells  
Weeks post infection 
0 1 4 
	 	
Po
pu
la
tio
n 
	 13	
that defines the memory precursors at effector stages are not exclusive and the 
selection gets complicated with other studies (Croom et al., 2011; Obar et al., 
2011). 
Despite extensive heterogeneity, memory T cells can be broadly categorised into 
two functional subsets by surface markers CCR7 and CD62L (Sallusto, F.et al., 
1999). Central memory T cells (TCM) express CCR7 and CD62L (CD62LhiCCR7hi) 
and have homing receptors to secondary lymphoid organs and bone marrow 
(Mazo et al., 2005; Sallusto et al., 1999; Kaech and Wherry, 2007). On the other 
hand, effector memory T cells (TEM) that do not express CCR7 
(CD62LlowCCR7low) are normally found in non-lymphoid tissues and can enter to 
inflamed tissue to have immediate effector functions (Masopust et al., 2001; 
Sallusto et al., 1999; Kaech and Wherry, 2007).  TCM lack immediate effector 
functions but they are sensitive to TCR simulation to mount a robust recall 
response and produce IL-2 after priming (Sallusto et al., 2004; Jameson and 
Masopust, 2009). TEM have effector functions and can produce cytotoxic proteins 
(Sallusto et al., 1999; Kaech and Wherry, 2007). Although TCM and TEM have 
different locations and functional properties, there is evidence that they could 
interconvert to each other (Kaech and Wherry, 2007; Bouneaud et al., 2005; 
Wherry and Ahmed, 2004). 
 
In addition, a third subset of memory T cells has been characterized as 
CD103hiCD69hiCD27low referred as tissue-resident memory T (TRM) cells 
(Masopust et al., 2001; Gebhardt et al., 2009; Sheridan and Lefrancois, 2011; 
Carbone, 2015). These nonrecirculating tissue-resident memory T cells provide 
protective local immunity against pathogen (Gebhardt et al., 2009; Carbone, 
2015). 
 
There are more accumulating data showing that ‘Memory-like phenotype’ CD8 T 
cells can also rise without effector differentiation when naïve T cells are 
adoptively transferred into lymphopenic hosts through a process named 
homeostatic-driven proliferation (Goldrath et al., 2000). In this process, excess 
availability of self-pMHC and IL-7 induce naïve T cells to quickly undergo 
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homeostatic expansion and acquire phenotypes and functional characteristics 
similar to memory T cells (Goldrath et al., 2000; Schluns et al., 2000; Tan et al, 
2001). This process was appropriated named as lymphopenia-induced 
proliferation (Min et al., 2003) and is dependent on MHC or IL-7 (Ernst et al., 
1999; Goldrath and Bevan, 1999; Schluns et al., 2000; Tan et al., 2001). These 
homeostatic proliferation memory T cells display similar memory phenotypic 
markers as antigen-driven memory cells (Jameson, 2005; Surh and Sprent, 2005; 
Goldrath et al., 2000). Like antigen-specific memory T cells, homeostatic 
proliferation memory T cells display rapid proliferative response and enhanced 
cytotoxic function, and increased effector cytokine production compared with 
naïve T cells (Jameson, 2005; Surh and Sprent, 2005; Goldrath et al., 2000). 
Haluszczak et al demonstrated the existence of memory-like T cells in 
nonimmunized animal which are termed ‘virtual memory’ (VM) to describe this 
antigen-specific T cells within the unprimed T cell population (Haluszczak et al., 
2009) 
 
 
Homeostasis of memory CD8 T cell 
 
The survival signals required by memory CD4 and CD8 T cells are still under 
investigation. Unlike naïve T cells, antigen and MHC molecules are not essential 
to sustain both CD4 and CD8 T cells (Surh and Sprent, 2005). It has been shown 
that the expression of common γ chain is not required for the survival of memory 
CD4 T cells (Lantz et al., 2000). However, IL-7 is essential to support the survival 
of CD4 T memory cells (Seddon et al., 2003).  
 
The survival of memory CD8 T cells is antigen-independent and is dependent on 
the cytokines IL-7 and IL-15 (Surh and Sprent, 2008). IL-7 is not necessary for 
antigen-induced expansion of CD8 T cells but is critical for generation of T cell 
memory (Schluns et al., 2000). In IL-7R-/- CD8 T cells, they have normal 
activation but are poor producer of memory CD8 T cells (Schluns et al., 2002). 
Selective expression of the IL-7Rα identifies the effector CD8 T cells that will 
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differentiate into memory T cell after infection or immunization (Kaech et al., 
2003). However, Hand et al., suggested that constitutive IL-7Rα expression has 
minimal effect the formation of memory CD8 T cell and is not sufficient to 
promote memory CD8 T cell development (Hand et al., 2007). These results 
implied that the generation and maintenance of memory CD8 T cells is a 
complicated process involving various cytokines and pathways.  Memory CD8 T 
cells can also be formed in the absence of IL-7 suggesting that the precursor of 
memory CD8 T cells are not dependent on the interaction of IL-7/IL-7Rα 
interaction (Klonowski et al., 2006). 
 
IL-15 together with IL-2, IL-4, IL-7, IL-9, and IL-21 stimulate receptors that all 
contain a common γ receptor subunit (Takeshita et al., 1992; Kondo et al., 1993; 
Russell et al., 1993; Giri et al., 1994; Asao et al., 2001). However, unlike other γC 
family members, IL-15 is presented on the cell surface and tightly bound to IL-
15Rα chain to induce signalling at the contact site between APC and CD8 T or 
Natural Killer (NK) cells (Reviewed by Ma et al., 2006).  IL-15 can bind to the 
IL-2/IL-15Rb complex to mediate a response without IL-15Rα and this binding 
affinity is not further augment by IL-15Rα (Giri et al., 1994; Giri et al., 1995; 
Anderson et al., 1995). The IL-15 receptors are heterotrimeric and contain the γC, 
IL-2/IL-15Rb (CD122) and IL-15Rα chain (Grabstein et al., 1994; Giri et al., 
1995). The up-regulation of IL-15Rα expression on effector CD8 T cells and 
sustaining of expression on memory CD8 T cells suggested that IL-15 is crucial 
for the generation and maintenance of memory CD8 T cells (Schluns et al., 2002).  
IL-15 has been first reported to have an important role in stimulating proliferation 
of memory CD8 T cells (Zhang et al., 1998). By studying IL-15 transgenic and 
deficient mice, IL-15 has been shown to be essential in survival and homeostatic 
proliferation of memory CD8 T cells. The generation of antigen specific memory 
CD8 T cells was impaired in IL-15 deficient mice and it correlated with decreased 
turnover in memory CD8 T cells (Schluns et al., 2002). Moreover, overexpression 
of IL-15 leads to increase persistence of antigen-specific CD8 T cells by 
preventing apoptosis during contraction phase of primary infection (Yajima et al., 
2002; Yajima et al., 2006).  
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Following the previous discussion, both IL-7 and IL-15 are important for memory 
CD8 T cells homeostasis. IL-7 is important for memory CD8 T cell survival, 
whereas basal homeostatic proliferation is largely depended on IL-15. Memory 
CD8 cells can utilize either IL-7 or IL-15 to undergo homeostatic proliferation, 
however, homeostatic proliferation fails to occur in the absence of both IL-7 and 
IL-15. (Tan et al., 2002). Kieper et al. demonstrated that normal memory 
precursor CD8 T cell number can be observed in the absence of IL-15 by 
overexpression of IL-7 using IL-7 TG mice (Schluns et al., 2000; Kieper et al., 
2002). Lymphopenia-induced proliferation of memory phenotype CD8 T cells 
was induced by excess amounts of IL-7 in lymphopenic mice with absence of IL-
15 (Goldrath, et al., 2002; Tan, et al., 2002). Antigen-specific CD8 T cells failed 
to undergo proliferative renewal and disappeared after infection in IL-15-/- mice 
(Becker et al., 2002). Therefore, IL-15 is required for homeostatic proliferation 
(Becker et al., 2002). In conclusion, long-term survival of memory CD8 T cells is 
dependent and regulated by both IL-7 and IL-15 with different roles supporting 
survival and inducing homeostatic renewal, respectively. 
 
Other factors or cytokines also contribute to the long lifespan of memory CD8 T 
cells. Autophagy is an intracellular degradation system that delivers cytosolic 
contents to the lysosome for cell degradation. Autophagy has been shown to 
dynamically regulate the survival of effector CD8 T cells and formation of 
memory T cells during LCMV infection in mice (Xu et al., 2014). The IL-10/IL-
21/STAT3 pathway has also been shown to be critical for the differentiation of 
virus-specific CD8 T cells to memory T cells in mice with acute LCMV infection 
(Cui et al., 2011). Consistent with the mouse findings, STAT3 has also been 
suggested to play a critical role in formation of human T cell memory and control 
of some chronic viruses (Siegel et al., 2011). Recently, IL-7 was discovered to 
induce glycerol channel aquaporin 9 (AQP9) expression which has an important 
role in supporting glycerol import for triglyceride (TAG) synthesis and storage in 
memory CD8 T cells (Cui et al., 2015). This study uncovers new mechanisms of 
memory CD8 T cells metabolism in long-term survival. 
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Thesis aims 
 
In this thesis, I analyse two mouse strains discovered by ENU-mutagenesis, with 
mutations in Dock2 and Senp2 named ‘dockland’ and ‘duan’, respectively, to 
define the role of these genes in the immune system. Dockland was identified 
through a splenocyte screen and duan was identified through a peripheral blood 
screen and both strains were analyzed by flow cytometry. 
 
The aim of dockland strain: 
 
To characterize the cellular phenotype of the dockland mice  
 
To map and identify the ENU variant gene responsible for the T cell lymphopenia 
 
The aim of duan strain: 
 
To characterize the cellular phenotype of the duan mice 
 
To map and identify the ENU variant gene responsible for the loss of peripheral 
CD8 T cell 
 
To investigate the effect of the Duan Senp2 mutation on T cell homeostasis in 
vivo 
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Chapter 2: Mice, materials and 
methods 
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2.1 Mice and procedures 
 
2.1.1 Mice 
 
All mice used for this work were housed in specific pathogen-free conditions. All 
procedures were approved by the Australian National University Animal Ethics 
and Experimentation Committee. 
 
The following mouse strains were used for the work detailed in this thesis: 
 
C57BL/6: in-bred mouse strain originally obtained from the Jackson Laboratory. 
 
C57BL/6.SJL-CD45.1: C57BL/6 strain congenic for CD45.1 derived from the 
SJL/J mouse strain 
 
CBA.H: in-bred mouse strain 
 
Dockland (Dock2doc/doc): ENU-derived mouse strain carrying a missense mutation 
in Dock2 gene on the C57BL/6 background. This allele was nicknamed 
‘dockland’ (doc). 
 
Duan (Senp2dua/dua): ENU-derived mouse strain carrying a missense mutation in 
Senp2 gene on the C57BL/6 background. This allele was nicknamed ‘duan’ (dua). 
 
Senp2 knockout mice (Chiu et al, 2008) were obtained from RIKEN BioResource 
Center. 
 
OT-I: Transgenic mouse strain produced on the C57BL/6 background expressing 
T cell receptor that recognises the OVA peptide SIINFEKL in association with 
MHC I protein H-2Kb (Hogquist et al., 1994). 
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Primurus (Dock8pri/pri): ENU-derived mouse strain carrying a missense mutation 
in Dock8 gene on the C57BL/6 background (Randall et al., 2009). This allele was 
nicknamed ‘primurus’ (pri). 
 
Thunder (HnRNPLLthu/thu): ENU-derived mouse strain carrying a missense 
mutation in Hnrpll gene on the C57BL/6 background (Wu et al., 2008). This 
allele was nicknamed ‘thunder’ (Thu). 
 
Rag1-/-: This strain, B6.129-Rag1tm1Mom, lacks all B and T cells (Mombaerts et al., 
1992) and was originally obtained from the Animal Resources Centre, Canning 
Vale, Western Australia, and maintained as a breeding colony at the Australian 
Phenomics Facility. 
 
2.1.2 Procedures 
 
2.1.2.1 ENU mutagenesis and breeding strategy 
 
100mg/kg ENU was injected into the intraperitoneal cavity to male C57BL/6 mice 
(Generation (G) 0) 3 times 1 week apart. These male mice were then used to start 
pedigrees by crossing to wild-type female C57BL/6 mice and inter-crossing their 
G 1 offspring. 
 
2.1.2.2 Bone marrow chimeras 
 
To test whether cellular phenotypes were of hematopoietic origin and cell 
intrinsic, bone marrow chimeras were generated by irradiating B6.SJL-CD45.1 
mice or Rag1-/- mice with 10 Gy and reconstituting with 2x106 donor bone 
marrow cells (50:50 mixture of wild-type (WT) B6.SJL-CD45.1 bone marrow and 
either mutant or WT B6 (CD45.2) bone marrow) or 100% mutant or WT 
(CD45.2). The recipient mice were analysed 8-10 weeks post reconstitution. 
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2.2 In vitro cell stimulation assays 
 
2.2.1 Buffers and reagents 
 
Sample collection media RPMI 1640 (GibcoBRL) 
 HI-FCS (sigma) 10% (v/v) 
 
 
Complete cell culture media (cRPMI) RPMI 1640 (GibcoBRL) 
  HI-FCS (sigma) 10% (v/v) 
 10 mM HEPES, pH7.4 (GibcoBRL) 
 1 mM sodium pyruvate (sigma) 
 50uM beta-mercaptoethanol 
(GibcoBRL) 
 0.1 mM non-essential amino-acid 
solution (GibcoBRL) 
 10mL L-glutamate and 
penicillin/streptomycin (GibcoBRL) 
 
 
2.2.2 Proliferation and overnight activation 
 
Proliferation and overnight activation of 2 x 106 lymphocytes was carried out in 
200uL complete media and stimulated with 5µg/mL anti-CD3 (0.5 mg/mL, clone: 
500A2, BD pharmingen) and 5µg/mL anti-CD28 (0.5mg/mL, clone: 37.51, BD 
pharmingen). 
 
2.2.3 IL-7 stimulation 
 
Splenocytes were resuspended in cRPMI at room temperature. 2 x106 cells (50:50 
mixtures of wild-type and mutant cells) were cultured in 1mL complete medium 
with 1µg/mL IL-7 (407-ML-005, R&D systems) at 37°C overnight. 
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2.3 Flow cytometry 
 
2.3.1 Buffers and reagents 
 
FACS wash 2 L phosphate buffer saline (PBS) 
 50 ml bovine serum albumin 2.5% (v/v) 
 20 ml sodium azide 1% (v/v) 
          
Red blood cell (RBC) lysis buffer 
(10X) 
8.99 g ammonium chloride 
(pH 7.3) 1 g potassium bicarbonate 
 37 mg EDTA 
 100 mL H2O 
 
 
2.3.2 Preparation of cells 
 
100-200 µL blood samples were collected from the retro-orbital sinus of mice into 
tubes containing 10-20ul heparin or EDTA. 50 µL of anti-coagulated blood was 
lysed with 200µL red blood cell (RBC) lysis buffer (made up to 1X with dH2O 
and adjusted pH to 7). After 5 minute incubation at room temperature, the lysed 
cells were centrifuged for 4 minutes at 1240 rpm at 12°C. The supernatant was 
discarded by flicking the plate and the pellets were resuspended in 200 µL RBC 
lysis buffer. The incubation and centrifugation steps were repeated. The pellet was 
washed twice with ice cold 200 µL FACS buffer and kept on ice. 
 
Mouse spleen and thymus were collected in 5 mL of RPMI1640 + 10 % FCS. 
Bone marrow cells were flushed from tibias and femurs in 3 mL of RPMI1640 + 
10 % FCS. Single cell suspensions of splenocytes, thymocytes and bone marrow 
cells were prepared by passing through a cell strainer and kept on ice. Cells were 
pelleted by centrifugation for 4 minutes at 1340 rpm at 4°C. Splenocytes were 
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lysed with RBC lysis buffer for 5 minutes and washed twice with 5mL RPMI1640 
+ 10% FCS. 
 
2.3.3 Surface staining of lymphocytes 
 
2 x 106 cells were added into each well of 96-well round-bottom plate (Nunc). 40 
µL of a cocktail of premixed fluorochrome-conjugated antibodies (Table 2) was 
added to each well and incubated at 4°C for 30 minutes in the dark. After 
incubation, the cells were washed twice with FACS buffer and resuspended in 70 
µL FACS buffer and transferred into cluster tubes. The samples were analysed on 
LSR II flow cytometer (BD Biosciences).  
 
Table 2.: Antibodies used for flow cytometry. 
 
Antibodies Clone Conjugate Vendor 
Anti-mouse CD122 TM-β1 Biotin BD pharmingen 
Anti-mouse CD127 A7R34 PE Cy5 eBioscience 
  A7R34 PE eBioscience 
Anti-mouse CD19 eBio1D3 Alexa Fluor® 700 eBioscience 
Anti-mouse CD21 7E9 PerCP Biolegend 
Anti-mouse CD23 B3B4 Pacific Blue Biolegend 
Anti-mouse CD24 M1/69 Pacific Blue Biolegend 
Anti-mouse CD25 7D4 FITC BD pharmingen 
  PC61.5 PE eBioscience 
Anti-mouse CD3 145-2C11 PE BD pharmingen 
Anti-mouse CD4 RM4-5 Alexa Fluor® 700 BD pharmingen 
  RM4-5 APC BD pharmingen 
Anti-mouse CD43 S7 PE BD pharmingen 
Anti-mouse CD44 IM7 Pacific Blue Biolegend 
  IM7 A700 Biolegend 
Anti-mouse CD45.1 A20 APC eBioscience 
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  A20 FITC BD pharmingen 
  A20 Pacific Blue Biolegend 
  A20 PE BD pharmingen 
Anti-mouse CD45.2 104 Pacific Blue Biolegend 
  104 FITC BD pharmingen 
Anti-mouse CD45R 
(B220) RA3-6B2 APC Cy7 BD pharmingen 
  RA3-6B2 Biotin eBioscience 
  RA3-6B2 PE Cy7 BD pharmingen 
  RA3-6B2 PerCP BD pharmingen 
Anti-mouse CD5 (Ly-1) 53-7.3 APC eBioscience 
Anti-mouse CD62L MEL-14 APC Cy7  Biolegend 
Anti-mouse CD69 H1.2F3 PE Cy7 eBioscience 
Anti-mouse CD8 53-6.7 APC eBioscience 
  53-6.7 APC Cy7 Biolegend 
  53-6.7 PE Biolegend 
Anti-mouse CD93 AA4.1 APC eBioscience 
Anti-mouse CD95   PE BD pharmingen 
Anti-mouse KLRG1 2F1 PE Cy7 eBioscience 
  2F1 APC eBioscience 
Anti-mouse IgD 11-26 Biotin eBioscience 
Anti-mouse IgM 11/41 PE Cy7 eBioscience 
Anti-mouse NK1.1 PK136 APC BD pharmingen 
  PK136 FITC BD pharmingen 
Anti-mouse Vα2 TCR B20.1 PE BD pharmingen 
 
 
2.3.4 Data acquisition and analysis 
 
Data were acquired using LSRII or Fortessa flow cytometers (BD Biosciences) 
and were analysed using flowJo software (Treestar). 
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2.4 Adoptive transfer experiments 
 
2.4.1 Adoptive transfer of OT-I CD8+ T cells 
 
Mice were sacrificed by cervical dislocation. Splenocytes were collected in 5 mL 
of RPMI1640 + 10% fetal calf serum (FCS). Single cell suspensions were 
prepared by mashing and filter through nylon mesh filter (BD Bioscience). Cells 
were diluted with trypan blue and counted using a haemacytometer. 200 uL of 10 
x106 WT OT-I or mutant OT-I cells were mixed at a 50:50 ratio in RPMI + 10% 
FCS. Recipient mice were immobilized in a restrainer and 200 µL of cell 
suspension were intravenously injected via the tail. 
 
2.4.2 Adoptive transfer of OT-I CD8+ T cells and immunisation with 
recombinant influenza A viruses HKx31-SIINFEKL and PR8-SIINFEKL 
 
Mice were sacrificed by cervical dislocation. Splenocytes were collected in 5 mL 
of RPMI1640 + 10% FCS. Single cell suspensions were prepared by mashing and 
filter through nylon mesh filter (BD Bioscience). Cells were diluted with trypan 
blue and counted using a haemocytometer. 1000 WT OT-I or mutant OT-I cells 
were mixed at a 50:50 ratio per 200 µL RPMI + 10% FCS for each recipient 
mouse. The recipient mice were immobilized in a restrainer and 200 µL of cell 
suspension were intravenously injected via the tail. The recipients were 
intraperitoneally injected with 200 HAU/µL influenza A virus HKx31-SIINFEKL 
on the same day. The second challenge was intraperitoneally injected on day 70 
post first challenge with influenza A virus PR8-SIINFEKL. Recombinant viruses 
were a gift of Dr Stephen Turner (Jenkins et al., 2006) and virus stocks were 
prepared in chicken eggs by Dr Ed Bertram. 
 
 
2.5 cloning and sequencing 
 
2.5.1 cDNA preparation and primers  
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2.5.1.1 Preparation of RNA 
 
Preparation of RNA was carried out in an RNA designated room and hood to 
avoid RNA degradation. Mouse spleen was collected in 5 mL of RPMI1640 + 10 
% FCS. Single cell suspensions of splenocytes were prepared by mashing and 
sieving under sterile condition and kept on ice. Cells were pelleted by 
centrifugation for 4 minutes at 1340 rpm at 4°C. Splenocytes are lysed with RBC 
lysis buffer for 5 minutes and 5 mL RPMI1640 + 10 % FCS was added. The cells 
were resuspended with 5 mL PBS and the cells were counted. 5 x 106 cells were 
pelleted in 1.5 mL eppendorf tube and mixed in 1mL of TRIzolTM (Invitrogen). 
200 ul chloroform was added to the tube and shaken vigorously for 30 seconds. 
The mixture was incubated at room temperature for 10 minutes and then 
centrifuged at 13000 g for 15 min at 4°C. The upper aqueous layer was transferred 
into new eppendorf tubes containing 500 µL isopropanol and incubated at room 
temperature (RT) for 10 -15 minutes. The samples were centrifuged at 13000 g for 
15 minutes at 4°C to pellet RNA. The supernatant was removed and the pellet was 
washed with 1 mL of 75% ethanol. The samples were centrifuged at 7500 g for 5 
minutes at 4°C and the ethanol supernatant was carefully removed. The pellet was 
air dried for 10-15 min and redissolved in 20 µL DEPC-treated water and stored at 
- 80°C. The concentration of RNA was determined by using Nanodrop 
spectrophometer (ND-1000, Nanodrop Technologies, USA) 
 
2.5.1.2 Preparation of cDNA 
 
This process was carried out by using SuperScriptTM II Reverse Transcriptase kit 
(Invitrogen, Cat. #: 18064-022). 500 ng of RNA was added to 0.5 mL eppendorf 
tubes together with 1 µL oligo dT and dNTP (10mM). DEPC-treated water was 
added to make a total volume of 12 µL. Each sample was heated at 65°C for 5 
minutes and quickly chilled on ice. A master mix of 4 µL 5X First-Strand buffer, 
2 µL DTT (0.1 M) and 1 µL RNAse out was added to each sample and incubated 
at 37°C for 2 minutes. 1 µL of SuperScript II reverse transcriptase was added to 
each sample and incubated at 42°C for 50 minutes. The sample was heated to 
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70°C for 15 minutes to inactivate the reaction. 1 µL RNAse-H was added and 
samples were incubated at 37°C for 20 minutes. The synthesized cDNA was 
stored at -20 °C. 
 
2.5.1.3 Oligonucleotide primers 
 
All primers used in this study were obtained from Gene Works: 
 
Senp2 
Forward: 
5’ CTCAAGCTTACCATGTACAGATGGCTGGCTAAGGTTC 3’ 
Senp2 
Reverse: 
5’ GCAGTCGACGACAGCAACTGCTGGTGAAGGATC 3’ 
 
 
2.5.2 PCR Amplification 
 
This process was carried out by using AccuPrimeTM Pfx DNA polymerase 
(Invitrogen, Cat. #: 12344-024). Each reaction contained the following: 
 
10x AccuPrimeTM Pfx Reaction mix 5 µL 
10mM forward primer 1.5 µL 
10mM reverse primer 1.5 µL 
AccuPrimeTM Pfx DNA polymerase 1 µL 
Template DNA 250 ng 
dH2O  Make up to 50 µL 
 
PCR program: 
Denature the template at 95°C for 2min: 
Denature 95°C for 15 seconds  
Anneal 52°C for 30 seconds X 35 cycles 
Extend 68°C for 2.5 minutes  
 
	 28	
2.5.3 DNA Cloning 
 
2.5.3.1 PCR product Purification and digestion 
 
 
The PCR products were purified by using PureLink PCR purification kit 
(Invitrogen, Cat. #: K3100-01). 
 
2.5.3.2 Digestion for PCR products (insert): 
 
10x Buffer 3 µL 
10x BSA 3 µL 
Enzyme 1: HindIII 1.5 µL 
Enzyme 2: SalI 1.5 µL 
DNA 2 µg  
MQ H2O Make up to 20 µL 
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2.5.3.3 vector 
   
 
 
Figure 2.5.3: The plasmid for cloning with restriction sites shown 
 
 
2.5.3.4 Digestion of plasmid: 
 
10x Buffer 5 µL 
10x BSA 5 µL 
Enzyme 1: HindIII 2.5 µL 
Enzyme 2: SalI 2.5 µL 
Plasmid DNA 1-3 µg  
MQ H2O Make up to 50 µL 
*following digestion, DNA was ran on an agarose gel. 
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2.5.4 Gel extraction 
 
DNA samples were extracted from the gel using QIAEX II gel extraction Kit 
(QIAGEN, Cat. #: 20021) 
 
2.5.5 Ligation and transformation 
 
Ligation was carried out using LigaFastTM Rapid DNA ligation system (Promega, 
Cat. #: M8221). 
 
Ligation Buffer 2.5 µL 
Ligase (T4) 0.5 µL 
Insert 1.5 µL 
Vector (pEGFP-N1) 0.5 µL 
Mix was incubated at room temperature for 10 min. 
 
The ligation product was added to 500 µL competent cells and incubated on ice 
for 15 minutes. The competent cells and DNA mix was heat shock for 30 seconds 
using 37°C water bath and followed by cooling on ice for 2 minutes. The sample 
was added to 450 µL L-Broth (LB) and incubated in shaker at 37 for 60 min. The 
cells were centrifuged at 10,000 rpm for 1 min and resuspend in 100 µL LB. The 
transfected cells were plated on agar plates. 
 
Molecular weight markers: 1Kb Plus DNA ladder (invitrogen) 
 
 
2.5.6 Sequencing 
 
Oligonucleotide Primers: 
eGFP forward 5' CGT GTA CGG TGG GAG GTC TA 3’ 
Senp2 forward 5' CAG GAG CAA GGT GTG ACA GA 3’ 
eGFP reverse 5' CGT CGC CGT CCA GCT CGA CCA G 3’ 
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Components of sequencing reaction: 
5X sequencing buffer (BRF, JCSMR, 
ANU) 
3.5 µL 
Forward or reverse primer (10mM) 1 µL 
Big dye (BRF, JCSMR, ANU) 1 µL 
DNA template 100 – 300 ng (3 µL) 
dH2O Make up to 20 µL 
 
 
2 µL 12.5 mM EDTA, 2 µL 3M NaOAC and 60 µL of 100% ethanol was added to 
each sample and centrifuged at 13000 rpm for 30 minutes. The supernatant was 
removed from each tube and 200 µL of 80% ethanol was added to wash the pellet. 
The sample was centrifuged at 13000 rpm for 5 min and vacuumed dried at room 
temperature. The samples were sequenced in The Australian Cancer Research 
Foundation (ACRF) Biomolecular Resource Facility (BRF), and the data was 
analysed using CodonCode aligner software.  
 
  
2.6 Immunofluorescence 
 
293T cells were grown to 90% confluence on slides in 6-well plate. The 
transfection was done by using Lipofectamine 2000 (Invitrogen, Cat. #: 11668-
027). 12 uL Lipofectamine 2000 was added to tube #1 with 150 uL DMEM 
(GibcoBRL). 10 ug of plasmid was added to tube #2 with 150uL DMEM 
(GibcoBRL). Mix tube #1 and #2 and incubate for 5 min. The DNA-lipid complex 
was added to the cells. 2 days after transfection, the slides were taken out and put 
in a new 6-well plate and gently rinsed with 2mL PBS. The coverslips were 
immersed in 4% paraformaldehyde for 30 min and followed by rinse with PBS. 
The coverslips were incubated in 1% TritonX-100/PBS at RT for 5 min and 
followed by wash with PBS 2 times for 10 min. The coverslips were placed in a 
humid chamber and inverted over 25-50 µL of blocking buffer and incubated at 
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RT for 30 min. The coverslips were inverted onto a slide containing 3-5 µL of 
anti-fade solution (Molecular Probe) and air-dried. The GFP expression 
photographs were taken using confocal microscope (Imaging and Cytometry 
Facility (ICF), JCSMR). 
 
 
2.7 Retroviral transduction 
 
2.7.1 Buffers and reagents 
 
Magnetic cell separation buffer 500 mL phosphate buffer saline (PBS) 
 (MACS buffer) 2 mL 2mM EDTA 
 2.5 mL HI-FCS (sigma) 0.5% (v/v) 
 
Complete DMEM (cDMEM) DMEM (GibcoBRL) 
 HI-FCS (sigma) 10% (v/v) 
 100 u/ml penicillin, 100 µg/ml 
streptomycin (GibcoBRL) 
 
 
2.7.2 Retroviral – mediated primary T cell transduction 
 
2.7.2.1 Transfection 
 
Phoenix cells were maintained in NUNC T75 flasks (Thermo Scientific) in 
cDMEM media at 37°C until reaching confluence.  
 
Experimental procedure: 
Day Procedure 
1 1x106 cells/ 5 mL phoenix cells were plated in 60 mm petri dish 
2 Cells were Transfected with Lipofectamine 2000 ((Invitrogen, Cat. 
#: 11668-027) as described above (For 60mm petri dish: 20 uL 
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Lipofectamine and 8 ug of plasmid DNA were used) 
3 Media was changed with 3 mL of cRPMI 
4 Viral supernatant was collected into 15 mL Falcon tubes and 
centrifuged at 1500 rpm to get rid of dead phoenix cells. 3 mL of 
fresh cRPMI was added (Viral supernatants were stored at 4˚C) 
5 Viral supernatant was collected into 15 mL Falcon tubes and 
centrifuged at 1500 rpm to get rid of dead phoenix cells. GFP 
expression of phoenix cells was confirmed by FACS 
 
2.7.2.2 Transduction 
 
Primary murine T cells were isolated from the spleen. To do this, CD8 cells were 
enriched from splenocytes by depletion using anti-B220 and CD4 biotinylated 
antibodies and streptavidin MACS beads (130-048-102, Miltenyi Biotec). After 
washing with 5 mL MACS buffer, the cells were passed through a magnetic 
column (LS columns, 130-042-401, Miltenyi Biotec) according to manufacturer’s 
instructions. The B220-CD4- eluted cells were cultured for 24 hours at 37°C, 10 % 
CO2 in 6-well plate at 2 x 106 cells/mL in cRPMI. Cells were activated by plate 
bound αCD3 (5µg/mL) and soluble αCD28 (5µg/mL). 24 hours after activation, 
primary cells were pelleted and resuspend with 2ml viral supernatant. Cells were 
added to 6 - well plate with 20 µL/10 x 106 cells DOTAP and spinoculated for 90 
minutes at 2800 rpm at 30°C. 
 
 
2.7.3 Cell lines 
 
2.7.3.1 293T cells 
 
293T cells were maintained in NUNC T75 flasks (Thermo Scientific) in cDMEM 
media at 37°C until reaching confluence. For passage, the cells were washed with 
10 mL PBS and then treated with 1.5 mL trypsin-EDTA at 37°C for 2-3 minutes 
to release the adherent cells. 8.5 mL cDMEM was added to inactivate the trypsin. 
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1 mL of cell suspension was seeded to a new flask containing 20 mL fresh 
cDMEM.     
 
2.7.3.2 phoenix cells 
 
Phoenix cells were maintained in NUNC T75 flasks (Thermo Scientific) in 
cDMEM media at 37°C until reaching confluence. For passage, the cells were 
washed with 10 mL PBS and then treated with 1.5 mL trypsin-EDTA at 37C for 
2-3 minutes. 8.5 mL cDMEM was added to inactivate the trypsin. 1 mL of cell 
suspension was seeded to a new flask containing 20 mL fresh cDMEM. 
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Chapter 3: Identification of 
causative mutation in DOCK2 
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 3.1 Aim 
 
The aim of this research project was to identify new mutant mouse strains with T 
cell abnormalities produced by N-ethyl N-nitrosourea (ENU) mutagenesis. 
Identification of mutations in these strains could help to investigate pathways 
important to the immune system.  
 
 
The production of novel mouse strains by ENU mutagenesis 
 
Over last decades, the mouse has been a powerful model to study the mammalian 
genome not only because of its’ short breeding period but also the mouse genome 
shares high similarity with the human genome sequence. Gene knock out (KO) 
techniques have been widely applied in biomedical research, but they require a 
priori knowledge in selecting which gene to mutate. As a complement to targeted 
gene knock-outs, genome-wide chemical mutagenesis coupled with a phenotypic 
screen is a powerful approach to identify novel genes and elucidate gene functions 
without requiring prior knowledge about specific genes of interest.  
 
N-ethyl-N-nitrosourea (ENU) has been shown to be an effective chemical 
mutagen that causes random point mutation in mouse spermatogonia (Russell et 
al., 1979 and Russell et al., 1982). ENU can transfer the ethyl group to reactive 
oxygen or nitrogen radicals of purine or pyrimidine resulting in mispairing during 
DNA replication in both somatic and germ cells (Singer and Dosahjh, 1990). 
ENU-mutagenesis is a powerful tool to generate a variety of alleles for 
investigation of gene function (Quwailid, et al., 2004). T/A base pairs are the most 
preferential targets by ENU. AT to TA tranversions and AT to GC transitions 
comprise 82% of the total lesions sequenced (Noveroske, et al., 2000) which is 
possibly due to the mispairing of alkylated O4-thymine and O2-thymine 
respectively (Justice et al., 1999). ENU-induced gene mutations resulting in 
Mendelian phenotypes comprise 64% missense, 10% nonsense and 26% splicing 
errors (Justice et al. 1999). This range of alleles mirrors many of the inherited or 
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de novo mutations found in human Mendelian diseases, providing a source for 
human disease models (Justice et al., 1999). 
 
My goal was to isolate new mouse models that might correspond to human 
immune disorders. The majority of ENU induced mutations produce recessive 
traits only detectable after three generations breeding to homozygosity. When 
injected to the founder “Generation 0” (G0) mice, ethylnitrosourea (ENU) 
produces single nucleotide substitutions in the DNA sequence of mouse 
spermatogonial stem cells (Beier, 2000).  
 
In my studies, once the males have regained fertility, they can be bred with WT 
females to produce G1 mice carrying approximately 50 heterozygous mutations in 
protein-coding sequences. After two more generations of breeding some of these 
mutations can be brought to homozygosity and the mice (G3) can be screened for 
phenotypes of interest (Vinuesa and Goodnow, 2004, Vinuesa et al., 2005, and 
Wu et al., 2008). Causal mutations can then be identified through the use of 
exome or whole genome sequencing (Andrews et al., 2012). Whereas previous 
screens have only tested blood, in my studies G3 mice were sacrificed after flow 
cytometric screening of blood and their spleen screened by flow cytometry for 
heritable recessive mutations. This would detect mutations affecting sessile 
lymphocyte subsets like marginal zone B cells, which are not detectable in blood. 
Mutant strains were propagated from parents and additional siblings, and further 
confirmed by peripheral blood, thymus, and bone marrow flow cytometric 
analysis.  
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Figure 3.1 Pedigree of the ENU16NIH19a ‘dockland’ strain. In the G3 
generation, 1 female and 4 males had a significant reduction of 
lymphocytes in spleen. Male mice = squares, female mice = circles. 
Affected mice = red filled symbols; unaffected mice = open symbols.  
 
 
3.2 Discovery of a mouse strain produced by ENU mutagenesis with absent 
marginal zone B cells and T cell lymphopenia 
 
In Figure 3.1, pedigree ENU7B6039 was found at the G3 generation with B cell 
lymphopenia and reduced CD4:CD8 ratio. Analysis of spleen cells from one G3 
mouse of this strain showed that it had higher CD44 expression on T cells (Figure 
3.2) and a reduced marginal zone B cell population (about 1/10 of the wild type) 
compared to normal mice. By screening of all G3 mice from the pedigree, 4 out of 
25 mice showed the same phenotype (Table 3.1). Following the Mendelian 
inheritance law, this strain was inferred to carry a recessive mutation.  
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Figure 3.2 Splenic subsets in dockland mouse. (A) Representative flow 
cytometry plots of B220+ and CD3+ splenocytes for either wildtype (G3 
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#23) or dockland mutant mice (G3 #22, colored in red). (B) Representative 
flow cytometry plots of CD4 and CD8 T splenocytes and histogram of 
CD44 expression on CD4 and CD8 T splenocytes for either wildtype or 
dockland mice (colored in red). The percentage of CD4 or CD8 cells falling 
within the CD44hi gate is shown. 
 
 
 
 
Table 3.1 The percentage of mice displaying the dockland 
lymphocyte trait (affected) in the ENU16NIH19a pedigree G3 
generation. 
 
 
The percentage of CD4 and CD8 in mice displaying the dockland trait (affected) 
and in unaffected littermates is plotted in Figure 3.3. As the mutant mice have 
lower CD4/CD8 ratio, and higher CD44 surface expression on CD4 and CD8 T 
cells, the affected mutant group could be separated from the normal littermates by 
using CD4% versus CD8%, and were best resolved by plotting CD44%+CD8 
versus CD8% (Figure 3.3). 
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Figure 3.3 dockland mutation leads to altered CD4/CD8 ratio and 
increased of CD44 expression on T cells. Flow cytometric analysis of 
blood. A) The percentage of CD4 T cells versus CD8 T cells. B) The 
frequency of CD44hi CD8 T cells versus CD8 T cells. Each symbol 
represents a single animal: Red = affected and Blue = unaffected. 
 
 
3.3 Mapping and sequencing to identify the causative dockland mutation 
 
To identify the dockland mutation, one affected mouse was outcrossed to mice of 
the CBA/H strain to generate an F1 generation. After intercrossing F1s, blood 
from the F2 generation was analysed by flow cytometry to identify affected 
individuals using the traits above. DNA was collected from affected individuals 
and typed for single nucleotide polymorphic markers throughout the genomes 
between C57BL/6 and CBA/H strain by the mapping team at the Australian 
Phenomics Facility. The affected mice shared a single chromosomal interval 
homozygous for DNA of B6 origin on Chromosome 11, whereas the unaffected 
mice were either heterozygous or homozygous for DNA of CBA origin in this 
part of Chromosome 11. By these criteria, the dockland mutation was narrowed 
down to chromosome 11 with an interval from 4.4 Mb to 47.4 Mb (Figure 3.4A). 
The recombinant genotypes of affected and unaffected animals excluded 
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everything proximal to the marker at 4.4 Mb, and everything distal to the marker 
at 47 Mb, but there were no recombinants that excluded the interval between 4.4 
and 23 Mb (Figure 3.4A). A search of the genes in this interval led to one strong 
candidate gene, Dock2.  Dock2 deficient mice have similar phenotypes such as T 
lymphopenia and loss of marginal zone B cells (Fukui, Y el al., 2001) therefore 
Dock2 was a candidate gene for the dockland mutation. Sequencing the Dock2 
gene in affected and in normal B6 DNA revealed a homozygous G to T single 
nucleotide substitution in exon 23 that produced a premature stop codon (TAA) 
instead of Glutamic acid residue 775 (GAA) (Figure 3.4B). The dockland (doc) 
mutation was thus predicted to truncate and eliminate the C-terminal half of the 
DOCK2 protein. 
 
 
A 
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Figure 3.4 Mutation in Dock2 in dockland mouse. (A) Results of DNA 
typing of individual affected and unaffected mice from dockland 
C57BL6/CBA F2 intercross showing linkage of the dockland mutation to a 
segment of chromosome 11 from 4.4MB to 47MB. . Each row is a single 
F2 mouse, and each column shows the genotype for a single nucleotide 
polymorphism at the indicated coordinate (megabasepair, mouse genome 
build 37) on Chromosome 11. (B) DNA sequence from C57BL/6 and 
dockland affected mice showed a G to T base change in exon 23, 
changing codon 775 from encoding Glutamic acid to a stop codon. The 
premature stop is downstream of DHR-1 domain of DOCK2 protein and 
upstream of the DHR-2 domain (schematically showed).  
 
 
3.4 DOCK2 expression and protein structure 
 
DOCK2 is a mammalian homolog of the Caenorhabditis elegans protein CED-5 
and the Drosophila melanogaster protein myoblast city, and is a guanine 
nucleotide-exchange factor (GEF) expressed mainly in haematopoietic cells 
(Meller et al., 2005; Cote and Vuori, 2007; Figure 6). Mouse DOCK2 comprises 
1828 amino acid residues, including an SH3 domain, a DOCK-homology region 1 
	 			SH3 DHR-1 DHR-2 * 775Eàstop codon 	DOCK2 
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(DHR-1) domain and a DHR-2 domain (Figure 3.5). DOCK2 protein can 
physically interact with ELMO1 through its SH3 domain. The DHR-1 domain 
binds phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) lipids generated 
by PI(3)K activity to promote localized membrane binding and activation. 
Moreover, DOCK2 can regulate cell migration, cytoskeletal dynamics and 
membrane polarization by activating Rac through its DHR-2 domain (Meller et al., 
2005; Cote and Vuori, 2007). Rac is a one of the Rho family GTPases that 
regulate membrane polarization and cytoskeletal dynamics in various cells. Rac is 
transformed from a GDP-bound inactive state to a GTP-bound active state upon 
exchanging GDP for GTP, which is stimulated by GTP exchange factors 
including the DOCK proteins (Hall, 1998; Penninger and Crabree, 1999). 
Previous analysis of Dock2 knock-out mice suggests that Dock2 functions as a 
central molecule that activates Rac and mediates cytoskeletal reorganization 
during lymphocyte migration (Sanui, et al., 2003; Terasawa et al., 2012). Dock2 
has been demonstrated to link TCR signals to the degradation and downregulation 
of IL-4Rα through Rac activation and microtubule dynamics (Tanaka et al., 
2007). In addition, Dock2 deficiency causes marked reduction of Vα14 NKT cells 
in the thymus, liver, and spleen by affecting the generation of Vα14 NKT cells 
(Kunisaki et al., 2006). The dockland mutant strain has acquired a stop codon 
immediately C-terminal to the DHR-1 domain, eliminating the DHR-2 Rac GTP-
exchange factor domain. In mice, Dock2 mRNA is primarily produced in 
hematopoietic cells (Figure 3.6).  
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Figure 3.5 Dedicator of cytokinesis (DOCK) family proteins. The 
structure and domains of mammalian DOCK family proteins. (Adapted 
from Nishikimi et al., 2013) 
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Figure 3.6 Dock2 mRNA is highly expressed in immunological cells 
and tissues. Affymetrix microarray profiling data from BioGPS showing 
relative amount of Dock2 mRNA in the indicated mouse tissues and cell 
types. (http://biogps.org/#goto=genereport&id=94176)  
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3.5 Lymphocyte deficiency in dockland mice 
 
The dockland homozygous mice were compared with age-matched wild-type 
controls and heterozygous mice. Spleen cells were investigated by flow 
cytometric analysis using the gating strategy shown in Figure 3.7. B cells (B220+) 
and T cells (CD3+) were gated from total lymphocytes (Figure 3.7A). T cells were 
further divided into CD4 and CD8 T cells (Figure 3.8) and both populations were 
analysed for CD44 and KLRG1 expression (Figure 3.7B and C). In the spleen, 
wild-type and doc/+ heterozygous mice had comparable percentages of 
lymphocytes (Figure 3.8A left). However, doc/doc homozygous mice had a 
significantly lower percentage of lymphocytes in the spleen compare to the other 
two groups (p<0.001), as well as significantly lower total lymphocyte numbers 
per spleen compared to wild-type (p<0.01) and doc/+ mice (p<0.05) (Figure 3.8A 
right). The doc/doc mice had a significantly lower percentage of B cells compared 
to the other two groups (p<0.001) (Figure 3.8B left). The doc/+ mice had an 
intermediate decrease in percentage of B cell compared to wild type mice 
(p<0.05). The absolute numbers of B cell were analysed (Figure 3.8B right). 
There was no significant difference between the wild type and doc/+ mice, but the 
doc/doc homozygous mice had significantly less B cells compare to wild type 
(p<0.001) and the doc/+ mice (p<0.01). Although there was no significant 
difference regarding the T cell percentage (Figure 3.8B left), the doc/doc mice had 
less T cells compared to the other two groups (Figure 3.8B right).  CD4 and CD8 
T cells were also analysed individually (Figure 3.8C). The doc/doc mice had a 
significantly lower percentage of CD4 T cells (p<0.001) and significantly lower 
numbers of CD4 T cells compared to wild type and doc/+ mice (p<0.01). For 
CD8 T cells, doc/doc mice had a slightly lower number of CD8 T cells, but no 
difference in the percentage of CD8 T cells. It was also noted that doc/doc mice 
have higher percentage of CD44hi cells among CD4 and CD8 T cells compared 
with doc/+ and +/+ mice and the typical FACS plots are shown in Figure 3.7B. 
KLRG1 was used to measure T cell differentiation into activated effector cells. 
The doc/doc mice had a higher percentage of KLRG1hi cells and more 
KLRG1hiCD44hi cells among CD4 and CD8 T cells compared to the other two 
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groups (typical FACS plots were shown in Figure 3.7C; analysis were shown in 
Figure 3.8D). The percentage of subsets and surface marker expression between 
dockland heterozygous mice and wild-type mice were similar. 
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Figure 3.7 Splenic T cell subsets in dockland mice. (A) Representative 
flow cytometry plots of splenic cells from wild-type (+/+), heterozygous 
(doc/+) and homozygous dockland (doc/doc) mice showing division of B 
cell (B220+) and T cells (CD3+) and percentage of CD4 T cells (CD4+) and 
CD8 T cells (CD8+) gated on T cells (CD3+). (B) Representative 
histograms of CD44 expression on the CD4 and CD8 T cells, and % 
CD44hi cells. (C) Representative histograms of KLRG1 expression on the 
CD4 and CD8 T cells, and % KLRG1 positive cells. 
 
 
A 
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Figure 3.8 Analysis of lymphocyte subsets in the spleen. (A) Graph of 
percentage of lymphocytes (left) and absolute number of lymphocytes in 
spleen (right) of individual wild-type mice (white circles), heterozygous 
mice (half filled circles) and homozygous dockland mice (filled circles). (B) 
Graph of percentage of B and T cells (left) and absolute number of B and 
T cells in spleen. (C) Graph of percentage of CD4 and CD8 T cells (left) 
and absolute number of CD4 and CD8 T cells in spleen. (D) Graph of 
percentage of KLRG1hiCD44hi CD4 and CD8 T cells (left) and absolute 
number of KLRG1hiCD44hi CD4 and CD8 T cells in spleen. Dots represent 
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single mice and the bars represent the mean. Statistical analysis by one-
way ANOVA and post analysis by Bonferroni test.  
 
 
As shown in the previous section, doc/+ heterozygous mice did not show any 
phenotype except a possible decrease in the percentage of B cells which was not 
seen in additional experiments. The absolute numbers were calculated for 
different splenic T cell subsets of doc/doc and wild-type mice with 4 mice in each 
group as a repeated experiment. As shown in Figure 3.9, the doc/doc mice had 
significantly reduced total number of lymphocytes in spleen compare to wild-type 
mice. Compared to wild-type mice, there were 3.7-fold fewer CD4 T cells and 3.3 
fold fewer CD8 T cells in doc/doc animals (Figure 3.9B). The CD4 and CD8 T 
cell were further sub-divided by marker CD44. The doc/doc mice had comparable 
numbers of CD44hi (activated/effector) CD4 and CD8 T cells compared to +/+ 
mice (Figure 3.9C). However, there were dramatically reduced numbers of 
CD44lo (naïve) CD4 and CD8 T cells in doc/doc splenocytes, accounting for the 
overall decrease in T cell numbers.  
 
 
A 
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Figure 3.9 Quantitation of splenocyte subsets. (A) Number of 
lymphocytes per spleen in wild-type (+/+, white circles) and homozygous 
mutant mice (doc/doc, black circles). (B) Number of CD4 and CD8 T cells 
per spleen from wild-type (+/+, white circles) and homozygous mutants 
(doc/doc, black circles). (C) Number of naïve (CD44lo) and activated 
(CD44hi) CD4 and CD8 T cells in the spleen of wild-type (+/+, white 
circles) and homozygous mutant (doc/doc, black circles). Mean is shown 
as bar and statistical analysis by unpaired t-test. 
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3.6 Peripheral T cell defects in dockland mice 
 
Analysis of the four subsets of peripheral T cells was also performed in blood 
(Figure 3.10). The doc/doc homozygotes had a lower percentage of blood T cells 
compared to wild type (8% vs 34%). The CD4 and CD8 T cells were sub-divided 
by CD44. Expressed as a percentage of blood lymphocytes, the mean percentage 
of CD4+ CD44lo was decreased 10-fold and the mean percentage of CD8+ CD44lo 
naïve T cells was decreased 7-fold in doc/doc mice, and these differences were 
reproducible and statistically significant (Figure 3.10B). By contrast, there was a 
similar mean percentage of CD44hiCD4 T cells and significantly higher mean 
percentage of CD44hiCD8 T cells in doc/doc mice compared to wild type mice.  
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Figure 3.10 T cell subsets in peripheral blood. A. Representative flow 
cytometry plots of T subsets and representative histogram of CD44 
expression on CD4 and CD8 T cells in blood from Dock2 wild type (+/+), 
heterozygous (doc/+) and homozygous (doc/doc) mice. B. Quantitation of 
naïve (CD44lo) and activated (CD44hi) CD4 and CD8 T cells in blood in 
wild type (white circles), heterozygous (doc/+) and doc/doc homozygotes 
(black circles). Mean is shown as bar and statistical analysis by two-way 
ANOVA and Bonferroni post-test.  
 
 
TCR-induced division of mutant and wild-type T cells was compared. CD44lo 
naïve T cells were sorted from the spleen of CD45.1 +/+ mice and from CD45.2 
+/+ or doc/doc mice, and the CD45.1 and CD45.2 T cells were mixed at a 50:50 
ratio, labelled with CFSE, co-cultured with 1ng/ml αCD3 antibody, and analysed 
for dilution of CFSE 3 days later. As shown in Figure 3.11, the unstimulated 
control had a single peak with no dilution of CFSE. In response to CD3 
stimulation, CD45.2 doc/doc and +/+ naïve CD4 and CD8 T cells diluted CFSE 
comparably to their co-cultured CD45.1 +/+ internal control T cells. Therefore 
there was no apparent disadvantage of TCR-induced cell division caused by the 
Dock2 mutation.  
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Figure 3.11 In vitro proliferation of wild type and Dock2doc/doc T cells. 
CD45.1 wild type and CD45.2 wild type or doc/doc naïve T cells were 
sorted from spleen and mixed in 50:50 ratio. They were CFSE labeled and 
stimulated with 1ng/ml of αCD3. Histograms show CFSE fluorescence 
after 3 days stimulation in CD45.1 wild type internal control T cells (blue 
histograms) superimposed on CFSE in co-cultured CD45.2 +/+ T cells 
(green histograms) or CD45.2 doc/doc T cells (red histograms) T cells, 
and CFSE fluorescence in unstimulated cells (shaded grey histogram). 
This experiment was performed twice.  
 
 
3.7 DOCK2 deficiency in thymus 
 
Thymocytes were analysed to investigate if the T lymphopenia in dockland 
homozygous mice was caused by a development deficiency in the thymus, as 
opposed to a survival or migration defect in the periphery. As shown in Figure 
3.12A, the proportion of T cell subsets in DN, DP, CD4SP and CD8SP stages in 
doc/doc mice were comparable to wild type mice. The DN stage could be further 
divided by CD44 and CD25 into DN1, DN2, DN3 and DN4. The doc/doc mice 
had a lower percentage of cells in DN1 stage and higher percentage of cells in 
DN4 stage. The absolute number for each subset was also calculated (Figure 
3.12B). The number of doc/doc thymocytes was reduced to 50% of the numbers 
in wild type mice. The doc/doc mice also had significantly less DP cells but there 
was no difference between doc/doc and wild type mice in DN cells. The number 
of CD4 SP cells in the thymus was also decreased in doc/doc mice (p<0.05). 
However, the mutation did not affect the number of CD8 SP cells. The surface 
expression of CD5 was also measured since its induction reports the strength of 
pre-TCR signaling in DP T cells and TCR signaling in SP T cells (Azzam et al, 
1998) (Figure 3.12C). The expression of CD5 was significantly lower on doc/doc 
mice in DP stage which suggested a lower signaling strength on doc/doc mice (DP 
stage) (Figure 3.12E) but there was no difference in the expression of CD5 
between doc/doc mice and wild type mice on CD4 and CD8 SP thymocytes. 
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CD69 is an activation marker that marks thymocytes undergoing positive or 
negative selection or having just been positively selected (Yamashita et al., 1993). 
In Figure 3.12C, the doc/doc mice had normal CD69 expression on DP stage 
thymocytes but proportionally more CD69-negative cells among CD4 SP and 
CD8 SP.  CD69 downregulates surface expression of the S1P1 receptor, a G-
protein-coupled receptor (GPCR) (Shiow et al., 2006; Alfonso et al., 2006; 
Bankovich et al., 2010) and the latter is expressed on fully mature thymocytes and 
required for thymocyte egress to the blood (Allende et al., 2004). The percentage 
of CD69- CD4 and CD8 SP cells are both significantly higher than wild-type 
controls (Figure 3.12D left). Since the overall number of DP and SP cells per 
thymus is diminished, while the number of CD69lo SP cells is not diminished 
(Figure 3.12D right), this implies that the doc/doc SP cells accumulate at the 
CD69lo stage consistent with a defect in thymus egress. Collectively, these results 
indicate that the dockland mutation cause peripheral T cell lymphopenia at least 
partly because of decreased T cell formation and export from the thymus.  
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Figure 3.12 Thymic T cell subsets in dockland mice. (A) 
Representative flow cytometry plots of thymocytes from wildtype (+/+) and 
mutant (doc/doc) mice, showing expression of CD4 and CD8 and the 
percentage of DN (CD4-CD8-), DP (CD4+CD8+), CD4 SP (CD4+CD8-) and 
CD8 SP (CD4-CD8+) cells. (B) Quantitation of thymocyte subsets in Dock2 
wild-type (white circles) and doc/doc (black circles) C57BL/6J mice. Bar is 
shown as mean. Statistical analysis by unpaired t-test. This experiment 
was repeated twice with at least 3 mice in a group. C) Representative 
overlay histograms of CD5 or CD69 expression on the thymic cell subsets 
listed on Dock2 wild-type (grey shaded) and doc/doc (red line) mice. D) 
Percentage of CD69 negative cells of CD4 and CD8 single positive cells 
(left) and quantitation of CD69 negative CD4 and CD8 single positive cells 
for Dock2 wild-type (white circles) and doc/doc (black circles) C57BL/6J 
mice. Bar is shown as mean. Statistical analysis by unpaired t-test. E) 
CD5 mean fluorescence intensity (MFI) values for Dock2 wild-type (white 
circles) and doc/doc (black circles) C57BL/6J mice. Statistical analysis by 
unpaired t-test.  
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3.8 B cell defects in dockland mice 
 
B-cell development occurs primarily in fetal liver and transfers to bone marrow 
after birth. Originating from a common lymphoid progenitor (CLP), B cell 
differentiation progresses through pro-B, pre-B and immature B stages based on 
the different expression of B cell antigen receptor subunits. Hardy et al. identified 
pro-B cells by cell surface expression of B220, CD43 and c-kit. Four fractions of 
pro-B cells can be further distinguished by differential expression of heat-stable 
antigen (HSA) and BP-1 (Hardy, R. et al., 1991). DNA rearrangement begins at 
this stage in the immunoglobulin heavy chain locus to bring individual DH and JH 
gene segments together. VH-DHJH rearrangement completes the heavy chain gene 
to express IgM heavy chains in the endoplasmic reticulum of large pre-B cells 
(Abbas and Lichtman, 2003). Once light chain rearrangement completes 
successfully, the cell expresses a unique IgM antigen receptor on its surface as an 
immature B cell (Abbas and Lichtman, 2003). Immature B cells leave the bone 
morrow and continue their development into mature B cells in the periphery 
(Loder, F. et al., 1999). 
 
B cell subsets in bone marrow of dockland mice were assessed by flow cytometry 
and divided into three stages based on their expression of IgD and IgM: Pre and 
pro B cells (B220+ IgD-IgM-), immature B cells (B220+ IgDloIgMhi) and mature B 
cells (B220+ IgDhiIgMint). As shown in Figure 3.13A, doc/doc mice had a lower 
percentage of B220+ B cells compared to +/+ mice. From the bottom panel of 
Figure 3.13A, doc/doc mice had a higher proportion of pre and pro B cells 
(IgDloIgMlo) (64%) compared to +/+ mice (54%). This might due to the reduction 
of circulating mature B cells (IgDhiIgMint) in doc/doc mice (6%) compared to +/+ 
mice (22%). Percentage of B cell was lower in mice with significant less B cells 
in doc/doc mice (Figure 3.13 B) When the percentage and absolute number of 
bone marrow B lineage subsets was calculated, there was lower percentage of 
mature B cells in the bone marrow between homozygous mutant and wildtype 
mice (Figure 3.13B). All the absolute cells numbers at pre/pro, immature, mature 
B stages were significant decreased in mutant mice (Figure 3.13B). 
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Figure 3.13 Bone marrow B cell subsets in dockland mice. (A) 
Representative flow cytometry plots of bone marrow lymphocytes showing 
the gating strategy to detect the various subsets of bone marrow B-lineage 
cells (B220+): pre and pro B cells (IgDloIgMlo), immature B cells (IgDloIgMhi) 
and mature B cells (IgDhiIgMint). (B) Quantification of cells of the subsets 
defined in A. Statistical analysis by unpaired t-test and this experiment 
was repeated twice. 
 
 
Analysis of subsets of peripheral B cells with wild type, doc/+ and doc/doc mice 
in the blood is shown in Figure 3.14A. The dockland homozygotes had 
significantly higher percentage of B220+ B cells, which might be secondary to the 
reduction of T cell subsets shown above (Figure 3.14B left). The surface IgM and 
IgD expression was also examined on B cells in these three groups of mice 
(Figure 3.14B right). Among B220+ cells in blood, the percentage of IgDhi mature 
B2-type B cells was significantly lower in doc/doc mice than in heterozygous or 
wild-type controls, whereas IgDloIgMhi transitional B cells were significantly 
higher in doc/doc mice. There was no difference observed between dockland 
heterozygous mice and wild type mice.    
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Figure 3.14 B cell subsets in the blood of dockland mice. (A) 
Representative flow cytometry plots of doc/doc, doc/+ and +/+ mice 
showing expression of IgD and IgM on B220+ cells in the blood, and the 
percentage of B cells falling with the indicated gates representing mature 
B2-type B cells (IgDhi), transitional B cells (IgDlow IgMhigh) and switched 
memory B cells (IgD- IgM-). (B) Left panel: percentage of B cells in blood 
lymphocytes from wild type (white circles), heterozygous (doc/+) and 
doc/doc homozygotes (black circles). Right panel: percentage of B2 B 
cells, transitional B cells, and memory B cells among total B220+ B cells. 
Mean is shown as bar and statistical analysis by two-way ANOVA and 
Bonferroni post-test. 
 
 
3.9 B subsets in spleen 
 
After development in bone marrow, newly formed immature B cells emigrate 
initially to the spleen. In spleen, they go through transitional stages and mature 
into follicular B cells and marginal zone B cells (Vitetta, E.S. et al., 1975; 
Allman, D.M. et al., 1992; Oliver, A.M. et al., 1997; Cariappa, A. et al., 2007).   
 
The marginal zone B cell subset is a unique population of B cells located in the 
marginal zone at the border of white and red pulp in the spleen, where blood 
percolates slowly through the marginal sinus. The marginal zone offers an ideal 
environment for the resident cells to encounter blood-borne microbes and 
antigens. Therefore, marginal zone B cells are critical for host immunity in early 
defense of blood–borne bacterial pathogens. Marginal zone B cells can be 
distinguished from follicular B cells by slightly larger cell volume, higher 
expression of CD21, CD1d, CD38, CD9 and CD25. They also express high level 
of IgM and very low levels of CD23 and IgD (Pillai et al., 2005). The exact 
developmental mechanisms of marginal zone B cell are still waiting to be 
elucidated. However, Notch2 and NF-kB1 seem to play indispensable roles 
(Lopes-Carvalho and Kearney, 2004; Pillai et al., 2005).  
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Flow cytometric analysis of splenic B cell subsets in dockland mice was based on 
the Allman classification (Allman and Pillai, 2008). The marker CD93 was used 
to separate immature B cells (CD93+B220+) from mature B cells (CD93-B220+). 
The immature B cells were further divided into T1 (IgMhiCD23lo), T2 
(IgMhiCD23hi), and T3 (IgMloCD23hi). The mature B cells were further divided 
into follicular cells (CD21int IgMint) and marginal zone B cells (CD21hiIgMhi) 
which can be subdivided into marginal zone cells (CD23loB220+) and marginal 
zone precursor (MZP) cells (CD23hiB220+) by using the marker CD23. 
 
Representative plots from a doc/doc homozygous mouse (16NIH19a:G3#22) 
compared with a wild-type littermate (16NIH19a:G3#23) are shown in Figure 
3.15. Although doc/doc mice had a lower percentage of B220+CD19+ cells 
compared to wild-type littermates, there was no difference in the surface marker 
expression of T1, T2 or T3 B cell subsets. In the mature B cells, there was no 
difference in the marker of follicular or marginal zone precursors. However, there 
were significantly fewer marginal zone B cells in doc/doc mice.  
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Figure 3.15 Splenic B cell subsets in dockland mice. A. Representative 
flow cytometry plots of B220+CD19+ splenocytes, subgated as CD93+ and 
CD93-. CD93+ cells were subsequently subgated into T1 (IgMhiCD23lo), T2 
(IgMhiCD23hi), and T3 (IgMloCD23hi) subsets. The CD93- B cells were 
further divided into follicular cells (CD21int IgMint) and marginal zone B cells 
(CD21hiIgMhi) which can be subdivided into marginal zone cells 
(CD23loB220+) and marginal zone precursor (MZP) cells (CD23hiB220+) by 
using the marker CD23 for Dock2 +/+ wildtype (upper panel) and doc/doc 
(lower panel) mice  
 
 
When the absolute number of each splenic B cell subset was calculated in 
multiple animals of each genotype (Figure 3.16), doc/doc mice had a significantly 
lower B cell number per spleen compared to wild-type mice, with a 3.7-fold 
reduction in mean B cell number. Upon further subdivision, doc/doc mice had 
significantly less cells in T1, T2 and T3 subsets (T1: decreased 3.4-fold, 
p=0.0003; T2 decreased 6.3-fold, and T3 decreased 6-fold, p<0.0001).  Compared 
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to wild-type mice, doc/doc animals also had 5-fold fewer mean number of 
follicular B cells (p<0.0001) and 59-fold fewer marginal zone B cells (p=0.001). 
 
 
 
 
 
Figure 3.16 Absolute number of B cell subsets in spleen of individual 
dockland mice and wild-type controls. Absolute number of total B cells, 
T1-3 transitional, follicular and marginal zone B cells for Dock2 wild type 
(white circles) and homozygous mutant (doc/doc, black circles) mice. 
Statistical analysis by unpaired t-test.  
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3.10 Analysis of mixed bone marrow chimeras 
 
The results above were performed in animals with mutant DOCK2 in all cells and 
tissues. To establish which of these traits were due to DOCK2 deficiency within 
haematopoietic cell subsets, and to understand the behavior of Dock2doc/doc cells in 
a competitive environment alongside blood cells with wild type DOCK2, 50:50 
mixed bone marrow chimeras were set up by transplanting mixtures of CD45.1 
+/+ and CD45.2 +/+ or doc/doc bone marrow cells. The bone marrow cell 
mixtures were injected into irradiated CD45.1 B6 recipient mice and allowed 8 
weeks for engraftment and reconstitution before they were bled, and mixed 
chimeras were sacrificed for spleen cell analysis at week 10 after marrow 
transplant (Figure 3.18A).  
 
The irradiated recipients were bled after 8 weeks of reconstitution. Mice that 
received a mix of 50% wild type CD45.1 and 50% doc/doc CD45.2 bone marrow 
showed less CD45.2 peripheral B cells ranging between 7% to 40% in individual 
chimeric animals (numbered 1 through 10) (Figure 3.17A). For control mice 
reconstituted with 50% CD45.2 wild-type bone marrow, CD45.2 cells accounted 
for 30%-60% of total B cells (numbered 11 through 20). Less than 1% of T cells 
came from CD45.2 doc/doc bone marrow cells in recipient mice reconstituted 
with 50% wild type CD45.1 and 50% doc/doc CD45.2 bone marrow, whereas 20-
40% of T cells were CD45.2 derived in control chimeras where the CD45.2 
marrow has wild-type DOCK2. Blood granulocytes were also analysed to provide 
a measure for the composition of their hematopoietic stem cell precursors, since 
granulocyte lifespan is short and their composition is not distorted by the 
processes of proliferation in the thymus or secondary lymphoid tissues that affect 
T and B cells. The mean percentage of CD45.2 cells among granulocytes did not 
differ significantly between recipients of CD45.2 wild-type or doc/doc marrow 
(Figure 3.17B), establishing that the doc/doc marrow engrafted comparably to 
wild-type marrow. 
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Figure 3.17 Analysis of peripheral blood from mixed bone marrow 
chimeras. A) Each column shows data for a single, numbered chimeric 
animal 8 weeks after irradiation and transplantation with a mixture of 
CD45.1 +/+ marrow and CD45.2 doc/doc or +/+ marrow. For each 
chimeric animal, the bar shows the percentage of CD45.2 doc/doc or 
CD45.2 +/+ cells within the B or T cell subsets. B) Each column shows 
data for a single, numbered chimeric animal 8 weeks after irradiation and 
transplantation with a mixture of CD45.1 +/+ marrow and CD45.2 doc/doc 
or +/+ marrow. For each chimeric animal, the bar shows the percentage of 
CD45.2 doc/doc or CD45.2 +/+ cells within the granulocyte subset (top). 
Relative percentage of CD45.2 wild type (+/+, white circles) and dockland 
(doc/doc, black circles) granulocytes in the recipient mice (bottom). Dots 
represent single mice and the bars represent the mean (statistical analysis 
by unpaired t-test). 
 
Analysis of the spleen in each chimera is shown in Figure 3.18B. Less than 2% of 
CD4 or CD8 T cells were derived from the CD45.2 doc/doc donor, in contrast to 
30% CD45.2 +/+ in control mixed chimeras (Figure 3.18B right panel). Naïve 
(CD44lo) and activated (CD44hi) CD4 and CD8 T cells were also analysed based 
on the expression of CD44 marker in Figure 3.18C. There were less than 1% of T 
cells in each of these subsets derived from the CD45.2 doc/doc bone marrow 
cells.  
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It was noticed that there were less than the expected mean of 50% CD45.2 +/+ 
cells in the T cell subset of the control mixed chimeras after 8 weeks’ 
reconstitution. The likely reason for this is that memory T cells are known to be 
radioresistant and hence recipient-derived CD45.1+ memory T cells proliferate in 
response to lymphopenia during the reconstitution phase after irradiation and add 
to the CD45.1+ population derived from the donor marrow. For more accurate 
results, RAG1 deficient mice could be used as recipients. The effect of recipient T 
cell reconstitution was nevertheless controlled for in the experiments here by 
comparing the frequency of CD45.2+ donor derived T cells in control chimeras, 
where the CD45.2+ cells had wildtype Dock2, and test chimeras where the 
CD45.2+ cells had mutant Dock2. By this comparison, it was clear that the Dock2 
mutation acts cell autonomously in T cells to diminish either their production by 
the thymus or their accumulation in the periphery. To answer this question, 
thymus of in each chimera were analysed (Figure 3.19) The CD45.2+ doc/doc 
bone marrow cells only constituted less than 20% of total DN cells. The 
percentage was further reduced in DP stages and more mature CD4 and CD8 SP 
stages. It suggests that the mutant T cells were outcompeted at the DP stage. 
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Figure 3.18 Bone marrow chimeras reveal profound T cell deficiency 
caused by dockland mutation during competitive repopulation. A) 
Schematic of 50:50 bone marrow chimera experiments. Bone marrow cells 
from CD45.1 WT and CD45.2 doc/doc or +/+ (WT) cells were injected into 
irradiated CD45.1 B6 recipient mice and the recipients were taken down 
after 10 weeks for spleen cell analysis. B) Each column corresponds to a 
single, numbered chimeric animal and shows the percentage of CD45.2 
doc/doc or +/+ cells within the B, CD4 or CD8 T cell subsets (upper panel) 
and within the naïve (CD44lo) and activated (CD44hi) CD4 and CD8 T cell 
subsets (lower panel). 
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Figure 3.19 Bone marrow chimeras reveal profound T cell deficiency 
caused by dockland mutation under competitive environment. Each 
column corresponds to a single, numbered chimeric animal and shows the 
percentage of CD45.2 doc/doc or +/+ cells DN DP stages (upper panel), 
DN1-DN4 stages (middle panel) and CD4 and CD8 single positive stages 
(lower panel). 
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To investigate whether the reduction in B cell subsets in the spleen observed in 
Fig 3.8 was due to an intrinsic defect in the B cells, spleen cells from the same 
50:50 mixed bone marrow chimeras were analysed. As shown in Figure 3.18B, 
30-40% of splenic B cells (B220+) were derived from CD45.2+ cells with wild-
type Dock2 in the control chimeras. However, CD45.2 doc/doc bone marrow cells 
only constituted 2-6% of splenic B cells in each of the test chimeras. As shown in 
Figure 3.20, there were 3-10% CD45.2 doc/doc cells in T1; 1-3% in T2 and 1-5 in 
T3 stage compared to 20-80% of CD45.2 +/+ cells in T1, 20-65% in T2 and 20-
65% in T3 stage in control chimeras. There was 2-7% of follicular B cells were 
contributed by doc/doc bone marrow cells compared to 35-50% came from 
CD45.2 +/+ in control group. There were even fewer (0.17-0.33%) CD45.2 
doc/doc cells within the marginal zone B cell subset. From the data showing here, 
it seems clear that doc/doc cells have a development disadvantage in a 
competitive environment. But because of the absence of a reference cell 
population unaffected by the mutation in Dock2, it is impossible to demonstrate 
the expected percentage of CD45.2 +/+ cells in each population and to perform a 
statistical test against the reference populations. 
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Figure 3.20 Bone marrow chimeras reveal B cell deficiency under 
competitive environment. Each column indicates the percentage of 
CD45.2 doc/doc or +/+ T1-3 transitional B cells (upper panel) and follicular 
and marginal zone B cells (lower panel) in an individual, numbered 
chimeric mouse after 10 weeks reconstitution. 
 
 
To investigate if dockland mutant B cells have normal T cell-dependent antibody 
response, germinal centre reactions were also studied in the 50:50 mix bone 
marrow chimeras. Germinal centres (GC) develop within B cell follicles when B 
cells are activated by T follicular helper cells (MacLennan, 1994). The germinal 
centre B cells could be detected by flow cytometry as having high expression of 
the markers of GL7 and CD95 (Han et al., 1997). The reconstituted chimeric mice 
were immunized with sheep red blood cells (SRBCs), which elicits a rapid and 
reproducible germinal response.  
 
The bone marrow chimeras were allowed to reconstitute for 8 weeks and were 
then immunized with SRBC and spleen cells analysed 7 or 10 days later. The 
contribution of CD45.2 doc/doc or +/+ cells to GC B cells 10 days after 
immunization is shown in Figure 3.21A. The immunization resulted in a clear 
population of GC B cells in each recipient mouse. Analysis of GC B cells (Figure 
3.21B) revealed a mean of only 0.18% of GC cells at day 7 and 0.63 % of GC 
cells at day 10 were derived from CD45.2 doc/doc bone marrow. By comparison, 
in the wild-type control mixed chimeras, there was a mean of 23.2% (day 7) and 
17.6% (day 10) of GC B cells derived from CD45.2 wild-type bone marrow. As 
CD45.2 doc/doc B cells have much lower overall frequency, their relative 
capacity to make GC cells was examined by measuring the percentage of GC cells 
among the CD45.2+ B cells in the spleen of each immunized chimera (Figure 
3.21C). There was a small but significantly lower mean of 1.6% GC cells among 
CD45.2 doc/doc B cells compared with a mean of 3.4% GC cells among CD45.2 
+/+ B cells on day 7. This apparent difference between CD45.2 +/+ and doc/doc 
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B cells in forming GC cells was not observed 10 days of immunization (Figure 
3.21C right). More experiments (possibly in mice receiving 80% doc/doc BM 
cells) to increase the frequency of mutant GC B cells would be required.  
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Figure 3.21 Effect of the dockland mutation on formation of germinal 
centre B cells after immunization of mixed chimeras with sheep red 
blood cells (SRBC). (A) Representative flow cytometry plots from three 
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mixed bone marrow chimeras receiving CD45.1 wild type (+/+) and 
CD45.2 doc/doc bone marrow (upper panel) and from three control 
chimeras reconstituted with CD45.1 wild type (+/+) and CD45.2 wild type 
(+/+) marrow (lower panel).  Plots are gated on splenic B220+ CD45.1+ or 
CD45.2+ cells 7 days after immunization with sheep red blood cells, and 
numbers show the % of gated cells that are Fas+ GL7+ germinal centre B 
cells. (B) Relative percentage of CD45.2 wild type (+/+, white circles) and 
dockland (doc/doc, black circles) cells among all splenic B cells and 
among germinal centre B cells 7 days after immunization with sheep red 
blood cells (upper panel) and 10 days after immunization (lower panel) 
with mean shown for doc/doc mice. (C) Percentage of GL7+ Fashi GC 
cells among all CD45.2+ B cells 7 or 10 days after immunization of 
chimeras transplanted with CD45.2 wild type (+/+, white circles) or CD45.2 
dockland (doc/doc, black circles) marrow. Dots represent single mice, and 
bars are arithmetic means. Statistical analysis by t-test. 
 
 
3.11 NKT cells in the dockland mice 
 
NKT cells were first described in 1995 as a subset of T cells expressing the 
NK1.1 marker (in mouse) and share some characteristics with natural killer (NK) 
cells (Makino, Y. et al., 1995). Type I NKT cells, or invariant NKT (iNKT) cells, 
are characterized by the expression of a particular TCR alpha chain formed by a 
canonical rearrangement of the Va14 gene segment to the Ja18 gene segment in 
mice (Matsuda et al., 2008). NKT cells recognize glycolipids such as alpha-
galactosylceramide (aGalCer) presented by the MHC class-I like molecule CD1d 
and are selected at the DP thymocyte stage by CD1d-expressing DP cells. 
 
Splenic iNK T cells in the dockland mice were analysed by staining with CD1d 
tetramers (Figure 3.22). There were fewer tetramer binding (CD1d+) CD3+ cells in 
the spleen of doc/doc mice expressed as a percentage of total lymphocytes (Figure 
3.22A). The absolute number of iNKT cells in spleen was also calculated. As 
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shown in Figure 3.22B, the doc/doc mice had significantly less iNKT cells 
compared to doc/+ (p=0.003) and +/+ (p<0.0001), whereas there was no 
difference between doc/+ and +/+ mice.  
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Figure 3.22 Analysis of NKT cells in the spleen. A. Representative flow 
cytometry plot of spleen from wild type (+/+) and dockland (doc/doc) mice, 
stained with fluorescent CD1d-aGalCer tetramers and antibody to CD3. B. 
Quantitation of spleen NKT cells in Dock2 wild type (white circles) and 
homozygous doc/doc mutant (black circles) as percentage of the 
lymphocyte gate and as absolute numbers. Mean is shown in bar and 
statistical analysis by two-way ANOVA and followed by Bonferroni post-
test. This experiment has been repeated twice.  
 
To understand if the decreased numbers of splenic NKT cells in doc/doc mice was 
due to developmental deficiency or a defect in migration/survival, thymic NKT 
cells were also analysed (Figure 3.23). There were fewer CD1d+ CD3+ cells 
present in the thymus of doc/doc mice expressed as a percentage of lymphocytes 
(Figure 3.23A), and their absolute number was decreased 10-fold compared to 
wild type mice (p=0.0005) (Figure 3.23B). 
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Figure 3.23: Analysis of NKT cells in the thymus. A. Representative 
flow cytometry plot of thymic NKT cells from wild type (+/+) and dockland 
(doc/doc) mice. B. Quantitation of thymic NKT cells in wild type (white) and 
doc/doc (black circles) as absolute numbers per thymus. Mean is shown in 
bar and statistical analysis by unpaired t-test. This experiment has been 
repeated twice.  
 
 
3.12 Comparison of influenza CD8 T cells response in DOCK2 deficient and 
DOCK8 deficient mice 
 
Previously, Katrina Randall discovered a novel mutation in mouse Dock8 gene 
named primurus. DOCK8 is also a member of DOCK family proteins and in 
DOCK-C subgroup (Fig. 3.5). DOCK8 is guanine nucleotide exchange factor  
(GEF) for Cdc42 and involved in the cytoskeletal rearrangements (Harada et al., 
2012 and Côté et al., 2007). The Dock8pri/pri mutation is a T-to-C substitution that 
changed codon 1827 from a highly conserved serine residue to a proline residue in 
its DHR2 domain (Randall et al., 2009). Dock8pri/pri B cells were unable to form 
marginal zone B cells or to persist in germinal centers and undergo affinity 
maturation. The Dock8pri/pri mice also have a cell autonomous reduction in 
peripheral naive T cells. The study of Dock8 in mouse is complemented by the 
independent discovery of DOCK8 mutations associated with immunodeficiency 
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in human. DOCK8 deficient patients have various viral infections and allergic 
diseases due to defects of different lymphocyte populations (Zhang et al., 2009).  
 
DOCK2 and DOCK8 deficiency appear to have similar effects, causing a lack of 
marginal zone B cells and T lymphopenia. To study if DOCK2 and DOCK8 play 
a similar role in the survival of memory CD8 T cells in a polyclonal repertoire, 
groups of mutant or control mice were challenged with influenza virus to measure 
the primary and secondary immune response. Dock2doc/doc, Dock8pri/pri and wild 
type C57BL/6 mice were intra-peritoneally challenged first with a modified H3N2 
influenza A virus expressing SIINFEKL (HKx31-SIINFEKL) followed by a 
secondary challenge with a serologically non-crossreactive H1N1 strain of 
influenza A virus expressing the same nucleoprotein (NP) and SIINFEKL (PR8-
SIINFEKL). The percentage of antigen-specific CD8 T cells that bound H2-Db 
MHC tetramers bearing the dominant influenza NP peptide epitope, NP366-374 
(NP+), among blood lymphocytes was analysed over time points representing 
different stages of the antigen-specific immune response: expansion, contraction 
and recall response. Two independent experiments were performed with different 
time lengths between primary and secondary challenge (Expt 1, Figure 3.24; Expt 
2, Figure 3.25). NP-tetramer binding CD8 cells were enumerated both as a 
percentage of all lymphocytes, and as a percentage of CD8 cells to normalize for 
the decreased overall numbers of CD8 T cells in doc/doc mice.  
 
At day 7 post primary challenge with HKx31, NP+ CD8 T cells had undergone 
clonal expansion to comprise a mean of 1.9% in total lymphocytes of wild type 
mice. The Dock2doc/doc mice had 0.35% NP positive cells, which was significantly 
lower than +/+ in both experiments but higher than naïve mice which had 0.13% 
NP positive cells representing the background level of tetramer staining. 
Dock8pri/pri mice also had fewer NP positive CD8 cells, comprising 0.46% of total 
lymphocytes. A similar day 7 result was observed in the 2nd experiment. 
 
After 35 days, NP positive CD8 T cells from mice in all groups dropped to just 
above the background level in naïve controls (Figure 3.24). To trigger a recall 
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proliferation of memory CD8 T cells, all experimental mice were re-challenged on 
day 42 with PR8 virus, which expresses the same NP antigen but a serologically 
distinct haemagglutinin and neuraminidase surface proteins to avoid neutralization 
by antibody against the first influenza exposure. All groups receiving the 2nd 
challenge elicited a recall NP positive CD8 T cell response. In wild type mice, NP 
positive CD8 T cells represented a mean of 4% of lymphocytes while both 
Dock2doc/doc (0.97%) and Dock8pri/pri (1.6%) mice had a significantly lower mean 
percentage of NP positive CD8 T cells of lymphocytes after secondary challenge 
(p<0.0001 and p<0.01 respectively). 35 days post secondary challenge, wild type 
and Dock2doc/doc mice had similar frequencies of NP positive CD8 T cells among 
blood lymphocytes while Dock8pri/pri mice had fewer (p<0.05) consistent with 
earlier evidence that DOCK8 is required for memory CD8 cells to persist (Randall 
et al. 2011). 
 
 
A 
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Figure 3.24 Frequency of influenza-specific CD8 T cells in wild type 
(Dock2+/+ and Dock8+/+), Dock2doc/doc and Dock8pri/pri C57BL/6 mice. 
Mice with the indicated genotypes were injected intraperitoneally with 
HKx31 influenza A virus at day 0, and boosted with PR8 influenza A virus 
on Day 42. An unchallenged group of wild type mice were also included as 
a naïve control. A) Frequency of NP tetramer positive CD8 T cells as a 
percentage of all CD8 T cells in blood at the indicated time points. B) The 
frequency of NP tetramer positive CD8 T cells as a percentage of total 
blood lymphocytes. 4 wild type mice, 3 Dock2doc/doc mice, 4 Dock8pri/pri 
mice and 4 naïve control mice were used in this experiment. Statistical 
analysis by two-way ANOVA (post-test by Bonferroni-test) showed a 
significant difference between challenged wild type +/+ and Dock8pri/pri NP-
binding cells as a percentage of CD8 T cell at Day 84 (p<0.05); between 
+/+ and Dock2doc/doc NP positive CD8 T cells as total lymphocytes at Day 
49 (p<0.001); and between +/+ and Dock8pri/pri NP positive CD8 T cells as 
percentage of total lymphocytes at Day 49 (p<0.01) and Day 84 (p<0.05). 
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The experiment shown above was repeated with increased time length before 
secondary challenge to reveal the behavior of true memory CD8 T cells. As 
shown in Figure 3.25, all challenge mice were kept until day 172 for generating 
memory CD8 T cells. Seven days after secondary challenge on day 179, wild type 
mice had significantly greater memory response (mean 6% of NP positive CD8 
cells among lymphocytes). Dock2doc/doc (mean 1.2%) and Dock8pri/pri (mean 1.1%) 
mice exhibited a recall NP positive CD8 T cell response that was significantly less 
than wild type mice (p<0.001).  
 
A 
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Figure 3.25 Frequency of influenza-specific CD8 T cells in wild type 
(Dock2+/+ and Dock8+/+), Dock2doc/doc and Dock8pri/pri C57BL/6 mice. 
Survival of polyclonal CD8 T cells in C57BL/6 (Dock2+/+ and Dock8+/+), 
Dock2doc/doc and Dock8pri/pri mice (long term). Wild type Dock2doc/doc and 
Dock8pri/pri mice were first challenge intraperitoneally with HKx31 at day 0, 
and rechallenged on Day 179 with PR8. An unchallenged group of 
C57BL/6 mice were also included as naïve control. A) Frequency of NP 
tetramer positive CD8 T cells at various time points as a percentage of 
CD8 T cells in blood. B) The frequency of NP tetramer positive CD8 T 
cells at various time points as a percentage of total lymphocytes in the 
blood. 4 wild type mice, 4 Dock2doc/doc mice, 4 Dock8pri/pri mice and 4 naïve 
control mice were used in this experiment. Statistical analysis: two-way 
ANOVA and Bonferroni post-test were performed and statistical analysis 
showed significant difference between wild type and Dock8pri/pri NP 
positive CD8 T cell as a percentage of CD8 T cell and total lymphocytes at 
Day 186 (p<0.001). The statistical analysis showed significant difference 
between wild type and Dock2doc/doc NP positive CD8 T cells as a 
percentage of CD8 T cells and total lymphocytes at Day 186 (p<0.001).  
 
 
3.13 Comparison of influenza lung infection in DOCK2 deficient and DOCK8 
deficient mice 
 
DOCK2 was shown to be indispensable for TLR7 and TLR9 mediated IFN-α 
induction in plasmacytoid dendritic cells (pDCs) (Gotoh et al, 2010). To examine 
the effect of the dockland mutation on the response to influenza infection in the 
lung, which is dominated by innate immunity in the first 5 days, C57BL/6 
dockland heterozygous and homozygous mice and wild-type controls were 
challenged intra-nasally with 0.01 HAU of PR8 influenza virus. The body weight 
of each mouse was recorded before the infection, and the percentage of starting 
body weight measured and calculated each day after infection. Mice were 
ethically culled if they lost >30% of original body weight.  From Figure 3.26, 
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body weight of all mice started to drop 3 days post infection and continue to 
reduce until day 9, with trend for greater weight loss in the Dock2 +/+ and doc/+ 
mice compared to doc/doc. Fewer doc/doc animals had to be ethically culled (4 
doc/doc mice survived compared to 2 doc/+ mice and 1 C57BL6 mice). Further 
analysis performed on day 6 before any mouse was culled indicated that there was 
no significant effect of genotype on the survival of mice.  
 
 
 
 
Figure 3.26 Weight loss of dockland mice after intra-nasally injected 
with flu virus. 5 doc/doc (red), 5 doc/+ (blue) and 5 C57BL6.JAX (white) 
mice were intra-nasally injected with 0.01 HAU PR8 virus and body weight 
for each mouse recorded each day and shown here as % of starting 
weight on Day 0.  
 
 
The experiment was repeated with addition of DOCK8 primurus mutant mice. 
The 5 groups of mice were: doc/doc, doc/+, +/+, pri/pri and C57BL6 mice. As 
shown in Figure 3.27, the results of each group were variable and both dockland 
and primurus mice didn’t show survival disadvantage with flu challenge. 
Combining the results of the two experiments (Table 3.2), a total of 8/10 doc/doc, 
2/10 doc/+, and 2/10 C57BL/6 survived without requiring to be ethically culled. 
	 90	
The survival of these 3 groups were analysed by chi-squared test yielding a p 
value = 0.007, strongly suggesting that the DOCK2 doc mutation had a protective 
effect on morbidity following influenza lung infection. 
 
 
 
Figure 3.27 Weight loss of dockland and primurus mice after intra-
nasally injected with flu virus. 5 doc/doc (red), 5 doc/+ (blue) 5 +/+ 
(black), 5 pri/pri (green) and 5 C57BL6.JAX (white) mice were intra-nasally 
injected with 0.02 HAU PR8 virus and the loss of body weight were 
calculated.  
 
 
 C57BL/6 doc/+ doc/doc 
Ethically culled 8 8 2 
Healthy 2 2 8 
 
Table 3.2 Combined morbidity data from two individual influenza 
lung infection experiments. There are a total of 10 mice in each group.  
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3.14 Effects of combined DOCK2 and DOCK8 deficiency 
 
To understand whether or not Dock2 and Dock8 serve overlapping roles in the 
immune system, the C57BL/6 dockland and primurus strains were intercrossed to 
generate double homozygous mice. As shown in Figure 3.28A, the double 
homozygous mice had lower T cells proportion and higher CD44 expression 
compared to either Dock2doc/doc or Dock8pri/pri single homozygous mice.  There 
was no difference in the percentage of B cells and total cell number of B cells in 
all groups of mice (Figure 3.28B). The double homozygous mice has significantly 
lower percentage of T cells, higher percentage of CD4 T cells and lower 
percentage of CD8 T cells compared to Dock2doc/doc mice, although these 
differences did not achieve significance when expressed as absolute cell numbers 
per spleen (Figure 3.28C). The double homozygous tended to have a lower 
percentage of NKT cells and total NKT cell number compared to Dock2doc/doc 
mice, although this was not statistically significant in the small number of animals 
available (Figure 3.28D).  
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Figure 3.28 Analysis of Dock2doc/doc Dock8pri/pri double deficient mice. 
A. Representative flow cytometry plot splenocytes from wild type (+/+), 
dockland homozygous (doc/doc), dockland heterozygous primurus 
homozygous (doc/+ pri/pri) and dockland:primurus double homozygous 
(doc/doc pri/pri) mice. B. Quantitation of lymph subsets for all 4 groups of 
mice. 3 mice were included in each group. Mean is shown as bar and 
statistical analysis by one-way ANOVA followed by Tukey’s test. * = 
p<0.05; ** = p<0.01.  
 
 
3.15 Discussion 
 
A search for novel mouse strains with lymphocyte defects in spleen led to the 
identification of the dockland mutant mouse strain in the ENU16:019a pedigree 
with T cell lymphopenia and absent marginal zone B cells in homozygous 
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mutants. The mutation was mapped to a large interval on chromosome 11 and 
identified as a G to T single nucleotide change in Dock2 gene introducing a 
premature stop codon instead of glutamic acid at codon 775 in the middle of the 
DOCK2 protein. Since this eliminates the DH2 domain responsible for GTP 
exchange factor activity, the E775X doc allele is likely to be a complete loss of 
function allele. The mutation may also trigger nonsense mediated decay of the 
mutant mRNA, although this was not tested. 
 
My analysis revealed doc homozygotes had fewer total lymphocytes and total T 
cells (both CD4 and CD8), but normal numbers of activated/memory (CD44hi) T 
cells in the spleen and blood. Homozygotes also had 2.5-fold fewer thymocytes 
and thymic DP and 3-fold fewer CD4 SP T cells. The lower CD5 expression on 
doc/doc thymic DP cells indicating lower pre-TCR signaling strength results 
lower SP T cells due to lack of efficient positive selection at DP stage. The fewer 
SP T cells indicated that the peripheral T lymphopenia was at least partly 
explained by diminished T cell formation in the thymus. The percentage of SP 
CD8 and CD4 T cells that were CD69-negative, representing the mature subset 
that normally express the S1P1R for thymic egress, was nevertheless increased in 
the thymus of homozygotes suggesting diminished thymus egress. A greater 
decrease in naïve (CD44lo) CD4 and CD8 T cells was observed in the peripheral 
blood and spleen of doc/doc mice (6-10 fold), implying either less thymic egress 
or diminished accumulation/survival in the periphery.  By contrast, CD44hi T cells 
were present in normal or increased numbers in homozygotes, consistent with 
lymphopenia-induced homeostatic proliferation to replace the depleted pool of 
naïve T cells. In mixed bone marrow chimeras, where numerical deficiency of 
Dock2 mutant T cells could be replaced by competing wild-type T cells, a mean 
of only 0.3% of blood T cells were derived from doc/doc mutant bone marrow, in 
contrast to 22.6% doc/doc mutant cells within the blood B cells and 30.5% within 
granulocytes in the blood of the same chimeric animals. Therefore, DOCK2 is 
required within T cells for normal accumulation of naïve T cells in the periphery. 
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DOCK2-deficient mice were first generated by homologous recombination in 
embryonic stem (ES) cells to produce a null allele encoding a DOCK2 protein 
truncated after 42 amino-acid residues which was undetectable in thymus and 
spleen (Fukui et al., 2001). DOCK2-/- mice were viable and born at the expected 
Mendelian ratio with no apparent physical abnormality. The loss of DOCK2 gave 
rise to an absence of marginal B cells and reduced total number of T and B cells 
in spleen and lymph nodes mainly due to impaired lymphocyte migration. Rac, a 
member of the Rho GTPase family, is known to regulate cell migration, 
membrane polarization, and cytoskeletal dynamics in various cells (Hall, A., 
1998; Penninger, J.M., and Crabree, G.R., 1999). DOCK2 has been shown to bind 
Rac protein through its DHR2 domain and mediates Rac2 activation, measured by 
GTP loading, following CXCL12 stimulation or T cell receptor stimulation. 
DOCK2 can regulate the TCR polarization and lipid raft clustering during 
immunological synapse (IS) and lymphocyte migration through inducing Rac 
activation in response to chemokine receptor signaling (Nombela-arrieta et al., 
2004; Sanui et al., 2003). There was no detectable chemokine-induced Rac 
activation in DOCK2-deficient mice and DOCK2-deficient lymphocytes migrated 
poorly to the lymphoid chemokines CXCL12/SDF1, CXCL13/BLC, CCL19/ELC 
and CCL21/SLC (Fukui et al., 2001). More functional roles of DOCK2 have been 
revealed by other studies. Although DOCK2 mediates most T and B cell 
migration, integrin activation is defective in DOCK2-/- B cells but was not 
affected in DOCK2-/- T cells (Nombela-arrieta et al., 2004). DOCK2 deficient 
mice spontaneously develop high serum IgE onto an allergy-prone genetic 
background due to impaired antigen-driven downregulation of IL-4Rα expression 
(Tanaka, Y. et al., 2007). 
 
Consistent with the findings above, homozygous doc mutation caused absence of 
marginal zone B cells. DOCK2-/- mice have normal B lymphopoiesis or 
myelopoiesis (Fukui et al., 2001). The doc mutation does not change the amount 
of pro-B, pre-B, immature B and myeloid cells in bone marrow. Consistent with 
DOCK2’s guanine exchange factor activity for the hematopoietic-specific Rac 
isoform RAC2, Rac2-deficient mice have marked reductions in marginal zone B 
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cells and peritoneal cavity B-1a lymphocytes (Croker et al., 2002). Mice lacking 
DOCK8 also lack marginal zone B cells (Randall et al., 2009). Fewer marginal 
zone B cells are present in mice genetically deficient for Lsc, encoding the murine 
homolog of human p115 Rho GEF and a member of Dbl-homology family of Rho 
GTP exchange factors (Girkontaite, I., et al., 2001). Formation or maintainance of 
marginal zone B cells thus requires multiple GTP-exchange factors that are not 
critical for mature follicular B cells. 
 
In 50:50 bone marrow chimeras, doc/doc homozygous haematopoietic progenitors 
contributed to the blood B cell compartment almost as well as they contributed to 
the blood granulocyte compartment, but the mutant B cells were ten-fold less well 
represented in the corresponding B cell subsets within the spleen. Since there is a 
smaller decrease in B cell numbers in the spleen of unmanipulated doc/doc mice, 
the competitive disadvantage of doc/doc B cells in the mixed bone marrow 
chimeras is likely to reflect their diminished responsiveness to CXCL12/SDF1, 
CXCL13/BLC, CCL19/ELC and CCL21/SLC (Fukui et al., 2001), which promote 
migration of blood B cells into the splenic white pulp (Arnon and Cyster, 2014). 
In addition to the diminished contribution to B cells, there appeared to be a small 
further decrease in the formation of GC B cells by doc/doc cells, which again may 
reflect diminished responsiveness to CXCL12 and CXCL13 that attract B cells 
into germinal centres (Arnon and Cyster, 2014). To further investigate whether 
the cell intrinsic defect in dockland GC B cells was due to a failure of production 
or sustaining germinal center B cells, SWHEL mice could be an ideal model to 
study the GC response. By adoptive transfer of comparable numbers of SWHEL 
cells with normal or mutant DOCK2, the antigen-specific B cells could be 
followed through the immune response.  
 
DOCK8 in DOCK-C subgroup and DOCK11 in DOCK-D subgroup are known 
and suspected, respectively, to have a role in the germinal centre. DOCK8 was 
shown to have a role within germinal centre B cells in sustaining antibody 
responses after immunization, which could be used as an important model to 
investigate the mechanisms of antibody persistence and affinity maturation 
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(Randall et al., 2009). DOCK11 was discovered for its high expression on 
germinal centre cells. It has been shown to bind Cdc42 but its role in GC has not 
been elucidated (Nishikimi et al., 2005). 
Vav2 and SWAP-70 are other guanine exchange factors implicated in GC 
formation. Vav2 is a Dbl-type guanine exchange factor for Rho-family GTPases. 
Although the Vav2 gene is expressed in T and B cells, loss of Vav2 does not have 
a prominent effect on the development of B and T cells. However, Vav2 deficient 
mice have defects in B cell activation and T-dependent and T-independent 
antibody responses and GC formation despite normal splenic architecture (Doody 
et al., 2001; Tedford et al., 2001). SWAP-70 is a Rac-interacting protein with a 
domain weakly homologous to the Dbl (DH) domain. SWAP-70 deficient mice 
have fewer and smaller GC upon immunisation with SRBCs or NP-KLH but 
increased antigen-specific antibody and antibody-forming B cells (Quemeneur et 
al., 2008).  
 
The findings here are consistent with published evidence that DOCK2 is required 
for early development of Va14 NKT cells in thymus (Kunisaki et al., 2006). 
Kunisaki et al showed that DOCK2 deficiency caused severe reduction of Va14 
NKT cells in the thymus, liver and spleen with no effect on NK cells in thymus 
and liver. Homozygotes for the dockland mutation had severely reduced numbers 
of NKT cells in both thymus and spleen. Similar as DOCK2 deficient mice, 
DOCK8-deficient mice have impaired development and survival of NKT cells 
(Crawford, G., et al., 2013). Failure of NKT cell formation is thought to be due to 
effects on the strength of TCR signalling and the threshold for positive selection 
(Kunisaki et al., 2006). 
 
Previously, DOCK2 has been shown to be involved in antiviral immunity. pDC 
can respond rapidly to viral exposure by secreting IFN-I for an efficient antiviral 
immune response. DOCK2 deficiency diminished TLR7- and TLR9-mediated 
INF-I induction through a requirement for DOCK2 in Rac activation following 
exposure to TLR nucleic acid ligands in pDCs (Gotoh et al, 2010). In this chapter, 
the doc mutation was shown to protect mice from morbidity during the early 
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phases of lung infection by influenza virus. One hypothesis to explain this 
protective effect of DOCK2 deficiency in vivo is that local production of 
interferon by infected lung epithelium, which expresses little DOCK2, occurs 
normally to control viral replication. By contrast, diminished production of 
systemic interferon by pDCs decreases morbidity. Future studies will need to test 
this possibility by measuring virus RNA and interferon RNA in fractionated cells 
from lung and by measuring interferon in blood plasma.  
 
Recently, five children with early onset invasive bacterial and systemic viral 
infections, including two fatal cases of systemic varicella and Klebsiella infection, 
were found to have bi-allelic inactivating DOCK2 mutations (Dobbs K et al 
NEJM 2015 PMID 26083206). One of the deceased patients inherited a 
homozygous frameshift truncating mutation at codon 744, p.F744Cfs*27, near to 
the dockland mutation at codon 775, which when expressed as a cDNA (obviating 
nonsense mediated decay) produced a truncated protein lacking the DH2 domain. 
Consistent with the mouse results here and published previously, all five cases 
had greatly decreased T cell numbers in the blood. Newborn blood spots from the 
p.F744Cfs*27 patient and one other patient were shown to have low T cell 
receptor excision circles below the normal cutoff, consistent with diminished 
thymic output. These results are also in line with the diminished thymocyte 
numbers and evidence of egress deficits observed in DOCK2 deficient mice. 
There was also diminished interferon alpha production by pDCs from the patients. 
Three of the five patients successfully underwent bone marrow transplantation 
and this corrected their recurrent infections and allowed cessation of intravenous 
gammaglobulin. These results are consistent with the evidence here that the T cell 
and B cell deficits are cell autonomous.   
 
Whereas systemic viral and bacterial infections dominate the clinical picture of 
human DOCK2 deficiency, human DOCK8 immunodeficiency is characterised by 
persistent and recurrent cutaneous infections with human papilloma viruses, 
molluscum contagiosum, and herpes simplex virus (Zhang, Q. et al., 2009 and 
Engelhardt, KR et al., 2009). Most DOCK8-deficient patients exhibit T cell 
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lymphopenia, albeit milder than DOCK2 deficiency, and high serum IgE and 
eosinophilia and CVID-like antibody and memory B cell abnormalities.  
 
DOCK8 has been shown to be critical for the survival of peripheral CD8 T cells in 
both human and mice (Randall et al., 2011 and Lambe et al., 2011). CD8 T cells 
in DOCK8-deficient human patients displayed exhausted CD45RA+CCR7- 
phenotype and fail to active, divide and expand in vitro. In mice, although 
DOCK8-deficient CD8 T cells are able to generate a comparatively normal 
primary clonal expansion after immunisation with Modified Vaccinia Ankara 
(MVA) or recombinant influenza virus, the memory recall response is greatly 
reduced (Randall et al., 2011 and Lambe, 2011). It remains unclear why cutaneous 
viral infections dominate DOCK8 deficiency in mice, whereas a more typical 
picture of severe combined immunodeficiency with systemic viral infections 
occurs in DOCK2 deficiency. The simplest interpretation is that T cell 
lymphopenia is more severe in DOCK2 deficiency, both in humans and in the 
side-by-side comparison of unchallenged T cell numbers in mice with DOCK2 or 
DOCK8 deficiency performed here. However, it is interesting that when I 
performed a side-by-side comparison of influenza NP-specific CD8 cells in the 
two mutant mouse strains, there was a similar decrease in effector CD8 cells after 
primary and secondary challenge in both mutant relative to wild-type controls.  
 
The observation here that the circulating naïve T cell frequency was further 
decreased in double mutant mice with homozygous mutations in DOCK2 and 
DOCK8 has two equally simple interpretations. First, both proteins may serve 
identical functions in T cell formation, thymic egress, and peripheral T cell 
survival with partial redundancy and DOCK2 bearing a much greater load for T 
cell chemotaxis. Alternatively, the two proteins may serve parallel functions that 
contribute to the efficiency of filling the T cell repertoire. This would be 
consistent with the presence of an SH3 domain in DOCK2 and not DOCK8, and 
the much greater defect in migration to chemokines observed in DOCK2 deficient 
lymphocytes.  
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Chapter 4: Identification of the 
causative mutation in SENP2 
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4.1 Introduction 
 
Since ubiquitin was first discovered in the late 80’s, its role has been well 
established: covalent ligation of ubiquitin to amino acid side-chains of other 
proteins triggers either protein degradation in the proteasome or assembly of large 
macromolecular signaling (Hershko and Ciechanover, 1998). During the last 
decade, a number of ubiquitin-like proteins have been isolated without clear 
functional role. The significance of these ubiquitin-related proteins was first 
elucidated by showing that a novel protein, SUMO (small ubiquitin-like 
modifier)-1, can be covalently conjugated to RanGAP1 and regulate its 
subcellular localization (Matunis et al., 1996; Mahajan et al., 1997). As the best-
characterized member of the family of ubiquitin-related proteins, SUMO has been 
shown to have other roles and does not mark proteins for degradation. 
 
The ubiquitin-like protein SMT3 from Saccharomyces cerevisiae was the first 
identified member of SUMO family (Meluh and Koshland, 1995). Subsequently, 
other SUMO members in human and mouse were reported by serveral groups 
with different names: sentrin, PIC1, SMT3, UBl1 (Mannen et al., 1996; Boddy et 
al., 1996; Mahajan et al., 1997; Matunis et al., 1996; Okura et al., 1996; Shen et 
al., 1997; Lapenta et al., 1997 Chen et al., 1998). In mouse and human, there are 5 
different SUMO proteins: SUMO1, SUMO2, SUMO3, SUMO4 and SUMO5. 
SUMO2 and SUMO3 share 86% sequence identity but both have lower identity 
(44%) to SUMO1 in humans (Su and Li, 2002). All 3 isoforms are ubiquitously 
expressed in the human and mouse (Chen et al., 1998;). SUMO1, SUMO2 and 
SUMO3 are localized at the nuclear membrane, nuclear bodies and cytoplasm, 
respectively (Su and Li, 2002). SUMO4 and SUMO5 are expressed in selective 
tissues (Rabellino et al., 2017).  
 
SUMO, like ubiquitin, is post-translationally attached by covalent linkage to other 
proteins. Unlike ubiquitination that has a pivotal role in marking proteins for 
degradation, SUMOylation affects activity, stability, and subcellular localization 
of the target proteins. SUMO is ~10 kDa in size and synthesized in an 
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inactive/precursor form with 2-11 amino acids adjacent to 2 invariable glycine 
residues at the carboxyl terminus (Figure 1). The C-terminal residues are cleaved 
to reveal the carboxy-terminal Gly-Gly motif before SUMO can be covalently 
conjugated to the target protein: a process that is mediated by sentrin-specific 
proteases (SENPs). Then the conjugation reaction is catalyzed by E1 heterodimer 
enzyme (AOS1-UBA2) and results in formation of a thioester bond between the 
C-terminal glycine and cysteine of E1 enzyme (Johnson et al., 1997; Desterro et 
al., 1999; Okuma et al., 1999; Gong et al., 1999). The SUMO group is then 
transferred to the cysteine of the E2 enzyme (UBC9) (Desterro et al., 1997; 
Johnson and Blobel, 1997; Lee et al., 1998; Okuma et al., 1999). Finally, the 
SUMO molecule is conjugated to the target protein by the formation of an 
isopeptide bond between the C-terminal glycine and the ε-amino group of a lysine 
side chain in the target protein. The last step is mostly catalyzed by a SUMO 
protein ligase (E3) (Hay, 2005; Johnson and Gupta, 2001; Takahashi et al., 2001). 
The best characterized E3 ligases are members of the Protein Inhibitor of 
Activated STAT (PIAS) family, which are encoded by four genes in mammals 
(Rabellino et al., 2017). 
 
SUMOylation is highly dynamic and reversible, with the deconjugation process 
mediated by a family of sentrin specific proteases (SENPs). The first member, 
SENP1, was first described to remove SUMO1 from RanGAP1 in vitro (Gong et 
al, 2000). There are 6 members in the SENP family. They can be further divided 
to 3 subgroups based on sequence homology and subcellular localization 
(Mukhopadhyay and Dasso, 2007): 
 
 
Group I - SENP1 and SENP2: both localize at the nuclear envelope and associate 
to the nuclear pore complex (NPC) 
Group II – SENP3 and SENP5: have the highest degree of homology and both 
localize to nucleoplasm 
Group III – SENP6 and SENP7: both localize to the nucleoplasm 
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Figure 4.1: The SUMOylation and deSUMOylation processs 
 
 
The human Senp2 gene encodes a 589 amino acid protein (588 in mouse). 
Although SENPs share homology in their catalytic domain, they have a wide 
diversity in N- and C- terminal primary sequence. The divergent regions in 
SUMO proteases have an important role in spatial regulation to their specific 
subcellular localization. Human SENP2 has been shown to associate with the 
nuclear pore through the N-terminal 70 amino acids. SENP2 binds Nup153, which 
is a constituent of the nuclear basket and is localized to the nucleoplasmic side of 
the nuclear pore complex (Pante et al, 1994). Removal of N-terminal sequences 
causes SENP2 to relocalize to other compartments in the cell and to increase its 
activity in promoting deconjugation of SUMO-1 conjugated species (Hang and 
Dasso, 2002). Later studies have shown that SENP2 has the KRRR-X-KR 
sequence that constitutes a bipartite nuclear localization signal (NLS) and a 
CRM1-dependent nuclear export sequence (NES) (Itahana et al., 2006). By using 
SENP2 mutants, SENP2 was shown to shuttle between the nucleus and cytoplasm.   
 
The aim of this project was to use a genome wide N-ethyl N-nitrosurea (ENU) 
mutagenetic screen screen in mice to identify novel genes involved in CD8 T cell 
development or function. This chapter describes the discovery and initial analysis 
of a Senp2 mutation affecting CD8 T cell accumulation. 
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4.2 Screening and identification of the duan strain 
 
Male B6 mice were injected with ENU and bred with wild-type female B6 mice to 
generate G1 offspring carrying multiple mutations. Each G1 mouse was bred with 
wild-type females to generate G2 offspring carrying heterozygous mutations. 
Sibling G2 mice were intercrossed to generate G3 mice, which had a 25% chance 
of being homozygous for any mutation carried by both of the G2 parents. The G3 
mice were bled around 8 weeks of age and the peripheral blood analysed by flow 
cytometry for abnormal frequencies of the T cell population.   
 
 
 
 
 
Figure 4.2 ENU7B6:039 pedigree segregating the duan mutation 
affecting CD8 T cell frequency. In the 27 offspring in the G3 generation, 
3 females and 1 male had a lower frequency of peripheral blood CD8 T 
cells. Male mice = squares, female mice = circles. Affected mice = red 
filled symbols; unaffected mice = open symbols.  
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In the ENU7B6:039 pedigree, 4 out of 27 G3 mice had a decreased percentage of 
CD8 T cells (Figure 4.2), which suggested that it is a homozygous recessive 
mutation. The affected animals had 6-10% CD8 T cells among blood 
lymphocytes, compared to 15% in wild type. Most mutant mice also had an 
increased fraction of CD8 T cells displaying high levels of CD44, corresponding 
to the subset of activated memory or effector CD8 T cells (Fig 4.3A). Breeding of 
affected G3 mice with unaffected carrier G3 siblings yielded approximately 50% 
of G4 offspring affected by the trait of low CD8 T cell frequency, while breeding 
of two unaffected carrier mice yielded ~25% affected offspring with no 
discernable physical abnormality. Scatter plots comparing the percentage of CD4 
versus CD8 T cells in the blood of individual animals (Figure 4.3A), or the 
percentage of CD44hi cells among CD8 T cells versus the frequency of all CD8 T 
cells (Figure 4.3B), showed a clear separation between affected and unaffected 
mice, consistent with a single mutation causing a fully penetrant, recessive 
Mendelian trait. 
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Figure 4.3 duan mutation leads to a loss of peripheral naive CD44low 
CD8 T cells. A. Representative FACS plots of lymphocytes in peripheral 
blood. The upper panel shows the percentage of CD4 and CD8 cells. The 
lower panel shows the expression of CD44 on CD8+ T cells, and the gates 
and percentage of CD44hi activated/memory CD8 cells resolved from 
CD44low naïve CD8 cells. B) The percentage of CD4 T cells versus CD8 T 
cells in individual mice. C) The frequency of CD44hi CD8 T cells versus 
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CD8 T cells in individual mice. Each symbol represents a single animal 
from G3 and G4 generations: Red = affected and Blue = unaffected. 
 
 
4.3 Meiotic mapping of the duan mutation to an interval on Chromosome 16 
The duan mutation was mapped and identified by Dr Lina Tze and Belinda 
Whittle prior to my PhD studies. Homozygous dua/dua B6 mice were crossed 
with C57BL/10 (B10) mice, and the F1 offspring intercrossed to produce an F2IC 
generation. In these animals the mutation-bearing C57BL/6 chromosomal 
segment could be distinguished from the corresponding wild-type chromosome 
from the B10 mapping partner strain using a genome-wide panel of single 
nucleotide polymorphisms. The flow cytometric traits above were used to identify 
the 25% of F2IC animals that were affected homozygotes for the mutation-
bearing B6 chromosome. 
 
In F2IC mice, the low CD8 T cell trait mapped to chromosome 16 in a 3.9 Mb 
interval bounded by two SNPs: rs4165081 at Ch16:19,883,079 and rs4165422 at 
Ch16:	 23,794,202 (GRCm38 coordinates).  This interval contained 70 annotated 
protein coding genes. Using DNA from a homozygous affected mouse, each exon 
of the 70 genes was PCR amplified with custom oligonucleotides, Sanger 
sequenced, and compared to the reference B6 genome sequence (these 
experiments were designed, performed and analysed by Belinda Whittle). Only 
one exonic mutation was present: a synonymous A>G substitution at 
Ch16:22,036,478 in exon 11 of Senp2. Allele-specific PCR primers were then 
used to establish an Amplifluor genotyping assay for the Senp2dua mutation. 
 
Once the mutation was identified, the flow cytometric difference between 
homozygous dua/dua animals and dua/+ heterozygous or +/+ siblings could be 
further analysed (Figure 4.4). The homozygous mice had a statistically significant 
decrease in the percentage of CD8 and CD4 T cells in peripheral blood compared 
to wild type or heterozygous littermates. Mutant mice had significantly higher 
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percentage of B cells as a reflection of lower percentage of both CD4 and CD8 T 
cells.  
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Figure 4.4 Lower percentage of CD8+ T cells in mice 
homozygous for the duan mutation in Senp2. Percentage of 
B220+, CD4+ and CD8+ T cells in blood lymphocytes of mice 
genotyped for the Senp2dua exon 11 mutation, with either wild-type 
(white circles), heterozygous (grey circles) or homozygous mutant 
genotypes (black circles). Dots represent single mice and the bars 
represent the arithmetic mean. Statistical analysis by one-way 
ANOVA followed by Bonferroni post-test. 
 
 
4.4 Lower CD127 expression on naïve Senp2dua/dua mice  
 
As reviewed in Chapter 1, CD127 (IL-7Rα) is expressed on and transmits 
IL-7 survival signals into naïve CD8 T cells. The expression of CD127  on 
the surface of naïve (CD44lo) and effector/memory (CD44hi) CD8 T cells 
from wild type, heterozygous and homozygous mice in the peripheral blood 
was compared. The results from Figure 4.4 showed that naïve CD8 T cells 
from homozygous Senp2 mutant mice had significantly lower expression of 
CD127 compared to naïve CD8 T cells from wild type or heterozygous mice 
(Figure 4.5A).  However, no difference in CD127 expression was seen in 
the effector/memory CD8 T cells (Figure 4.5B). 
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Figure 4.5 Lower expression of CD127 (IL-7Ra) on Senp2dua/dua naïve 
CD8 T cells. Graph of geometric mean of CD127 expressed on naïve 
(CD44lo) CD8 T cells (A) and effector/memory (CD44hi) CD8 T cells (B) in 
the blood of wild-type Senp2+/+(white circles), heterozygous Senp2dua/+ 
(grey circles) and homozygous Senp2dua/dua mice (black circles). Dots 
represent single mice and the bars represent the arithmetic mean. 
Statistical analysis by one-way ANOVA followed by Bonferroni post-test. 
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4.5 Splicing consequences of the synonymous coding mutation in Senp2 exon 
11 
 
As described above, mapping and sequencing revealed a single A to G base 
change in exon 11 of the Senp2 gene. This synonymous mutation did not alter the 
encoded amino acid, Glycine 313 (Figure 4.6A), but its location 9 bp downstream 
from the splice acceptor site of exon 11 (Figure 4.6B) raised the possibility that it 
might affect mRNA splicing. Reverse transcriptase PCR (RT-PCR) was 
performed with primers in exons flanking exon 11. This revealed two different 
size products in approximately equal amounts in cDNA from homozygous 
mutants (Figure 4.6C and D): a large product corresponding to the predominant 
species in cDNA from wild type mice and a smaller sized band corresponding to a 
trace species accounting for a mean of 5% of amplified Senp2 cDNA in wild-type 
(+/+) mice. The percentage of the smaller product among the two amplified 
cDNA bands was significantly increased to a mean of 30% in Senp2dua/+ 
heterozygotes and 55% in homozygous Senp2dua/dua mutants (Figure 4.6C, D). 
Belinda Whittle excised both bands from wildtype and homozygous mutant mice 
and performed Sanger sequencing, finding the smaller product results from 
skipping exon 11 in mutant and wild-type mice, while the larger product retains 
normal splicing of exon 10 to exon 11 and of exon 11 to exon 12 in mutant mice. 
Thus, the exon 11 mutation appears to interfere with an exonic splicing enhancer 
in exon 11, decreasing the fraction of mRNA where exon 10 is spliced to exon 11 
to encode full-length SENP2 protein. 
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Figure 4.6 Mutation in Senp2 in duan mice causing exon skipping. A) 
DNA sequence traces for forward and reverse strands of exon 11 from 
dua/dua mice, aligned to the reference B6 mouse genome sequence 
above, showing the A to G base change. B) Schematic showing location of 
the mutation in the wobble position of the Glycine 313 codon in exon 11, 
and the location of annotated domains in the SENP2 protein including a 
nuclear export signal (NES) encoded by exon 11. C) RT-PCR analysis 
with primers in exons 9 and 13 from spleen cDNA of mice with the 
indicated Senp2duan genotypes. (Forward primer: 
GCGTCAGAACAACCCATTTT and reverse primer: CACAGATCCTGTG 
GCCTTTT). This experiment was performed by Belinda Whittle. (D) 
ImageJ quantitation of bands in panel C corresponding to correctly spliced 
and exon 11 skipped PCR products. Columns show arithmetic means, and 
each dot corresponds to a single sample showing the % skipped from the 
sum of the areas of both peaks. The lanes on far left and right were 
omitted from the analysis because of low total PCR product. Statistical 
analysis by ANOVA with Tukey’s multiple comparison test. The difference 
between +/+ and dua/dua was also significant at p<0.0001.  
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4.6 SENP2 expression and protein structure 
 
The mouse Senp2 gene encodes a protein of 588 amino acids (589 AA in humans) 
and is classified as a member of the sentrin-specific proteases family. The SENP2 
protein is involved in the processing and deconjugation steps of ‘SUMOylation’ 
which is the covalent conjugation of SUMO molecule to the target protein. 
SENP2 has both isopeptidase and hydrolase activities. However, the 
deconjugation step is shown to be more efficient (Zuccolo et al, 2007). SENP2 
contains both NLS and NES sequences suggesting it undergoes 
nucleocytoplasmic shuttling.  
 
SENP2 contains several functional domains (Figure 4.5B): 
NLS: nuclear localization signal – region required for proper nuclear localization 
NES: nuclear exporting signal  
SUMO-recognition motif 
CD: Catalytic domain  
 
 
A 
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Figure 4.7 Senp2 mRNA is expressed in immunological cells and 
tissues. A) Senp2 expression in immune system, measured by Affymetrix 
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microarrays in the IMMGEN database 
(http://www.immgen.org/databrowser/index.html). 
B) Affymetrix microarray profiling data from BioGPS showing tissue 
distribution of Senp2 mRNA in various mouse tissues 
 (http://biogps.org/#goto=genereport&id=75826). 
 
 
SENP2 has previously been shown to be highly expressed in trophoblast cells and 
is indispensible for modulating the p53-Mdm2 pathway in trophoblast 
development (Chiu et al., 2008). Other studies have shown that SENP2 can 
colocalize and associate with SUMO conjugated MDM2 in PML bodies and 
catalyzed the desumoylation step of SUMO conjugated MDM2. The 
desumoylated MDM2 can bind to and promote p53 degradation, leading to the 
hypothesis that decreased SENP2 would decrease Mdm2 activity and thereby 
increase p53 to respond to genotoxic stresses (Jiang et al., 2010). Senp2 mRNA is 
expressed widely in cells of the immune system (Figure 4.7A), with somewhat 
higher expression in naïve OT-I CD8 T cells than in WT naïve CD8 T cells. 
Interestingly, T cells express lower amounts of Senp2 mRNA than most other 
tissues (Figure 4.7B), raising the possibility that they may be particularly sensitive 
to small decreases in SENP2 activity. 
 
 
4.7 Investigating the subcellular localization of the mutant SENP2 protein 
 
The Senp2dua/dua mutation caused exon 11 skipping in approximately half the 
amplified spleen cDNA, with the alternatively spliced product encoding a 
normally minor protein isoform lacking the nuclear export signal (NES). To 
determine if the alternative splicing affects the subcellular localization of the 
resulting protein, full-length (WT) and exon 11 deleted (ex11_del)  SENP2-GFP 
fusion proteins were overexpressed in 293T cells. The localization of both 
proteins was examined 48 hours after transfection. Transiently expressed full-
length GFP-SENP2 protein showed typical nuclear punctate localization in 
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HEK293T cells. (Figure 4.8) The mutant SENP2 displayed a similar localization 
to WT. Measured in this way, the lack of the NES had no discernable effect on the 
subcellular localization of SENP2. 
   
 
 
 
Figure 4.8 SENP2 localizes to the NPC. 293T cells were transiently 
transfected with cDNA high expression vectors (pEGFP-N1) encoding 
EGFP-SENP2 (left) or EGFP-SENP2ex11_del (right), fixed and stained with 
DAPI, and examined by epifluorescence microscopy. Representative 
images showing EGFP fluorescence in green and DAPI staining in blue.  
 
 
It has been reported that when expressed at low levels, SENP2 localized around 
the periphery of the nucleus (Zhang et al, 2002). To study if the duan mutation 
affects the expression of SENP2 when expressed at low level, cDNAs encoding 
SENP2 SENP2 ex11_del 
DAPI 
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SENP2-GFP or SENP2ex11_del-GFP fusion proteins were expressed from the 
retroviral vector pMX in transiently transfected 293T cells. The localization of 
protein was determined by direct immunofluorescence 48 hours after transfection. 
WT SENP2 signal localized as a ring around the nucleus. (Figure 4.9) The 
expression of the mutant SENP2 protein was similar as the WT SENP2 protein. 
Therefore, the mutation does not appear to affect the subcellular localization of 
SENP2 even when the protein is expressed at lower levels. It would be valuable to 
analyse localization in CD8 T cells, given the numbers of these cells were 
specifically diminished by the mutation, but time did not permit me to perform 
these follow up experiments. 
 
 
 
 
Figure 4.9 Lower expression of SENP2 reveals localization to a 
discontinuous ring around the nucleus. 293T cells were transiently 
transfected with pMX expressing EGFP-SENP2 and EGFP-SENP2(ex11_del), 
SENP2 
DAPI 
SENP2 ex11_del 
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fixed and stained for immunofluorescence. fixed and stained with DAPI, 
and examined by epifluorescence microscopy. Representative images 
showing EGFP fluorescence in green and DAPI staining in blue.  
 
 
4.8 Senp2dua/dua OT-I TCR-transgenic mouse model  
 
To study the effect of the Senp2dua mutation in antigen specific CD8 T cells, 
Senp2dua/dua mice were bred to the OT-I TCR transgenic strain to generate a 
monoclonal population of OT-I CD8 T cells that recognize the ovalbumin (OVA) 
peptide in the context of H-2Kb. The percentage of CD8+Vα2+ double positive 
cells was measured to indicate OVA-specific T cells (Fig. 4.10A). Interestingly, in 
the TCR transgenic setting the percentage of CD8 T cells was not decreased: OT-
1 Senp2dua/dua mice had similar frequencies to OT-1 Senp2+/+ mice (4.10A). There 
was also a similar proportion of CD44high OT-I CD8 T cells in Senp2dua/dua mice 
and WT controls. (Fig. 4.10B). Thus, in OT-1 transgenic Senp2dua/dua mice the 
CD8 T cell lymphopenia was not observed as seen on the nontransgenic 
background. The particularly high TCR affinity for self peptide – MHC 
complexes conferred by the OT-I TCR may rescue this phenotype. 
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B 	
				
Figure 4.10 Comparison of OT-I CD8 T cell proportions in wild type 
(+/+) and Senp2dua/dua (dua/dua) OT-I mice. (A) Representative flow 
cytometry plots (top) and graph of the percentage of CD8+ Vα2+ cells 
among lymphocytes in the spleen of wild type (+/+) and Senp2dua/dua 
(dua/dua) OT-I mice. Statistical analysis by t-test. (B) Representative 
histograms show the expression profile of cell surface CD44 on gated 
CD8+ Vα2+ splenic OT-I CD8 T cells of wild type (+/+) and Senp2dua/dua 
(dua/dua) OT-I mice, and the percentage falling within the CD44low and 
CD44hi gates. 
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4.9 Poor survival of naïve Senp2dua/dua OT-I T cells in lympho-replete 
recipients 
 
To compare the survival of mutant and wild-type OT-1 CD8 T cells, five million 
wild-type and Senp2dua/dua OT-I CD8 T cells were mixed and co-transferred into 
the lympho-replete wildtype recipients (Fig. 4.11). The two donor populations 
could be distinguished from one another and from recipient lymphocytes by their 
differential expression of the congenic marker CD45.1/CD45.2. The blood of 
recipients was analyzed at the indicated time points and the population of wild 
type or Senp2dua/dua OT-I CD8 T cells enumerated by flow cytometry along with 
surface expression of CD44 to assess their activation status. 	
		
Figure 4.11 Experimental design to compare the survival and 
persistence of CD8 T cells bearing Senp2dua/dua mutation with control 
T cells bearing wild-type Senp2. Schematic diagram showing the 
experimental design to study whether the survival defect of Senp2dua/dua 
OT-I T cells is cell intrinsic. A 10 x 106 cells mixture comprising a ratio of 
50:50 wild type (+/+) or Senp2dua/dua OT-I CD8 T cells were injected 
intravenously into the tail vein of each recipient wild type B6 mouse.  
Recipient mice were bled at various time points and the blood samples of 
animals were analyzed by flow cytometry. 
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As shown in Fig. 4.12A, representative flow cytometry plots show the gating 
strategy applied to identify donor-derived wild type or Senp2dua/dua OT-I CD8 T 
cells from recipient-derived T cells. The OT-I (donor) cells were first gated using 
CD8+ and Vα2+ markers and further distinguished using CD45.1, since the B6 
recipient-derived CD8+Vα2+ cells were homozygous CD45.2 whereas the donor 
cells were CD45.1 positive. The donor-derived OT1 cells were either 
heterozygous CD45.1/CD45.2 in the case of Senp2+/+ wild type OT-I CD8 cells or 
homozygous CD45.1/CD45.1 in the case of Senp2dua/dua OT-I CD8 T cells. 
 
On day 1 after transfer, Senp2dua/dua (dua/dua) OT-I CD8 T cells comprised 47% 
of all the OT-1 T cells in the blood, but steadily decreased to 30% by day 15 post 
transfer, 13% at day 30, and only 6% by day 50 (Figure 4.12B top panel). The 
surface expression of CD44 was nevertheless comparable on wild type and 
Senp2dua/dua OT-I CD8 T cells at each time point (Figure 4.12B bottom panel). 
 
The survival of wild type and Senp2dua/dua OT-I CD8 T cells was analysed as a 
percentage of all blood lymphocytes in the recipient mice, where they comprised a 
small minority competing with a full repertoire of normal CD8 and CD4 T cells 
(Figure 4.13A). Wild type OT-I and Senp2dua/dua OT-I CD8 T cells started on Day 
1 with similar percentages, between 0.05 and 0.1% of lymphocytes, but the 
Senp2dua/dua OT-I CD8 T cells were significantly reduced compared to wild type 
cells by day 15 post transfer and became more severe at days 30 and 50 post 
transfer. Wild-type OT-1 T cells declined slowly, reaching 50% of the day 1 
percentage only after 50 days, whereas homozygous mutant OT-1 T cells 
decreased with a half-life of approximately 10 days.  
 
To show the survival defect caused by the mutation in Senp2 was not due to a 
minor histocompatibility rejection from the recipients, a control group of 
recipients received a mixture of CD45.1/CD45.1 Senp2dua/+ (dua/+) heterozygous 
mutant OT-1 T cells (from litter mates of the Senp2dua/dua mice used in the 
experimental group) mixed with CD45.1/CD45.2 wild type (+/+) OT-I T cells . 
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As shown in Fig. 4.13B, there was no significant difference between the wild type 
and Senp2dua/+ (dua/+) OT-I CD8 T cells as a percentage of all lymphocytes in the 
recipients at any time point post transfer.  
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Figure 4.12 Comparison of the persistence of wild type and 
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recipients. A total number of 107 cells, comprising wild type 
(CD45.1/CD45.2) and mutant (CD45.1) CD8 T cells mixed at a 50:50 ratio, 
were injected into the tail vein of each B6 wildtype (CD45.2) recipient. (A) 
Representative flow cytometry plots showing the gating strategy applied to 
identify the wild type (+/+) or Senp2dua/dua (dua/dua) OT-I CD8 T cells from 
the host-derived cells. (B) Representative flow cytometry plots show the 
survival of donor cells (wild type (+/+) or Senp2dua/dua (dua/dua) OT-I CD8 
T cells) at day 1, day 15, day 30 and day 50. The number indicates the 
percentage of Senp2dua/dua OT-I CD8 T cells among donor OT-I CD8 T 
cells (top). Representative histograms show the expression profile of 
CD44 marker on wild type (grey) and Senp2dua/dua (solid red line) OT-I CD8 
T cells at the same time points (bottom).  
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Figure 4.13 Comparison of the persistence of naïve wild type and 
Senp2dua/dua OT-I CD8 T cells in wild type recipients. (A) Frequency of 
wild type (+/+) OT-I CD8 T cells (black symbols) and Senp2dua/dua (dua/dua) 
OT-I CD8 T cells (red symbols) expressed as a percentage of total blood 
lymphocytes in individual recipients at the indicated days after co-transfer. 
Two-way ANOVA and Bonferroni post-tests were performed to compare 
statistical differences in +/+ and dua/dua at the indicated time points: at D2 
(ns), D16 (p<0.001), D30 (p<0.001) and D50 (p<0.001). 5 animals 
analysed per time point. This experiment was performed three times. (B) 
Frequency of wild type (+/+) OT-I CD8 T cells (black symbols) and 
heterozygous Senp2dua/+ (dua/+) OT-I CD8 T cells (blue symbols) 
expressed as a percentage of total recipient lymphocytes on the indicated 
days after co-transfer. Two-way ANOVA and Bonferroni post-tests were 
performed to compare statistical differences in +/+ and dua/+ at the 
indicated time points: D2 (ns), D16 (ns), D30 (ns) and D50 (ns). 5 animals 
were analysed per time point.  
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4.10 Retroviral complementation to confirm Senp2dua is responsible for 
diminished survival of T cells from duan mice  
 
The data in the previous sections show that the synonymous Senp2 duan mutation 
decreased normal splicing of the mRNA but did not cause any obvious difference 
in subcellular localization of the short protein isoform. While the Senp2 mutation 
was the only mutation detected by exon sequencing of the 70 annotated genes in 
the mapped chromosome 16 interval, it was necessary to confirm that the 
mutation found in the Senp2 gene was responsible for the phenotype seen in the 
duan mice. To prove that the mutation in Senp2 was responsible for the survival 
defect in CD8 T cells of duan mice, a retroviral based gene transfer experiment 
was carried out. The dua/dua OT-I cells were transduced with a retroviral vector 
encoding WT full-length SENP2 or a control retroviral vector (empty vector, EV), 
and then injected into B6 recipients and tracked for survival in vivo to determine if 
the survival of the dua/dua CD8 T cells could be restored.  
 
The pMIG II bicistronic plasmids encoding either wildtype Senp2 and enhanced 
green fluorescent protein (EGFP) or EGFP alone (empty vector, EV) were 
transfected into the Phoenix retroviral packaging cell line which expresses env, 
gag and Pol virus proteins. The supernatants containing infective retroviral 
particles were used to transduce mouse primary T cells from Senp2dua/dua or 
Senp2+/+ CD45.1 OT-I TCR-transgenic mice that had first been activated with 
anti-CD3 and anti-CD28 and cultured for 3 days in vitro. Because there were 
limited numbers of transduced cells, these were injected into the tail vein of single 
C57BL/6J recipients which were followed longitudinally by flow cytometric 
analysis of GFP expression among the donor T cells in peripheral blood. To 
provide a staining control to distinguish the GFP+ and GFP- population, non-
transduced wild-type OT-I splenocytes were also injected into C57BL.6J mice. As 
shown in Figure 4.14A upper panel and C, donor OT-1 CD8 T cells 
(CD45.1+CD8+) were reliably separated from the rest CD8 T cells by using 
CD45.1 marker, and the GFP+ subset could be readily distinguished among them. 
Three days after transfer, 34% of Senp2dua/dua OT-I CD8 T cells were GFP+ 
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expressing the Senp2-GFP vector, and 32% of WT OT-I CD8 T cells transduced 
with EV were GFP+ (Figure 4.14A upper panel). By day 97 after transfer, the 
percentage of GFP+ cells increased to around 37% in the Senp2dua/dua OT-I CD8 T 
cells while the percentage of GFP+ cells in the WT OT-I CD8 T cells remained at 
22%. By day 140, the percentage of GFP+ cells increased to 47% in the 
Senp2dua/dua OT-I CD8 T cells but remained at 20% for the WT OT-1 controls 
(Figure 4.14 lower panel).  
 
The recipient mice were sacrificed 328 days after transfer and spleen cells 
analysed. As shown in Figure 4.14C, the WT OT-1 cells with no transduction 
lacked GFP+ cells while the WT OT-I CD8 T cells transduced with EV had 8% 
GFP+ cells. By contrast, the GFP+ cells had dramatically increased to 88% of the 
Senp2dua/dua OT-I CD8 T cells transduced with WT SENP2.  
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Figure 4.14 Preferential survival of Senp2dua/dua OT-1 CD8 T cells 
transduced with a retroviral vector encoding full length SENP2. (A) 
Representative flow cytometry plots show the gating strategy applied to 
identify the GFP+ cells on CD45.1+CD8+ donor cells in blood 3 days after 
transfer into C57BL/6 recipients. (upper panel) Results of sequential flow 
cytometry testing of blood on the indicated days after transfer of OT-1 T 
cells into C57BL/6 mice, showing the percentage of GFP+ cells among 
CD45.1+ CD8+ Senp2dua/dua OT-I T cells transduced with WT SENP2 
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(close circles) and among WT OT-I CD8 T cells transduced with EV (open 
circles) (lower panel) (B) Results of decline of GFP+ or GFP- cells as % of 
lymphocytes. (C) Flow cytometry of spleen cells on day 328 after transfer, 
gated on CD45.1+ CD8+ lymphocytes, showing the % that were GFP+ 
cells in recipients of no donor cells, non-transduced WT OT-I CD8 T cells, 
EV-transduced WT OT-I CD8 T cells, and WT SENP2-transduced 
Senp2dua/dua OT-I CD8 T cells. 
 
The retroviral complementation experiment was then repeated with 2 recipient 
mice receiving the Senp2dua/dua OT-I splenocytes transduced with WT SENP2 and 
1 recipient receiving the WT OT-I splenocytes transduced with EV. As shown in 
Figure 4.15A, at the first timepoint after transfer 5% of WT OT-I CD8 T cells 
were GFP+ and 10% of Senp2dua/dua OT-I CD8 T cells were GFP+. Similar to the 
previous experiment, the percentage of GFP+ cells had increased to 23% in both 
recipients 88 days after transfer and more than 30% after 180 days in the SENP2 
transduced Senp2dua/dua OT-I CD8 T cells. By contrast, there was little increase in 
the percentage of GFP+ cells in EV-transduced WT OT-I CD8 T cells at the same 
timepoints. When the recipient mice were sacrificed at day 329 after transfer 
(Figure 4.15B), the percentage of GFP+ cells in the Senp2dua/dua OT-I CD8 T cells 
transduced with WT SENP2 in individual recipients had increased to 45% and 
65%.  
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Figure 4.15 Preferential survival of Senp2dua/dua CD8 T cells with 
retroviral expression of full length SENP2. (A) Results of sequential 
flow cytometry testing of blood on the indicated days after transfer of OT-1 
T cells into C57BL/6 mice, showing the percentage of GFP+ cells among 
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CD45.1+ CD8+ Senp2dua/dua OT-I T cells transduced with WT SENP2 
(close circles) and among WT OT-I CD8 T cells transduced with EV (open 
circles). (B) Flow cytometry of spleen cells 329 days after transfer, gated 
on CD45.1+ CD8+ lymphocytes, showing the % that were GFP+ in 
recipients of no donor cells, non-transduced WT OT-I CD8 T cells, EV-
transduced WT OT-I CD8 T cells, and WT SENP2-transduced Senp2dua/dua 
OT-I CD8 T cells. 
 
 
The experiments above left open the possibility that overexpression of full length 
SENP2 might enhance survival of OT-1 cells generally, regardless of the duan 
mutation. To test this possibility, a separate experiment was designed. C57BL/6J 
mice were injected with WT OT-I splenocytes that had been transduced with the 
full length SENP2 EGFP vector or the empty EGFP vector. The recipient mice 
were bled at various time points to check if enforced SENP2 expression could 
increase the survival of WT OT-I CD8 T cells. As shown in Figure 4.16, at the 
first time after transfer there were 10-13% GFP+ cells among blood CD45.1+ 
CD8+ OT-I T cells transduced with WT SENP2 or EV, and these percentage 
remained steady between 10-16% from day 20 to day 125. The lack of any 
increase in GFP+ cells when SENP2 vector was introduced into OT1 cells with 
wildtype Senp2 genes contrasted with two experiments above where the 
percentage of GFP+ cells progressively increased over time when the SENP2 
vector was introduced into Senp2dua/dua OT1 cells. This gene complementation 
experiment supports the conclusion that the deficiency of full-length SENP2 
protein is responsible for the survival defect of CD8 T cells in duan mice. 
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Figure 4.16 Retroviral expression of full length SENP2 does not give 
wild type OT-1 T cells an extra survival advantage. (A) The percentage 
of GFP+ cells among CD45.1+ CD8+ WT OT-I cells transduced with WT 
SENP2 (grey circles) or among WT OT-I CD8 T cells transduced with EV 
(open circles), measured sequentially in blood lymphocytes of individual 
recipients on the indicated days. 
 
 
4.11 Outcross to knockout strain shows that the Senp2 gene is responsible for 
the duan phenotype 
 
To further confirm that the duan mutation in Senp2 causes the CD8 T cell 
phenotype, Senp2dua/+ mice were crossed to Senp2+/- mice heterozygous for a 
targeted null allele that causes early embryonic lethality in homozygous state due 
to developmental defects in all three trophoblast layers (Chiu et al, 2008). As 
shown earlier (Fig 4.4), the dua mutation is recessive, so that dua/+ animals with 
one wild type Senp2 allele have normal frequencies of CD8 T cells. If the exon 11 
variant in Senp2 was the causative mutation, then inactivation of the wild type 
allele in dua/- compound heterozygotes should either yield the same T cell 
deficiency as observed in dua/dua homozygotes or a more severe phenotype (due 
to a further loss of full length SENP2).  As shown in figure 4.17A and B, there 
was no discernable decrease in CD8 T cells comparing Senp2+/+ and Senp2+/- 
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mice heterozygous for the null allele whereas the number of CD8 cells was 
significantly lower in Senp2dua/- compound heterozygous mice, comparable to 
dua/dua homozygotes. Likewise, the percentage of CD44hi cells among CD8 T 
cells was higher in compound heterozygous Senp2dua/- mice than in Senp2+/+ and 
Senp2+/- controls (58% vs 25% and 21%) (Figure 4.17A) and the number of 
CD44low CD8 T cells was diminished even more than the total number of CD8 
cells (Figure 4.17B). Senp2dua/- compound heterozygous mice and dua/dua 
homozygotes were comparable in all analysis (Figure 4.17B). Thus, the duan 
mutation was not complemented by a null mutation in Senp2, confirming that the 
SENP2 loss of function is responsible for the diminished number of naïve CD8 T 
cells in the duan strain. 
 
Interestingly, the Senp2dua/- compound heterozygous mice had significantly fewer 
B cells and CD4 T cells compared to Senp2+/+ and Senp2+/- mice, whereas the 
decrease in these numbers was not statistically significantly in the dua/dua mice 
analysed alongside  (Figure 4.17B) and no significant decrease in B cells or CD4 
T cells was found in independent cohorts of dua/dua mice analysed in the next 
chapter. This raises the possibility that B cell and CD4 T cells are not affected by 
the reduced amount of correctly spliced Senp2 mRNA in dua/dua homozygotes, 
but are affected when the normal mRNA is further decreased because one of the 
alleles carries the exon 11 dua mutation and the other is unable to make Senp2 
mRNA at all. 
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Figure 4.17: Lower percentage of CD8+ T cells in Senp2dua/- 
compound heterozygotes like Senp2dua/dua homozygotes. (A) 
Representative FACS plots of peripheral blood lymphocytes, showing 
the percentage of CD4 and CD8 cells (upper panel) and %CD44low 
and CD44hi among CD8 cells in mice with the indicated genotypes. 
(B) Absolute number of B220+, CD4+, CD8+, CD8+CD44lo and 
percentage of CD44hiCD8 lymphocytes in the spleen of individual 
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mice of the indicated genotypes. Dots represent single mice and the 
bars represent the arithmetic mean. Statistical analysis by one-way 
ANOVA followed by Bonferroni post test: * p<0.5, ** p<0.005, 
***p<0.0005. 
 
 
4.12 Discussion 
 
The findings presented in this chapter reveal a mouse strain, ENU7B6:039, with 
CD8 T cell lymphopenia caused by a recessive decrease-of-function mutation in 
Senp2. Homozygous mutant mice had decreased numbers of CD8 T cells and 
especially reduced number and percentage of naïve CD44low CD8 T cells, and 
shorter persistence of naïve CD44low CD8 T cells when transplanted into 
syngeneic wild-type mice. The mutation was mapped to a 3.9 Mb interval on 
chromosome 16 and identified as a synonymous mutation in exon 11 of the Senp2 
gene that decreased splicing of exon 10 to exon 11. Mice with a Senp2 null allele 
fail to develop beyond the earliest stages of embryogenesis (Chiu et al, 2008), and 
an immunological role for SENP2 has not been previously reported.  
 
From our RT-PCR data, the ‘dua’ mutation decreased the percentage of amplified 
cDNA product splicing exon 10 to exon 11 from 95% to 45% (Figure 4.6D). 
While the remaining amplified PCR product skipped exon 11 and spliced exon 10 
to the unmutated exon 12 acceptor, it is not possible from the PCR study to 
determine how much the mutation decreases the overall abundance of full-length 
Senp2 mRNA. In wild-type mice, 5% of the PCR product skipped exon 11 and 
spliced to exon 12. If the exon 11 mutation does not enhance splicing to exon 12 
but simply decreases splicing to exon 11, then the increase of the skipped product 
from 5% to 30% of the amplified material in the heterozygotes would imply an 8-
fold decrease in the abundance of full-length mRNA from the mutant allele. In the 
homozygotes, where the skipped product comprises 55% of both products, this 
would represent a 23-fold decrease in full-length product assuming the rate of 
splicing to exon 12 is unaltered. However if there is competition between the exon 
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11 and exon 12 splice acceptors, the exon 11 mutation may increase the efficiency 
of the competing splicing reaction to exon 12 as much as it decreases splicing to 
exon 11. In this scenario there would be no decrease in overall Senp2 mRNA and 
the abundance of full-length mRNA would be decreased by 55%.   
 
As shown here, heterozygosity for a null Senp2 mutation on its own did not cause 
CD8 T cell deficiency, indicating that complete loss of half the normal gene dose 
is insufficient to recapitulate the homozygous dua/dua T cell phenotype. 
Conversely complete lack of normal SENP2 in homozygous knockouts is 
embryonic lethal (Chiu et al, 2008), indicating that the duan mutation preserves 
some normal SENP2.  Based on the reasoning above and the intermediate 
proportion of skipped PCR product in heterozygotes, it was theoretically possible 
that T cell deficiency in dua/dua homozygotes was caused by increased 
production of the exon 11 skipped product above a threshold crossed in dua/dua 
homozygotes but not in dua/+ mice with only one mutant allele. This possibility 
is nevertheless excluded by the finding that CD8 T cell deficiency was at least as 
severe in mice with a single dua mutant allele when the other Senp2 allele was 
null. Thus it is likely that diminished CD8 T cells in duan mice results from a 
decrease in the production of normally spliced Senp2 mRNA and protein by more 
than 55%, and potentially as much as 96% (23-fold), but less than 100%. Since 
the PCR experiments only examine one part of the mRNA, it is also possible the 
loss of normally spliced Senp2 mRNA involves some transcripts from the gene 
and not others, for example originating at different promoters or using alternative 
exons 5’ or 3’ to exons 10-12. It would be useful in future studies to compare the 
total amount of Senp2 mRNA in dua/dua, +/+ and +/- CD8 T cells by quantitative 
RT-PCR with primers from different regions of the cDNA, and to measure the 
amounts of different SENP2 protein species by western blotting of sorted CD8 T 
cells.  
 
Inefficient splicing of Senp2 exon10 to exon 11 has also been associated with 
another mutation causing diminished T cell survival and lower CD127 expression, 
involving a distinct gene, Hnrpll, which encodes an RNA-binding splicing 
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regulator (Cho et al., 2014). In that study, deep sequencing of oligo-dT primed 
cDNA from OT1 CD8 T cells revealed that splicing of Senp2 exon 10 to exon 11 
is normally delayed compared to the other exons, so that a substantial proportion 
of the sequence reads retained parts of the intron. In T cells with a destabilizing 
HNRPLL mutation a larger fraction of reads retained this intron and less mRNA 
encoding full-length protein was present. Poor survival of Hnrpll mutant OT1 
CD8 T cells could be corrected by retroviral expression of cDNA encoding full 
length SENP2 (Cho et al.,2014). Hence the inefficient splicing of Senp2 exon 11 
appears to be an important rate-limiting step controlling CD8 T cell survival. 
 
The nuclear export signal (NES) encoded by Senp2 exon 11 is located in the 
nonhomologous domains of SENP2 and can be blocked by CRM1 inhibitor 
leptomycin B (LMB) (Itahana et al., 2006). We hypothesized that the mutation in 
SENP2 protein might affect the subcellular localization of the mutant protein. 
However, overexpression of the mutant in HEK293T cells revealed no difference 
in the subcellular localization compared to the WT SENP2 protein. The loss of 
NES was dispensable for proper subcellular localization. The phenotype is 
unlikely caused by the mislocalization of protein, or mislocalization might occur 
selectively in CD8 T cells. Alternatively, as appears to be the case in Hnrpll 
mutant CD8 T cells, a further decrease in an already slow splicing reaction 
between exon 10 and exon 11 may simply decrease the overall abundance of 
SENP2 mRNA and protein by more than 50% and as much as 90% as discussed 
above. 
 
The results here showing that the NES skipped SENP2 product of the duan 
mutation has apparently normal subcellular localization is consistent with 
previous work showing that the localization of SENP2-GFP was not affected by 
mutating the essential leucine residues in the NES (Itahana et al., 2006). In that 
study, the NES mutation only had an effect when combined with NLS deletion 
mutants, resulting in substantial nuclear accumulation. It was suggested that the 
NES in SENP2 functions in the protein especially when NLS was deleted.  
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Survival of Senp2dua/dua OT-I CD8 T cells, but not their +/+ counterparts, was 
enhanced by retroviral expression of full-length Senp2 cDNA. This provides 
further evidence that the Senp2dua/dua exon 11 mutation is the causal mutation 
responsible for the CD8 T cell lymphopenia phenotype. The analysis of Senp2dua/- 
compound heterozygous mice that were generated from outcross of the ‘dua’ 
mutation to Senp2+/- knockout mice showed reduced naïve CD8 T cells frequency 
and number in spleen. The failure of the Senp2 null allele to complement the dua 
allele proved that Senp2 was the causal mutation.  
 
The Senp2 null mutation is embryonic lethal at embryonic day 10 due to a defect 
in accumulation of SUMOylated Pc2/CBX4 resulting in a defect in embryonic 
cardiac development (Kang, X., et al., 2010). SENP2 has been previously shown 
to be highly expressed in trophoblast cells and is indispensible for modulating the 
p53- Mdm2 pathway during trophoblast development (Chiu et al., 2008). Further 
study showed SENP2 can co-localize and associate with SUMO conjugated 
MDM2 in PML bodies where it catalyzes the desumoylation step of SUMO 
conjugated MDM2 (Jiang et al., 2010). The desumoylated Mdm2 binds to p53 and 
promotes its degradation. Their study proposes a negative regulation of SENP2 in 
the MDM2-p53 circuit that is important for genotoxic stresses (Jiang et al., 2010). 
By contrast homozygous duan mice are born normally without any physical 
abnormalities, indicating that the essential embryonic functions of Senp2 are 
preserved by the point mutant allele.  
 
SENP1, a closely related member of SENP2 in the Sentrin-specific protease 
family, has been studied extensively in mice. Inactivation of the mouse SENP1 
gene leads to embryonic lethality due to placental defects (Yamaguchi et al., 
2005). The mutant SENP1 causes an increase in the overall levels of SUMO-1 
conjugation but not the levels of SUMO-2 or SUMO-3 conjugation revealing a 
role for SENP1 in both conjugation and deconjugation of SUMO-1. SENP1 also 
has an indispensable role in the immune system. Conditional knockout mice have 
shown that SENP1 is essential in the early development of B and T cells (Nguyen 
et al., 2012). In SENP1-/- B and T cells, the SUMOylated form of STAT5 
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accumulates and sumoylated STAT5 remains inactive and unable to form dimers 
or translocate to the nucleus to activate transcription. STAT5 signalling in 
developing B and T cells is critical for transmitting survival signals from the 
cytokine, IL-7. It is interesting that CD127, the alpha chain of the IL-7 receptor, is 
decreased on the surface of dua/dua CD8 T cells, raising the possibility that both 
SENP proteins contribute in distinct ways to regulate IL-7 signalling for 
lymphocyte survival. 
 
SENP3 and SENP5 are members of the second SENP subfamily. SENP5 localizes 
mainly to the nucleolus and nucleus (Gong and Yeh, 2006). Sequences in the N 
terminus of SENP5 are responsible for nucleolar localization. It has been shown 
that SENP5 has C-terninal hydrolapse activity against SUMO-3 and isopeptidase 
acitivity against SUMO-2 and SUMO-3 conjugates. As a closely related member 
of SENP5, SENP3 also shows similar subcellular localization and substrate 
specificity. 
 
As most divergent members of the SUMO protease family, SENP6 and SENP7 
catalyze the deconjugation of SUMO-2 and SUMO-3 and the di-SUMO chains 
composed of SUMO-2 and SUMO-3. However, they have a lower preference for 
processing SUMO precursors (Lima and Reverter, 2008).  
 
It has been shown by Itahana et al that the protease function of SENP2 is not 
affected by the induction of mutations of two essential leucine residues in the 
NES (Itahana et al., 2006). To answer if duan mutation affects the protease 
function of the protein different from the mutant form in other studies, an in vivo 
sumoylation assay could be performed to determine the desumoylation activity of 
mutant protein. Moreover, quantitative PCR and protein half-life assay would also 
be useful to understand the causal mutation at mRNA and protein level. 
 
Currently there is no known point mutation reported in SENP2 protein in mice or 
human. The duan mice offer us a unique resource to understand how a mutation in 
a Sentrin-specific protease affects T cell homeostasis, and appear to reveal a novel 
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control over peripheral CD8 T cell survival. This issue is explored in more detail 
in the following chapter. 
 
  
	 145	
Chapter 5: Functional analysis 
of CD8 T cells in duan mice 
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5.1 Aim 
 
The aim of the experiments in this chapter were to understand the role of SENP2 
in the survival of naïve CD8 T cells and persistence of activated/memory CD8 T 
cells. First of all, I wanted to know if the naïve Senp2dua/dua CD8 T cells could 
survive in the periphery (section 5.2). Then, I studied whether the Senp2dua/dua 
CD8 T cells could undergo activation and proliferation in vivo (section 5.4). I also 
investigated the possible causes of the survival defects by analyzing IL-7 and 
TCR signaling pathway in vivo and in vitro (section 5.3). 
 
 
5.2 Senp2dua/dua mice have normal thymic development 
 
T cells originate from common lymphoid progenitor cells (LPC) and migrate into 
the thymus for further maturation. To understand if the reduced CD8 T cell 
phenotype in the periphery was caused by a developmental defect of T cells in the 
thymus or a survival defect of mature T cells in the periphery, thymocyte subsets 
from wild type and homozygous mutant mice were assessed by flow cytometry. 
The CD4 and CD8 double negative (DN) thymocytes can be divided into four 
developmental stages based on their expression of CD44 and CD25: DN1 (CD25-
CD44+), DN2 (CD25+CD44+), DN3 (CD25+CD44-) and DN4 (CD25-CD44-) 
(Godfrey et al., 1993). From Figure 5.1A (bottom panel), there was a similar 
percentage of wild type and Senp2dua/dua cells in each developmental stage: 13% 
vs 16% in DN1, 5% vs 5% in DN2, 50% vs 47% in DN3 and 32% vs 32% in DN4 
respectively. There was also a normal percentage of double positive (DP) and 
CD4 and CD8 single positive T cells present in senp2dua/dua thymocytes (Figure 
5.1A upper panel). The absolute numbers of thymic subsets from both groups 
were also analysed (Figure 5.1B). The dua/dua mice had comparable numbers of 
total thymocytes compared with wild-type mice. There was no significant 
difference in the cell number of DN1-4, DP and CD4 and CD8 SP cells between 
both groups. Therefore, the duan mutation has no discernable effect on T cell 
development in the thymus. 
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Figure 5.1: The Senp2dua/dua mutation does not affect T cell 
development in the thymus. (A) Representative FACS plots of 
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thymocytes from wild type and dua/dua mice showing (upper panels) CD4 
versus CD8 and the gates and percentage of DN, DP, CD4SP and CD8SP 
subsets, and (lower panels) CD44 versus CD25 gated on CD4- CD8- 
thymocytes, showing gates and percentage of DN1 (CD25-CD44+), DN2 
(CD25+CD44+), DN3 (CD25+CD44-) and DN4 (CD25-CD44-) subsets. B) 
Absolute number of different subsets in thymus of individual wild-type 
(white circles) or homozygous mutant mice (black circles). Dots represent 
single mice and the bars represent the arithmetic mean. Statistical 
analysis by unpaired t-test: n.s., not significant p>0.05. This experiment 
has been repeated twice with 3 mice in each group. 
 
 
5.2.1 SENP2 mutant mice have reduced CD8 T cells in spleen 
 
Spleen cells from dua/dua homozygous mice were compared with age-matched 
wild-type controls as shown in Figure 5.2. Wild-type and duan mice had 
comparable percentages of CD4+ T cells and there was no significant difference 
when group analysis was performed (Figure 5.2B). The absolute numbers of 
CD4+ T cells for both groups was also calculated and there was no significant 
difference between the groups (Figure 5.2C middle panel). The analysis of 
percentage of splenic B cells is also shown in 5.2B, compared with wild-type 
controls, dua/dua mice have slightly increased percentages of B cells which is 
likely due to a decrease in the CD8+ T cell subsets.  There was no significant 
difference in the absolute number of total B cell between the groups. 
 
CD8 T cell numbers in the duan mice were significantly lower compared to wild-
type mice (Figure 5.2B). When the T cell populations were subdivided into naïve 
(CD44lo) and effector (CD44hi) cells, there was no difference in the numbers of 
both naïve and memory CD4 T cells or in memory CD8 T cells between wild type 
and duan mice. By contrast, the mutant mice had significantly fewer naïve CD8 T 
cells (p<0.0055) (Figure 5.2C bottom panel). CD4 and CD8 T cells were stained 
for the surface markers CD44, KLRG1 and CD62L. CD44 expression was 
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comparable on wild type and senp2dua/dua CD4 T cells but the duan mice had a 
diminished peak of CD44lo naïve CD8 T cells and a higher peak of CD44hi cells 
due to the selective decrease in CD44lo CD8 cell numbers. 
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Figure 5.2: Analysis of lymphocyte populations in the spleen. (A) 
Representative flow cytometry plots of splenic lymphocytes. The plots in A 
show gates and percentage of CD4+ and CD8+ cells in one representative 
SENP2 wild-type (left) and one SENP2 mutant (right) mouse. (B) 
Percentage of different subsets among lymphocytes (top row), and the 
absolute number of B cells (medium row, left), CD4 and CD8 T cells 
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(medium row, right), and activated/memory and naïve CD4 and CD8 T 
cells (bottom row) in the spleen of individual wild-type (white circles) and 
homozygous mice (black circles). Dots represent single mice and the bars 
are the arithmetic mean. Statistical analyses by unpaired t-test: ns, not 
significant p>0.05. (C) Representative flow cytometry plots of different 
surface markers gated on spleen CD4 or CD8 T cells from dua/dua (red) 
or +/+ (grey) mice. 
 
 
The expression of CD127 (IL-7Rα) was measured on T cell subsets in spleen, 
since this receptor is essential for naïve T cell survival. As shown in figure 5.3A, 
naïve Senp2dua/dua CD8 T cells (CD44loCD8+) had lower CD127 expression 
compared to naïve WT CD8 T cells, as was also documented in blood T cells in 
chapter 4. The difference was not apparent in the activated/memory CD8 T cells 
(CD44hiCD8+) of the two groups, nor in naïve or activated/effector subsets of 
CD4 T cells between Senp2dua/dua and WT mice (Figure 5.3B).  
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Figure 5.3: Expression of IL-7R on Senp2dua/dua T subsets in spleen. 
(A) Representative flow cytometry plots of CD127 staining gated on spleen 
CD4+ CD44lo, CD4+CD44hi, CD8+ CD44lo or CD8+CD44hi T cells from 
dua/dua (red) or +/+ (grey) mice. (B) Geometric mean fluorescence 
intensity (MFI) of CD127 on naïve (CD44lo) CD4 T cells and 
effector/memory (CD44hi) CD4 T cells (upper panels), or naïve (CD44lo) 
CD8 T cells and effector/memory (CD44hi) CD8 T cells (lower panels), in 
individual wild-type (white circles) or homozygous mutant mice (black 
circles). Dots represent single mice and the bars represent the arithmetic 
mean. Statistical analysis by unpaired t-test: *, P<0.05; n.s., not significant. 
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5.3 Naïve CD8 T cell deficit is cell intrinsic (Bone marrow chimeras) 
 
From experiments in Chapter 4, transplantation of T cells from duan or wildtype 
OT-I TCR-transgenic mice revealed a survival defect in dua/dua naïve CD8 T 
cells. The lower expression of IL-7R on the surface of Senp2dua/dua naïve CD8 T 
cell could be an intrinsic property of mutant T cells contributing to their poor 
survival in transplantation, or it could be a cell extrinsic secondary effect of 
elevated IL-7 levels in the lymphopenic environment of dua/dua mice. To find out 
if the survival defect and decreased IL-7R on Senp2dua/dua CD8 T cells was cell 
autonomous or secondary to other cells, we generated mixed bone marrow 
chimeras by reconstituting irradiated Rag1-/- recipient mice with a 50:50 mix of 
wild-type CD45.1 marked bone marrow and either wild-type or mutant CD45.2 
marked bone marrow (Figure 5.4A). At the same time, two groups of mice were 
reconstituted with 100% wild type BM cells and 100% Senp2dua/dua BM cells to 
serve as controls. The irradiated recipients were bled 6 weeks after the 
reconstitution and every 2 weeks after, and flow cytometry performed to check 
the proportions of CD8 T cells in the peripheral blood and the IL-7Rα expression 
on CD8 T cells. The percent of CD8 T cells derived from 100% wild type BM 
cells was comparable to normal mice. The recipients with 100% mutant BM cells 
displayed the same phenotype of lower percentage of CD8 T cells as observed in 
unmanipulated mutant mice (Figure 5.4B). Mice that received a mix of 50% wild-
type CD45.1 and 50% dua/dua mutant CD45.2 bone marrow showed equal 
reconstitution of the splenic B cells by the CD45.2 positive mutant cells, ranging 
between 40% and 60% of B cells in individual chimeric animals (numbered 1 
through 5, Figure 5.4C). By contrast, in the CD8 T cells in each chimeric mouse 
CD45.2+ dua/dua cells accounted for approximately half the percentage observed 
in the B cells, ranging between 7% and 30% of CD8 T cells. In control mixed 
chimeras where the CD45.2+ cells were wild type, CD45.2+ cells accounted for 
40-60% of CD8 T cells and mirrored the contribution of CD45.2 cells to the B 
cell compartment. The failure of mutant cells to contribute to the CD8 T cell 
compartment equally to WT cells indicates that the effect of the Senp2 mutation 
was cell intrinsic.  
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Figure 5.4: The defect in dua/dua CD8 T cell accumulation was cell 
intrinsic in bone marrow chimera experiments. (A) Experimental 
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design of bone marrow chimera experiments. Bone marrow either 100% 
marked with congenic marker CD45.2 or 50:50 CD45.2/CD45.1 was 
injected into irradiated Rag1-/- recipient mice. (B) Representative analysis 
of mice receiving 100% WT bone marrow (left) or 100% mutant bone 
marrow (right) (top panel). Representative flow cytometry plots of gating 
strategies for CD45.1+ and CD45.2 B cells (middle panel) and CD45.1+ 
and CD45.2+ CD4 and CD8 T cells (bottom panel).  (C, D) Each column 
indicates the percentage of CD45.2+ cells in the indicated cell subsets in 
the peripheral blood of an individual 50:50 chimera mouse constructed as 
in part A. Each bar is the percent reconstitution of a cell subset in an 
individual mouse (indicated by the number below the bar). In the upper 
panels of C and D the CD45.2+ cell are dua/dua, while in the lower panels 
the CD45.2+ cells are wild-type. (E) Representative flow cytometry 
histograms of CD44 on WT and mutant CD45.2+ CD8+ cells in 50:50 
mixed chimeras (CD45.1 +/+ (grey); CD45.2 +/+ (blue) and CD45.2 
dua/dua (red)). 
 
The longitudinal analysis of CD45.2+ CD8 T cells in each of the 50:50 bone 
marrow chimeras is shown in Figure 5.5. From Figure 5.5A, the percentage of 
CD45.1 and CD45.2 CD8 T cells raised from WT bone marrow cells remained 
stable over time after the first 6 week bleed, with Senp2+/+ CD45.2 cells 
accounting for 40-60% of CD8 T cells even 30 weeks after marrow 
transplantation. As shown by the red triangles and lines in Figure 5.4B, 
Senp2dua/dua CD45.2 cells accounted for 40% and 55% of CD8 T cells 6 weeks 
after transplantation in mice 3 and 4, respectively, but decreased to 20% and 35% 
by 10 weeks after bone marrow transplantation, and further decreased to 4% and 
15% 30 weeks after transplantation. In the other three mixed chimeras in this 
group, dua/dua CD45.2+ cells were already decreased to 20-28% of CD8 T cells 
at 6 weeks and further decreased or remained at similar low proportions at 30 
weeks.  These results are consistent with the T cell transfer experiments in 
Chapter 4 indicating a cell autonomous shortening of CD8 T cell peripheral 
lifespan.  
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Figure 5.5: CD8 T cell autonomous defects of duan mice. Two groups 
of mixed bone marrow chimeras were generated as shown in Figure 5.4A, 
with CD45.2 marrow from either (A) +/+ or (B) dua/dua donors mixed with 
CD45.1 marrow from +/+ donors. The percentage of CD45.2+ and 
CD45.1+ cells among peripheral CD8 T cells from each recipient mouse 
was analysed in sequential blood samples collected 6, 8, 10, 14 and 30 
weeks after marrow transplantation. The day 0 data represents the % of 
Ly5a/jLy5b cells in the injected BM. 
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The longitudinal data for B cells and CD4 T cells in the same chimeric animals 
are shown in Figure 5.6. CD45.2+ cells ranged between 40-60% of B cells at 6 
weeks but then tended to increase gradually by 30 weeks after marrow 
transplantation, regardless of whether the CD45.2 cells were mutant or wild-type. 
This may reflect a subtle difference between the CD45.1 and CD45.2 congenic 
C57BL/6 strains, but indicates no discernable effect of the duan mutation within 
B cells. By contrast, dua/dua CD45.2 cells accounted for a lower percentage of 
CD4 T cells at the 6, 8 and 10 week timepoints, ranging between 15% and 50%, 
but by 30 weeks after reconstitution the percentage of dua/dua CD45.2 cells was 
comparable to +/+ CD45.2 cells among CD4 T cells. Thus, while there may be 
subtle and transient effects intrinsically within CD4 T cells, the long-term survival 
defect intrinsic to dua/dua CD8 T cells was not apparent in the other lymphocyte 
subsets.  
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Figure 5.6: Effect of the duan mutation on CD4 T cells and B cells in 
50:50 mixed bone marrow chimeras. Analysis of the same chimeric 
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animals as Figure 5.5, showing results of sequential blood samples 
analyzing (A) B cells, and (B) CD4 T cells.  
 
CD127 (IL-7Rα) expression on the CD44lo CD8 cells derived from the CD45.1 
and CD45.2 marrow donors was also measured in the same two groups of mixed 
chimeras at each time point after marrow transplantation. In the control mixed 
chimeras, there was no significant difference in the geometric mean of CD127 
between the CD45.1 WT or CD45.2 WT derived naïve (CD44lo) CD8 T cells at 
any time after marrow transplantation (Figure 5.7A). In the test group of mixed 
chimeras (Figure 5.7B), however, the naive (CD44lo) CD8 T cells derived from 
CD45.2 Senp2dua/dua BM cells showed a comparable level of CD127 expression to 
their wild-type counterparts at 6, 8 and 10 weeks after marrow transplantation, but 
CD127 was slightly decreased at 14 weeks and a dramatic decrease 30 weeks after 
transplantation (Figure 5.5B). The relative CD127 on CD45.2+ cells between the 
+/+ and dua/dua group of chimeras at each timepoint (divide MFI CD45.2 CD8+ 
by MFI CD45.1+ CD8 cells in the same chimera) is also calculated in Figure 5.7C. 
The difference in the relative CD127 between the +/+ and dua/dua groups after 10 
weeks further showed duan mutation results in a cell-autonomous decrease in 
CD127.   In conclusion, the results showed that the Senp2dua/dua mutation acts cell 
autonomously to lower expression of IL-7R. Interestingly, this phenotype 
developed later than the decrease in naïve CD8 T cell numbers following bone 
marrow transplantation, making it unlikely that decreased IL-7R expression is the 
cause of poor T cell survival.  
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Figure 5.7: Lower IL-7Rα expression on Senp2dua/dua naïve CD8 T cells. 
Analysis of CD127 on the CD45.2+ and CD45.1+ subsets of CD44low 
CD8+ T cells in sequential bleeds from each of the mixed bone marrow 
chimeras analysed in Figure 5.5. (A, B) CD127 mean fluorescence 
intensity (MFI) values for CD45.2+ and CD45.1+ cells in each animal. 
These were compared by unpaired t-test at each time-point: * p<0.05; ** 
p<0.01, ***p<0.0005. (C) The relative CD127 on CD45.2+ cells in each 
chimera at each timepoint expressed relative to the MFI of CD45.1+ CD8 
cells in the same chimera. Statistical analysis by unpaired t-test at each 
timepoint: * p<0.05; ** p<0.01, ***p<0.0005. 
 
 
5.4 Poor survival of naïve Senp2dua/dua OT-I cells in lymphopenic hosts 
 
Transplantation of Senp2 mutant OT-I T cells into Rag1 (recombination activation 
gene 1) deficient recipients was performed to study survival of antigen-naïve 
peripheral CD8 T cells without ongoing thymic output as existed in the mixed 
chimeras above and without competition by an established repertoire of T cells as 
occurred in the OT-I T cell transplant experiments in Chapter 4. RAG1 is an 
essential enzyme subunit for V(D)J recombination, and Rag1-deficient mice lack 
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mature B and T lymphocytes due to the absence of immunoglobulin or TCR gene 
rearrangement (Mombaerts et al, 1992). The Rag1-deficient recipients provide 
transplanted donor OT-I T cells with increased availability of cytokines and 
growth factors and empty peripheral “niches” to undergo lymphopenia-induced 
proliferation. 10 million splenocytes, comprising a 50:50 mixture of congenically 
marked wild type and Senp2dua/dua OT-I spleen cells, were adoptively co-
transferred into Rag1-deficient recipients. The blood from recipient mice was 
analysed at multiple time points. 
 
Figure 5.8 shows representative flow cytometry plots and the gating strategy 
applied to identify wild type and Senp2dua/dua OT-I CD8 T cells. I used CD8+Vα2+ 
to measure the percentage of OT-I donor-derived T cells among blood 
lymphocytes, and then applied CD45.1 and CD45.2 to measure the percentage of 
wild type (CD45.1/CD45.2 heterozygous) and Senp2dua/dua (CD45.1/CD45.1 
homozygous) cells among the donor-derived OT-I CD8 T cells. OT-I CD8 T cells 
were only 1-2% of blood lymphocytes 1 day after transplantation, but 
progressively increased to (15-30%) by day 69 and remained at these frequencies 
on day 157 (Figure 5.8B). Among the OT-1 CD8 T cells, the percentage of 
CD45.1/CD45.1 Senp2dua/dua cells declined from a mean of 54% at day 1 to a 
mean of 31% on day 157 (Figure 5.8C). Compared to the percentages on day 1, 
the percentage of dua/dua cells among OT-I cells was significantly decreased on 
day 18, 32, 69 and 157 (Figure 5.8C). CD44 expression did not differ between 
wildtype and mutant OT-I T cells any any of the timepoints from days 1 and 157. 
  
As the survival defect of Senp2dua/dua OT-I CD8 T cells in Rag1-deficient mice 
were not as pronounced as they were in lymphoreplete mice, the mice were 
observed up to day 490 to see if there was a dramatic difference in longer term. 
Two mice were ethically culled and one mouse was excluded from the data as it 
developed lymphoma. The two remaining mice were euthanised and the 
splenocytes were analysed, revealing that the percent of Senp2dua/dua OT-I CD8 T 
cells had declined to 15% and 17% (Figure 5.8D). CD44 expression was slightly 
higher on the Senp2dua/dua OT-I CD8 T cells at this timepoint.  
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Figure 5.8 Accumulation and persistence of Senp2dua/dua OT-I CD8 T 
cells in Rag1-deficient recipients. Rag1-deficient mice were 
intravenously injected on day 0 with an equal mixture of spleen cells from 
Senp2 mutant and wild-type CD45-marked OT-I TCR transgenic mice. (A) 
Representative flow cytometry plots of blood on the indicated days after 
transplanting the T cells, showing the gating strategy applied to identify 
lymphocytes (left column), and within lymphocytes to identify donor OT-I T 
cells (middle left column), and within the OT-I T cells to distinguish 
Senp2+/+ wild-type (+/+, CD45.1/CD45.2 heterozygous) or Senp2dua/dua 
mutant (dua/dua, CD45.1 homozygous) cells (middle right column). The 
right-most column shows expression of CD44 on the wildtype and mutant 
OT-I T cells. (B) Percentage of CD8+Vα2+ OT-I cells among lymphocytes 
in individual recipients on the indicated days after transplantation. These 
were compared by unpaired t-test at each time-point: * p<0.05; ** p<0.01, 
***p<0.0005. (C) Percentage of wild type (close circles) or Senp2dua/dua 
(red close circles) cells among OT-I CD8 T cells in individual mice. Lines 
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show arithmetic mean. These were compared by paired t-test compare 
percentage of dua/dua cells among OT-1 cells at each later timepoint with 
the percentage of dua/dua cells at day 1 at each time-point: * p<0.05; ** 
p<0.01, ***p<0.0005. (D) Percentage of wild type and Senp2dua/dua cells 
among donor OT-I CD8 T in the spleen of two individual Rag1-deficient 
recipients 490 days after transplantation, and their expression of CD44.  
 
 
5.5 Effect of SENP2 deficiency on survival of naïve CD8 T cell: TCR and IL-
7 signaling pathways 
 
As discussed in the introduction chapter, TCR signaling and IL-7 signaling are 
both required for naïve CD8 T cell survival. These pathways were investigated 
separately in Senp2dua/dua CD8 T cells to determine whether either is affected.  
 
 
5.5.1 TCR signaling 
 
Firstly, the TCR signaling pathway was tested by transplanting a 50:50 mixture of 
CD45.1/CD45.2 wild type and CD45.2/CD45.2 Senp2dua/dua OT-I CD8 T cells into 
TAP1 deficient recipients. TAP1 deficient mice express very little cell surface 
MHC class-I, depriving transplanted naïve CD8 T cells of survival signals from 
MHC-self peptide TCR interaction. Consequently transplanted CD8 T cells only 
survive approximately one week and do not undergo lymphopenia induced 
proliferation despite the deficiency of CD8 T cells in the TAP1-deficient 
recipients (Tanchot et al., 1997; Murali-Krishna et al., 1999). Recipient mice were 
bled on the next day post transfer and sacrificed for spleen cell analysis on day 4. 
As shown in Figure 5.9A, 1 days after transfer, there were slightly fewer mutant  
OT-I CD8 T cells than wild-type OT-I cells in each recipient which may simply 
reflect slight differences in their ratio in the injected inoculum. After 4 days, the 
percentages of both OT-I populations among lymphocytes had dropped to half 
due to the lack of MHC survival signals. However the relative ratio between WT 
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and Senp2dua/dua OT-I CD8 T cells remained similar (Figure 5.9B). CD44, CD127, 
KLRG1 and CD5 (spleen) markers were compared between WT and Senp2dua/dua 
OT-I CD8 T cells and no difference were seen between the two populations at two 
time points (Figure 5.9C) These experiments indicate that mutant naïve CD8 T 
cells appear neither more nor less short-lived than their wild-type counterparts 
when deprived of self pMHC I stimulation, although this does not shed light on 
their poor long-term survival when self pMHC I is present. 
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Figure 5.9 Persistence of naïve Senp2dua/dua and wild-type OT-I CD8 T 
cells transplanted into TAP1 deficient recipients. An equal mixture of 
spleen cells from CD45.1/CD45.2 Senp2+/+ and CD45.2/CD45.2 
Senp2dua/dua OT-I TCR transgenic mice was injected into the tail vein of 
Tap1-/- C57BL/6 mice, and the donor Va2+ CD8+ subsets enumerated in 
the blood on day 2 and in spleen on day 4 after transfer by flow cytometry. 
(A) Frequency of wild type (+/+) OT-I CD8 T cells (black circles) and 
Senp2dua/dua (dua/dua) OT-I CD8 T cells (red circle) expressed as a 
percentage of total lymphocytes in individual mice (linked by line). Two-
way ANOVA and Bonferroni post-tests were performed to compare 
statistical differences in +/+ and dua/dua at the indicated time points: at D2 
(ns), D4 (ns). 5 animals were analysed per time point. The experiment was 
performed three times. (B) The percentage of OT1 +/+ and dua/dua cells 
in each mouse at both time points. Paired t-test was performed to compare 
statistical differences in percentage of OT-I dua/dua cells of total donor 
cells at  D2 and D4(ns). (C) Representative histograms of CD44, CD127 
and KLRG1 at each timepoint, gated on dua/dua OT-I CD8 cells (red) and 
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+/+ OT-I CD8 cells (grey). 
 
 
5.5.2 IL-7 signaling 
 
The IL-7 signaling pathway was tested by measuring the ability of Senp2dua/dua 
OT-I CD8 T cells to induce phospho-STAT5 (pSTAT5) upon IL-7 stimulation. 
STAT5 is a key signaling molecule downstream of the IL-7 receptor 
(Mazzucchelli and Durum, 2007). There are two STAT5 isoforms: STAT5a and 
STAT5b. Upon IL-7 stimulation, both isoforms can be phosphorylated and form 
homo- or heterodimers. The activated STAT5 dimer then translocates to the 
nucleus and induces the expression of Bcl-2 and Mcl-1 to inhibit the 
mitochondrial pathway of apoptosis (Surh and Sprent, 2008). It has been shown 
that mice carrying a deficiency in either Stat5a or Stat5b alone do not have a 
severe lymphopenic phenotype. However, the combined deficiency of both 
STAT5A and STAT5B can lead to severe early developmental defects of B and T 
lymphocytes.  
 
pSTAT5 levels were measured by cytoplasmic staining and flow cytometry and 
expressed as the mean fluorescent intensity (MFI) at 1 min, 15min, 30min, 60min 
and 180min with different IL-7 concentrations. pSTAT5 MFI progressively 
increased with increasing IL-7 concentrations, peaking at 15min followed by a 
rapid decline, with no discernable difference between the wild type and 
Senp2dua/dua CD8 OT-1 T cells.  
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Figure 5.10 IL-7 induction of Stat5 phosphorylation in wild type and 
Senp2dua/dua OT-I CD8 T cells. A 50:50 mixture comprising 2 million cells 
of Senp2+/+ wild type (CD45.1/CD45.2) and Senp2dua/dua (CD45.1/CD45.1) 
OT-I spleen cells were co-cultured. The indicated concentrations of IL-7 or 
no IL-7 (unstimulated) were added for the indicated times prior to fixing the 
cells, performing immunofluorescent staining for pSTAT5, CD8, and 
CD45.1/CD45.2, and analysis by flow cytometry. (A) Gating strategy used 
to measure pSTAT5, and representative overlay histograms of +/+ (grey) 
OT-I +/+ 
OT-I dua/dua 
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and dua/dua (red) OT-I T cells at 15 minutes with 0 or 0.1 ng/ml IL-7. (B) 
Graphs show the mean fluorescent intensity (MFI) of phospho-STAT5 in 
wild type (+/+) or Senp2dua/dua (dua/dua) OT-I CD8 T cells at each time 
point. 
 
 
In naïve T cells, IL-7 stimulation can suppress cell-surface expression of its own 
receptor to allow unsignaled T cells access to IL-7 (Park et al, 2004). To study 
whether Senp2dua/dua CD8 T cells could up-regulate IL-7R in absence of IL-7 
stimulation and down-regulate IL-7R in response to IL-7 stimulation, we next 
measured surface expression of CD127 (IL-7Rα). One million Senp2+/+ wild type 
splenocytes (CD45.1/CD45.2) and one million Senp2dua/dua splenocytes 
(CD45.2/CD45.2) were co-cultured on day -1 with 1ng/mL of IL-7 (Figure 
5.11A). On day 0, half of the wells were washed and cultured without IL-7 and 
the other half remained stimulated with 1ng/ml IL-7. Cell surface CD127 was 
analysed at 2, 24, and 48 hours and 6 days by flow cytometry. 
 
The expression of CD127 on naïve Senp2dua/dua CD8 T cells at 2h of continued IL-
7 stimulation was lower than on the co-cultured wild type naïve T cells, and 
CD127 remained lower on mutant naïve T cells at all the subsequent timepoints 
(Figure 5.11B). In parallel cultures where IL-7 had been removed, CD127 was 
remained lower on mutant naïve CD8 T cells than on wild-type naive cells 2 
hours after IL-7 removal. However 24 hours after IL-7 removal, naïve CD8 cells 
had recovered high levels of surface CD127 that were indistinguishable between 
mutant and wild type cells, and this remained the case 48 hrs and 6 days after IL-7 
removal (Figure 5.11C). The exaggerated downregulation of surface CD127 on 
mutant naïve CD8 cells during continued IL-7 stimulation was not observed in 
CD44hi CD8 cells (Figure 5.11B, C). 
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Figure 5.11 Up-regulation of IL-7Rα on wild type and Senp2dua/dua CD8 
T cells after IL-7 exposure withdrawal. (A) Experimental design to 
investigate the up-regulation of IL-7 receptor after an initial period of IL-7 
exposure in vitro. Wild type (CD45.1/CD45.2) and Senp2dua/dua 
(CD45.2/CD45.2) splenocytes were co-cultured on day -1 with 1ng/mL IL-
7. On day 0, cells in half the wells continued to be cultured in IL-7 and 
cells in the rest of the wells were washed and cultured without IL-7, and all 
the cells were analysed for cell surface CD127 by flow cytometry at the 
indicated subsequent times. (B, C) Representative histograms of CD127 
staining on co-cultured mutant and wild-type naïve (CD44lo) and activated 
(CD44hi) CD8 T cells cultured with continued exposure to IL-7 (B), or 
cultured without further stimulation by IL-7 (C), at the indicated time points. 
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down-regulation following acute IL-7 exposure (Figure 5.12A). One million 
Senp2dua/dua splenocytes (CD45.2/CD45.2) and one million wild type cells 
(CD45.1/CD45.2) were co-cultured overnight without IL-7 in 24 well plates to 
fully up-regulate IL-7 receptor expression. The cells were then cultured with 
1ng/mL IL-7 and analysed by flow cytometry at different time points, subdivided 
into naïve CD44lo CD8 cells and activated CD44hi CD8 cells. Two hours after IL-
7 exposure, the CD127 expression was decreased on mutant and wild-type naïve 
CD8 cells (Figure 5.12B, D) when compared to the CD127 expression on naïve 
CD8 cells at the same timepoint cultured without IL-7 (Figure 5.12C, D). 
However a distinct subset of Senp2dua/dua naïve CD8 T cells had much more 
dramatically down-regulated CD127 by 2 hrs (Figure 5.12B). After 4 hrs IL-7, the 
CD127 expression was further decreased on wild-type naïve CD8 cells but it was 
now 5-fold lower on mutant naïve CD8 cells in the same culture (Figure 5.12B, 
D). The exaggerated CD127 downregulation on mutant naïve CD8 cells persisted 
after 6 and 8 hrs IL-7 exposure, although the difference became smaller because 
the CD127 expression continued to decrease on the wild-type cells at the later 
times. Exaggerated CD127 on Senp2 mutant cells was limited to naïve CD8 cells 
and was not apparent in comparison of mutant and wildtype CD44hi CD8 T cells. 
This experiment was repeated once, a similar trend of CD127 down-regulation 
was also observed in later time point (6 hrs) (Figure 5.12E). Collectively, the 
experiments in Figures 5.11 and 5.12 show that the Senp2 mutation selectively 
exaggerates IL7RA downregulation on naïve CD8 T cells in response to acute or 
chronic IL-7 exposure, explaining the lower IL7RA on mutant naïve CD8 cells in 
vivo. 
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Figure 5.12 Down-regulation of IL-7Rα on wild type and Senp2dua/dua 
CD8 T cells after IL-7 stimulation. (A) Experimental design to investigate 
the downregulation of IL-7 receptor. Wild type (CD45.1/CD45.2) and 
Senp2dua/dua (CD45.2/CD45.2) splenocytes were co-cultured on day -1 
without IL-7 to recover from any IL-7 exposure received in vivo. On day 0, 
half the wells were cultured with 1ng/mL of IL-7 and the rest of the wells 
were cultured without IL-7. (B, C) Histograms showing CD127 expression 
on mutant and wild-type naïve (CD44lo) and activated (CD44hi) CD8 T 
cells with 1ng/mL IL-7 (B) or without IL-7 stimulation for the indicated times. 
(D) 4 line graphs showing peak CD127 on naïve CD8 dua/dua (red line) 
and +/+ cells (blue line) with IL-7 stimulation and naïve CD8 dua/dua 
(black dash line) and +/+ cells (grey shade) without IL-7 stimulation at 
each time. (E) This experiment was repeated once and 4 line graphs 
showing peak CD127 on naïve CD8 dua/dua (red line) and +/+ cells (blue 
line) with IL-7 stimulation and naïve CD8 dua/dua (black dash line) and 
+/+ cells (grey shade) without IL-7 stimulation at each time. 
 
 
5.6 Effect of Senp2dua/dua mutation on the activation of T cells and persistence 
of memory T cells with antigenic challenge 
 
In the previous chapter, naïve Senp2dua/dua OT-I CD8 T cells were shown to have a 
2h 4h 6h 8h 
CD127 
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survival defect in vivo but proliferated normally in vitro when stimulated with 
anti-CD3 antibody. We therefore wished to extend these studies to analyse the 
response of naïve Senp2dua/dua OT-I CD8 T cells to antigen in vivo, including 
clonal expansion and persistence of antigen-specific memory CD8 T cells. A 
mixture of 1000 FACS sorted (B220-CD4-) Senp2+/+ wild type and Senp2dua/dua 
OT-I CD8 T cells, congenically marked as CD45.1 heterozygous or homozygous 
respectively, were injected into the circulation of wild type B6 (CD45.2) recipient 
mice. Six hours later, the recipient mice were challenged intraperitoneally with 
recombinant H3N2 Influenza A virus expressing OVA peptide (amino acid 
sequence SIINFEKL; HKx31-OVA). The recipient mice were first bled at day 7 
post primary challenge to measure the expansion of Senp2dua/dua OT-I CD8 T cells 
at the peak of the primary immune response. The second bleed was done at day 70 
post challenge to measure antigen-specific memory CD8 T cells. Lastly, the 
recipient mice were received a second challenge on day 77 with H1N1 Influenza 
A virus expressing OVA (PR8-OVA), which carried serologically non-
crossreactive surface haemagglutinin and neuraminidase but expressed the same 
OVA epitope as HKx31-OVA. The recipient mice were bled 7 days after the 
secondary challenge (day 84 post primary challenge) to measure the recall 
response of Senp2dua/dua OT-I CD8 T cells upon secondary challenge. 
 
Flow cytometry showed that wild type OT-I cells (CD45.1+ CD45.2+) comprised 
55% and Senp2dua/dua OT-I cells (CD45.1+ CD45.2-) comprised 45% of the donor 
CD8 T cell mixture injected into recipient mice, and there was no difference in 
their expression of CD44 (Figure 5.13A). Seven days after the recipients received 
the primary HKx31-OVA virus challenge both wild type and Senp2dua/dua OT-I 
CD8 T cells had undergone dramatic clonal expansion, accounting for 2-7% of all 
blood lymphocytes. Within individual recipients, the Senp2dua/dua OT-I CD8 T 
cells had expanded to equal or slightly lower percentages than the wild type OT-I 
CD8 T cells in the same recipient (Fig 5.13C). At day 70 post primary challenge, 
the virus-expanded wild type OT1 cells had contracted to 0.1-0.3% of blood 
lymphocytes while Senp2dua/dua OT-I cells in the same recipients had contracted 
much more dramatically to one tenth the frequency of their wild type OT1 
	 184	
counterparts. A second PR8-OVA virus challenge given i.p. on day 77 elicited a 
recall response in the OT-I memory CD8 T cells, measured at day 84. Wild-type 
OT-1 cells increased to 8% of blood lymphocytes while mutant OT-1 cells 
increased to less than 1% of lymphocytes. As there were less memory Senp2dua/dua 
OT-I CD8 T cells surviving at day 70 prior to the second virus administration, a 
smaller pool of mutant memory CD8 cells may account for the smaller number of 
Senp2dua/dua OT-I CD8 T cell progeny formed 7 days after secondary challenge. 
 
In summary, Senp2dua/dua OT-I CD8 T cells could undergo clonal expansion 
similar to wild type cells. However Ag-specific Senp2dua/dua OT-I CD8 T cells had 
poor survival during the memory phase of the response. The cells remaining were 
able to recall to approximately the same extent as wild type however due to the 
poor survival at day 70 post primary challenge, Senp2dua/dua OT-I CD8 T cells led 
to a lower recall response after the secondary challenge. 
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Figure 5.13. Analysis of antigen-specific Senp2mut/mut CD8 T cells for 
persistence and recall response after viral challenge. Congenically 
marked OT-I T cells with either wild-type SENP2 (CD45.1/CD45.2 
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heterozygous) or mutant SENP2 (CD45.1 homozygous) were mixed in a 
50:50 ratio and 1000 cells were injected into the tail vein of normal 
C57BL/6 recipients, which were then injected i.p. with recombinant HKx31-
OVA influenza virus. (A) Analysis of cells in the donor inoculum at the time 
of adoptive transfer. (B) Representative flow cytometry plots show the 
gating strategy applied to distinguish the two donor T cell populations on 
days 7, 70 and 77. (C) Percentages of wild-type (open) and Senp2dua/dua 
(closed) OT-I CD8 T cells in blood lymphocytes at the indicated time 
points, with lines connecting data from the same recipient mouse. 
 
 
To understand whether the effector Senp2dua/dua OT-I CD8 T cells could undergo 
normal differentiation and generate memory cells, expression of CD44, CD62L, 
CD127 (IL-7Rα) and KLRG1 on Senp2dua/dua OT-I CD8 T cells and their wild 
type OT-1 counterparts was examined at various time points (Figure 5.14). At the 
peak of the primary immune response (day 7 post challenge), there were no 
differences in the expression of CD44, CD62L, CD127 and KLRG1. Examination 
of the cells on day 70 were inconclusive due to the low numbers of cells to assay. 
At the peak of the recall response (day 84, 7 days post secondary challenge), the 
expression of all the markers was similar on both donor populations. These results 
showed that the survival defect caused by the Senp2dua/dua mutation was not due to 
a preferential formation of short-lived effector cells. 
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Figure 5.14 Expression of surface markers on OT-1 CD8 T cells 
during in vivo activation, differentiation and survival. Donor-derived 
Senp2+/+ wild type and Senp2dua/dua OT-I CD8 T cells in the experiment in 
Figure 5.13 were stained for the cell surface markers CD44, CD62L, 
CD127 and KLRG1. Representative histograms from a single mouse show 
wild type (+/+) and Senp2dua/dua (dua/dua) OT-I CD8 T cells and 
endogenous (endog.) CD8 T cells. 
 
 
5.7 Effect of Senp2dua/dua mutation on in vitro T cell proliferation 
 
In the previous section, Senp2dua/dua OT-I CD8 T cells had almost normal 
expansion upon antigen challenge but the memory cells could not survive longer 
term like the wild type cells. I next tested the ability of Senp2dua/dua OT-I CD8 T 
cells to proliferate in vitro to anti-CD3. CFSE-labeled and CD45-marked wild 
type and Senp2dua/dua OT-I CD8 T cells were co-cultured with 0 (unstimulated), 
0.1ug/mL, 1ug/mL and 10ug/mL anti-CD3 antibody, and cell division measured 
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by flow cytometric analysis of CFSE dilution 3 days later. As shown in Figure 
5.15, Senp2dua/dua OT-I CD8 T cells diluted CFSE comparably to wild type OT-I 
CD8 T cells at each of the doses of anti-CD3 tested which indicates Senp2dua/dua 
OT-I CD8 T cells have normal T cell proliferation in vitro.  
 
 
 
 
 
Figure 5.15 In vitro division of wild type and Senp2dua/dua OT-I CD8 T 
cells in response to anti-CD3 antibody. CD45.1/CD45.2 wild type OT-I 
CD8 T cells and CD45.1/CD45.1 Senp2dua/dua OT-I CD8 T cells were mixed, 
labeled with CFSE, and co-cultured with 0, 0.1, 1, 10 μg/mL of anti-CD3. 
CFSE dilution was measured by flow cytometry after 3 days in wild type  
(blue), and Senp2dua/dua  (red) CD8 T cells. 
 
 
5.8 Discussion 
 
This chapter examined the consequences of the Senp2 duan mutation for CD8 T 
development and response to TCR and IL7RA stimulation. Homozygous Senp2 
duan mice were found to undergo normal T cell development in the thymus. The 
mutant mice had normal thymocyte cell percentages and absolute number at 
different stages of thymic development. However, there was a significant 
reduction in naive CD8 T cell numbers in the spleen, consistent with the decrease 
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in blood demonstrated in Chapter 4. These data indicate that the Senp2 mutation 
does not affect T cell development but disrupts the accumulation of mature naïve 
CD8 T cells in the periphery. However memory CD8 T cell numbers were not 
affected. The duan strain was first identified by a lower percentage of CD8 T cell 
in the peripheral blood and most CD8 T cells carried CD44hi phenotype. This 
could be explained by decreased numbers of CD8 T cells in the naïve 
compartment but normal numbers of CD44hi CD8 T cells. The numbers of mutant 
CD44hi CD8 T cells were likely to be maintained by lymphopenia induced 
proliferation, which was shown to be normal in T cell transfers.  
 
The peripheral naïve CD8 T cell pool is maintained for long periods in cell cycle 
interphase by TCR:self-pMHC interactions and IL-7 signaling (Kirberg et al., 
1997; Nesic, D. and Vukmanovic,S., 1998; Schluns, K.S., et al., 2000; Benoist, C. 
and Mathis, D., 2001). After being transplanted into lymphoreplete recipients, 
naïve donor CD8 T cells compete with host T cells for survival signals from 
pMHC I and IL-7. The transfer experiments in Chapter 4 showed Senp2dua/dua OT-
I CD8 T cells decreased rapidly with a half-life of less than 10 days under these 
conditions, whereas co-transferred wild type OT-I CD8 T cells declined with a 
half-life of ~50 days.  
 
Diminished persistence of the Senp2 mutant CD8 T cells could theoretically 
reflect abnormalities in either TCR/pMHC I or IL-7/IL7RA signals.  It has been 
shown that naive CD8 T cells decline rapidly after induction of TCR deletion, 
with a half life about 16 days after induction of TCR deletion compared to l62 
days for WT CD8 T cells (Polic et al., 2001). The actual time of CD8 T cells 
survival after TCR is eliminated is believed to be shorter because of the time 
delay for loss of TCR. Brown et al. also demonstrated that CD8 T cells could not 
survive longer than 2 weeks after adoptively transfer into recipients without 
appropriate MHC-TCR signals (Brown, E., et al., 2005). 
  
When naïve CD8 T cells were adoptively transferred into IL-7-/- mice, donor cells 
decreased dramatically and were undetectable at 30 days after cell transfer (Tan et 
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al., 2001). It has been shown that combination of a deficiency in IL-7 signaling 
with impairment of TCR signaling causes a more rapid decline of T cell numbers 
(Seddon and Zamoyska, 2002). 
 
We tested the role of pMHC I in the poor survival of Senp2 mutant naïve CD8 T 
cells by transferring OT-I CD8 cells into TAP-1 deficient mice, which are unable 
to load peptides into MHC-I and consequently have very low MHC-I on cell 
surfaces. There was no obvious survival disadvantage for Senp2dua/dua CD8 T cells 
compared to wild type cells in TAP1-deficient recipients. A confounding factor in 
this experiment is that the transplanted wild-type and mutant CD8 T cells declined 
much more rapidly in the absence of pMHC-I than the T cell decline caused by 
Senp2 mutation in wild type B6 recipients. Since OT-I transgenic mice have a 
high affinity TCR for self peptide MHC but still have survival defects, this 
suggests the Senp2duan survival defect was not due to a problem with TCR 
signaling, although the results are ambiguous on this point. 
 
Additional evidence that TCR signaling was not affected by the mutation comes 
from the finding that Senp2dua/dua OT-I CD8 T cells were able to divide normally 
when stimulated with anti-CD3 in vitro, and undergo normal primary clonal 
expansion upon viral antigen stimulation in vivo. After the viral antigen was 
cleared, however, the memory Senp2dua/dua OT-I CD8 T cells persisted at ten-fold 
lower frequencies than their wild type OT-I counterparts. It has been shown that 
IL-2, IL-7 and IL-15 are non-dispensable for memory CD8 T cell persistence or 
recall. IL-2 during primary infection provides important signals for CD8 memory 
T cells to mount a full recall response (Williams et al., 2006). IL-15 was required 
for primary expansion of CD8 T cells challenged with vesicular stomatitis virus 
(VSV) and also indispensable for the generation and maintenance of memory 
CD8 T cells (Schluns et al., 2002). Without IL7RA activity, CTL could convert to 
memory cells but cannot persist (Carrio et al., 2007). It was shown that the IL7RA 
deficient cells decreased to undetectable levels between 14 and 28 days after 
adoptive transfer into the B6 mice while wild type cells still persisted. 
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The CD8 T cell defects caused by the SENP2 duan mutation resemble those in 
‘Thunder’ mice carrying a point mutation in the Hnrpll gene that destabilizes one 
of three RNA-binding domains of the hnRNPLL protein. Thunder mice have 
selectively diminished peripheral CD4 and CD8 T cell accumulation and 
peripheral survival without affecting proliferation by Wu et al., 2008. The 
Hnrpllthu/thu mice undergo normal T cell development in the thymus. The reduced 
T cell numbers are restricted to naïve (CD44lo) CD4 and CD8 T cells while 
activated/memory (CD44hi) T cells numbers are normal. Transfers into 
lymphoreplete recipients established that Hnrpllthu/thu CD8 T cells had a greatly 
shortened lifespan compared to wild type cells. Also like Senp2 mutant OT-1 T 
cells, Randall et al. showed Hnrpllthu/thu OT-I CD8 T cells could undergo normal 
in vitro proliferation and in vivo clonal expansion on day 7 after viral challenge, 
but persistence of Hnrpllthu/thu memory cells after the contraction phase was 
greatly decreased 4 weeks post challenge (Randall et al., 2011). hnRNPLL is a 
memory-induced RNA-binding protein that regulates mRNA splicing. In 
Hnrpllthu/thu mice, mutant hnRNPLL fails to exclude exons 4, 5 and 6 of the T cell 
Ptprc mRNA.  
 
Recently, RNA-seq was performed to study hnRNPLL-dependent splicing events 
in the Hnrpllthu/thu OT-I CD8 T cells. Remarkably, splicing of Senp2 exon 10 to 
exon 11 was one of the highest ranked targets of hnRNPLL, with defective 
hnRNPLL causing retention of parts of the intron and decreasing the formation of 
exon 10-11 spliced products (Cho et al., 2014). The transduction of Hnrpllthu/thu 
OT-I CD8 T cells with normally spliced Senp2 cDNA could restore the survival 
of the Hnrpllthu/thu T cell indicating that inefficient splicing of exon 11 in Senp2 is 
responsible for the CD8 T cells survival defect in the Hnrpllthu/thu mice.  
 
CD127 IL-7Rα chain is displayed at lower levels on naïve CD8 T cells in 
Senp2dua/dua and Hnrpllthu/thu mouse mutants. In Hnrpll mutant T cells low cell 
surface protein was accompanied by low Il7ra mRNA (Wu et al., 2008). Here I 
showed low IL-7Rα expression on Senpdua/dua naïve CD8 T cells was a cell 
autonomous trait in mixed bone marrow chimeras, albeit one that developed 
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relatively late in the reconstitution of these chimeras. IL-7 nevertheless induced 
acute STAT5 phosphorylation at indistinguishable levels and with identical 
kinetics in mutant and wild type naïve CD8 T cells exposed to sub-saturating and 
saturating IL-7 concentrations. Likewise, there was no effect of the Senp2 
mutation on up-regulation of IL-7Rα after IL-7 withdrawal in vitro. However, the 
Senp2 mutation caused markedly exaggerated IL-7Rα downregulation within 2 
hrs of IL-7 exposure in vitro, again selectively on naïve and not on CD44hi 
activated/memory CD8 T cells. Provided IL-7 stimulation continued, the 
exaggerated IL-7Rα downregulation on mutant naïve CD8 T cells persisted for at 
least 6 days in vitro. Collectively, these results identify a specific or rate-limiting 
role for SENP2 in opposing IL-7Rα downregulation selectively on naïve CD8 T 
cells. 
 
IL-7 is a prosurvival cytokine constitutively produced by stromal cells, monocytes 
and some epithelial cells (Jiang, Q et al., 2005). IL-7 signaling initiates expression 
of anti-apoptotic genes such as Bcl-2 in T cells. Once signaling from IL-7 is 
initiated, transcription of the Il7ra gene is inhibited in T cells as a negative 
feedback mechanism (Park, et al, 2004).  Park et al (2007) also demonstrated that 
transcription of CD8 coreceptor can be activated by IL-7 signaling. Moreover, IL-
7 signaling is negatively regulated by TCR signaling stimulated by self pMHC-I 
and results in a reduction of CD8 expression.  Hence, they identified a dynamic 
feedback loop that promotes CD8 T cell survival through modulating IL-7 
receptor and CD8 coreceptor expression.  
 
Negative regulation of IL-7Rα by its cognate ligand IL-7 is mediated by the 
transcriptional repressor, growth factor independent 1 (GFI-1), in CD8 T cells but 
not in CD4 T cells (Park, et al., 2004). The selective effect of Senp2 and Gfi1 
mutations on CD8 T cells and not CD4 T cells raises the hypothesis that 
sumoylation enhances the effect of GFI-1, so that GFI-1 has an exaggerated 
inhibitory effect on IL7RA expression when less SENP2 is available to remove 
SUMO. There is no published evidence that GFI-1 itself is SUMOylated, but GFI-
1 interacts with the STAT3 inhibitor and Sumo-specific ligase, PIAS3 (Rodel et 
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al., 2000). In Tarik Moroy’s recent review (Moroy and Khandanpour, 2011), he 
states: “It remains open, whether the activity of PIAS proteins as E3 ligases for 
SUMO residues plays a role in this interaction, but it is attractive to speculate that 
GFI1, which has so far not been shown to be sumoylated, may serve as a docking 
site for other proteins that are to be sumoylated. This function although highly 
speculative may be enabled by an interaction with proteins such as PIAS3.” To 
test this hypothesis, western blotting or mass spectrometry could be used to 
determine the levels of GFI-1 protein and SUMOylation of GFI1 and other 
proteins in resting and IL-7 stimulated Senp2dua/dua cells. A genetic test for a role 
of GFI1 in mediating the effects of Senp2 mutation would be to breed Senp2dua/dua 
mice with one Gfi1 allele inactivated, and measure whether the decreased Gfi1 
gene dose could restore normal IL7RA expression on Senp2 mutant CD8 T cells.  
 
While the experiments here point to abnormal response to IL-7 signalling as the 
explanation for poor survival of SENP2 mutant naïve CD8 T cells, other signaling 
pathways could also be affected by the mutation. The Wnt signalling pathway is 
involved in various cellular activities including cell fate determination, 
differentiation, and proliferation (Logan et al., 2004). In the absence of Wnt 
signal, β-catenin is phosphorylated after binding to a ‘destruction complex’ that 
consists of Axin, APC and the protein kinase GSK-3, and degraded after 
polyubiquitination. Once exposed to Wnt signals, the complex is disrupted and the 
degradation of β-catenin is inhibited. Zhao et al. found constitutive activation of 
Wnt signalling pathway can stabilize β-catenin and favors the formation of 
antigen-specific memory CD8 T cells (Zhao et al., 2010).  Sumoylation is also 
involved in the regulation of the Wnt signaling pathway (Kadoya et al, 2002). 
Axam (Axin-associating molecule) has a similar C-terminal sequence to SENP1 
and has been shown to function as a desumoylation enzyme and remove SUMO-1 
molecule from target proteins. The desumoylation activity of Axam is involved in 
downregulation of β-catenin. Therefore, it could negatively regulate the Wnt 
signaling pathway. Since duan mice have less antigen-specific memory CD8 T 
cells compared to wild type mice, it could be hypothesized that the loss of exon 
11 caused by the duan mutation results in a gain function mutation with increased 
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desumoylation activity against β-catenin. This over activity of desumoylation 
could downregulate β-catenin and shrink the antigen-specific memory CD8 T cell 
pool by suppressing the Wnt signaling pathway. However, the results in Chapter 4 
establish that the effects of the duan mutation on CD8 T cells were recessive and 
equally severe when a single copy of the duan allele was present along with a null 
allele, arguing against a gain-of-function hypothesis. 
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Chapter 6: Discussion 
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ENU-mutagenesis: a non-biased approach to identify novel genes in immune 
system 
 
ENU mutagenesis screen is a powerful tool to identify novel genes involved in 
immune system in a nonbiased manner. The Goodnow group has been using ENU 
mutagenesis screens to identify genes important in adaptive immune cell 
development, function and homeostasis (Miosge et al., 2002; Jun et al., 2003; 
Vinuesa et al., 2005, Wu et al., 2010, Randall et al., 2009).  
 
Although ENU mutagenesis is a widely applied phenotype-driven approach to 
understand gene function, it is inevitable to isolate additional alleles of genes that 
are already well characterised by knockout mice, like DOCK2. My studies of the 
dockland mouse strain have led to the discovery of a mutation in exon 23 of 
Dock2 gene that produced a premature stop codon. Because the mutation 775E to 
stop codon is right after DHR-1 domain (Figure 3.4), any remaining protein 
product lacks the DHR-2 domain. Like all the DOCK family proteins, the DHR-2 
domain of DOCK2 binds to Rho-family G proteins and promotes GTP-GDP 
exchange to activate local cytoskeletal changes, cell migration and polarization 
(Meller et al., 2005; Cote and Vuori, 2007). All these cell activities are abolished 
with the loss of the DHR-2 domain. The results in Chapter III suggest that our 
dockland mutation is probably equivalent to the knockout allele first described by 
Fukui (Fukui et al. 2001) and to recessive alleles recently discovered in children 
with severe combined immunodeficiency (Dobbs et al., 2015). 
 
The powerful ENU mutagenesis can also lead us to discover novel genes. The 
critical immunological role of another DOCK family protein, DOCK8, was 
discovered by Randall et al, 2009 through isolation of a missense mutation that 
changes a conserved serine in the Rac/Cdc42 binding site of the DHR2 domain 
(Randall et al., 2009). Before the discovery of primurus mutation, the in vivo 
function of DOCK8 had remained unknown, and a human DOCK8 
immunodeficiency syndrome was discovered independently and after the mouse 
mutant was identified.  
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Moreover, the strength of ENU mutagenesis is that by starting with an abnormal 
immune system phenotype we can identify entirely new genetic elements of 
adaptive immunity. For genes where complete loss of function mutations are 
embryonically lethal, like Senp2, discovering their immune function by the gene 
knockout approach is confound by the absence of viable progeny. The SENP2 
protein and gene have been already well studied at molecular level, but knockout 
mice are lethal at very early stage in development. The discovery of ‘duan’ 
mutation in Senp2, with a subtle loss of function allele, revealed an apparently 
rate-limiting role for SENP2 in peripheral CD8 T cell survival.   
 
 
In summary Dock2doc/doc mice has: 
 
	 	 	
DOCK2-deficient summary Reference Dock2doc/doc 
reduced total number of spleen cells Fukui et al., 2001 ✔ 
atrophic lymphoid follicles Fukui et al., 2001   
Markly reduced MZ B cells Fukui et al., 2001 ✔ 
reduced thymocyte number Fukui et al., 2001 ✔ 
defect mature thymocyte egress 
from thymus Fukui et al., 2001   
abnormal thymic architecture Fukui et al., 2001   
peripheral blood T lymphocytopenia Fukui et al., 2001 ✔ 
disrupted lymphocyte migration in 
response to chemokine and S1P 
Fukui et al., 2001; 
Nombela-Arrieta 
et al., 2007   
normal B-lymphopoiesis Fukui et al., 2001 ✔ 
Impaired immunological synapse 
formaiton in T cells Sanui et al., 2003   
reduction of NKT in thymus and 
spleen   ✔ 
reduction in pDC; defective IFN-α 
production Gotoh et al.,2008   
normal antigens-specific CD8 T cell 
immune response    ✔ 
surival advantage in innate immune 
response   ✔ 
	 198	
   The study and analysis in the first part of this thesis showed that the 
characteristics of our dockland mutation in DOCK2 have no difference from 
DOCK2-deficient mouse (Fukui et al., 2001). The mutation causes a stop codon 
instead of Glutamic acid after DHR-1 domain. If the protein can be made, there is 
no functional domain for GEF activity. Western blotting has not been done 
successfully. 
 
The dedicator of cytokinesis (DOCK) family proteins belong to guanine 
nucleotide exchange factors (GEFs) that regulate the activation of Rho GTPases. 
There are more than 20 Rho GTPases that act as molecular switch by cycling 
between GDP-bound inactive and GTP-bound active states and their GTP-GDP 
exchange is mediated by GEFs. Rho GTPases like Rho, Rac, Cdc42 are well 
known for their ability to regulate the actin cytoskeleton and variety of cellular 
processes. There are 11 members of DOCK proteins. DOCK2 is a member of the 
DOCK-A family and it has been studied extensively in mice during last decade. 
DOCK2 is predominantly expressed in hematopoietic cells and has been shown to 
be indispensable for lymphocyte migration in response to chemokine (Fukui et al., 
2001; Sanui et al., 2003) DOCK2 knockout mice display T lymphopenia, atrophy 
of lymphoid follicles and loss of marginal zone B cells. Homozygous DOCK2 
knockout mice leads to B and T cell migration defect in response to chemokines, 
T cell lymphopenia and absence of marginal zone B cells.  
 
Migration of lymphocytes is of central importance for effective adaptive immune 
response. T cells need to actively migrate out of the thymus medulla and into the 
bloodstream, attracted by the sphingosine metabolite S1P acting upon the receptor 
S1P1 (Allende et al., 2004; Schwab and Cyster, 2007). T and B cells continually 
actively migrate from the blood into specialized subcompartments of secondary 
lymphoid organs to survey the antigen, returning to the blood by active migration 
into the lymphatic vessels, and then via the blood into another lymph node or into 
tissues to survey for the pathogens if fail to encounter their antigen. This 
trafficking of lymphocytes into and within secondary lymphoid organs is guided 
by two families of G protein-coupled receptors: chemokines such as CCL21, 
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CCL19, CXCL12, and CXCL13, while egress to lymphatics is guided by the 
sphingosine S1P1 receptor system (Cyster, 2005; Von Andrian et al., 2003). 
Activated T cells will transit into tissues to survey for pathogens only when they 
are really activated, otherwise, they will transit back into circulation then back to 
lymph nodes. 
 
Although normal cells could migrate efficiently to these chemokines in a dose 
dependent manner, DOCK2 deficient lymphocytes have severe defects responding 
to these chemokines (Fukui et al., 2001). Surprisingly, the small white pulp in 
DOCK2-deficient mice has normal segregation of lymphocytes into T and B cell 
areas which was not seen in mice lacking chemokines CCL19, CCL21 or 
CXCL13 (Fukui et al., 2001; Reif and Cyster, 2002). It also has been shown in 
DOCK2-deficient mice that there is still some residual chemotaxis (cell migration 
~10% normal level). This evidence may suggest the existence of an independent 
chemotaxis pathway operating in the presence of DOCK2 or there is a pathway 
becomes active in the absence of DOCK2. Nombela-Arrieta et al. showed that 
there is a phosphoinositide-3-kinase (PI3K)-dependent cell migration in DOCK2 
deficient lymphocytes (Nombela-Arrieta et al., 2004). Lymphocyte migration is 
mediated by a largely DOCK2-dependent manner. However, a minor PI3K-
dependent pathway is also observed in DOCK2-deficient lymphocytes (Nombela-
Arrieta et al., 2004). It is also suggested that PI3K-dependent T cell chemotaxis 
depends on PI3Kγ, whereas B cell migration depends on other PI3K isoform 
(Nombela-Arrieta et al., 2004). In the absence of both DOCK2 and PI3Kγ, T cell 
migration to chemokines is totally abolished in vitro and the homing capacity 
towards SLOs is further reduced (Nombela-Arrieta et al., 2004). 
 
The other subfamilies of lymphocyte-expressed G protein-coupled receptors 
(GPCRs), S1P receptor 1 (S1P1) also plays an essential role in thymic emigration 
and lymphocyte recirculation through the secondary lymphoid organ (Matloubian 
et al., 2004; Shiow et al., 2006; Cyster, 2005). T-cell-specific deletion of S1P1 
receptor results in reduction of total numbers of T cells in peripheral blood and 
peripheral lymphoid organ (Allende, et al., 2004). DOCK2 is required for efficient 
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interstitial T and B cell motility and DOCK2-deficient T and B cells displayed 
markedly reduced S1P1-mediated migration (Nombela-Arrieta et al., 2006) It is 
suggested that DOCK2 has a central role during T and B cell intertitial migration 
with a minor but significant role of PI3Kγ specifically in S1P1-mediated T cell 
migration (Nombela-Arrieta et al., 2006). 
 
S1P1-deficient thymocytes are unable to egress from the thymus and mature S1P1-
deficient thymocytes fail to exit SLO (Allende et al., 2004). CD69 can inhibit 
S1P1 and lymphocytes egress by acting downstream of interferon-a/b (IFN-a/b) 
(Shiow et al., 2006). As shown in Chapter III, Dock2doc/doc mice have reduced DP 
and mature SP thymocytes. The CD69 expression was reduced on both CD4 and 
CD8 SP thymocytes from our data. CD69 involves in the generation of mature SP 
thymocytes and has a potential/putative role in thymic emigration (Feng et al., 
2002; Nakayama et al., 2002). The blockade of CD69 can cause a reduction in the 
number of SP and increased number of DP (Nakayama et al., 2002). Although 
lack of CD62L marker, there was no significant difference in the number of the 
CD69low CD4 and CD8 SP thymocytes between our Dock2doc/doc and wild type 
mice. Although there is only 5% normal efficacy of thymic emigration in 
DOCK2-deficient thymocytes (Fukui et al., 2001; Allende, et al., 2004), our data 
suggested that the recent mature Dock2doc/doc SP thymocytes did not accumulate in 
the thymus. Combined with above, DOCK2 has been shown to have a dominant 
role in lymphocytes recirculation like homing, interstitial migration and egress. 
 
DOCK2 also has a role in TCR signaling. Sustained TCR interaction with MHC-
peptide complexes in the immunological synapse (IS) at the interface of T cell and 
antigen-presenting cells (APCs) is required for T cell activation (Paul and Seder, 
1994; Norcross, 1984). The mature IS has been defined by the formation of a 
bull’s eye pattern with supramolecular activation clusters (SMACs) whose center 
(cSMAC) is enriched with for TCR and MHC-peptide complexes. The peripheral 
SMAC (pSMAC) contains a ring of the cognate integrin LFA-1 (lymphocyte 
function-associated antigen 1) and its immunoglobulin superfamily ligand ICAM-
I (intercellular adhesion molecule 1) (Grakoui et al., 1999; Monks et al., 1998 and 
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Wulfing and Davis, 1998).  The signaling molecules like protein kinase C θ 
(PKC-θ) and the src family kinase Lck are also in the cSMAC on the cytoplasmic 
side of the IS.  
 
In DOCK2-/- T cells, TCR-mediated Rac activation is totally abolished (Fukui et 
al., 2001; Sanui et al., 2003). During the formation of immunological synapse, the 
signaling molecule PKC-θ and adhesion molecule LFA-1 are not affected in 
DOCK2 deficient T cells and can still polarize to the cell surface. However, TCR 
and lipid raft can accumulate at the interface during formation of IS in wild-type T 
cells, and this clustering is not seen in DOCK2-/- T cells (Sanui et al., 2003).  
 
DOCK2 deficiency also affects antigen-specific T cell proliferation. The 
proliferative response of 2B4αβ Tg T cells decreased to less than 25% in Dock2 
deficient mice compared to wild-type level (Sanui et al., 2003). From our in vitro 
proliferation experiment, naïve (CD44lo) Dock2doc/doc CD4 and CD8 T cells could 
proliferate as well as wild type controls with 1ng/ml αCD3 stimulation. More 
studies have been shown that the antigen-specific T cell proliferation still occurs 
in DOCK2 deficient mice (Sanui et al., 2003). However, they required higher 
concentrations of antigenic peptides to reach the similar proliferative response as 
wild type (Sanui et al., 2003). As our in vitro proliferation was done under a 
single concentration condition, different results might be seen with lower 
concentration of αCD3 condition. Defective TCR polarization and lipid raft 
clustering may affect the threshold for T cell proliferation (Sanui et al., 2003). 
Different gangliosides, the major components of lipid raft are presented in CD4 
and CD8 T cells, may contribute to different effector response following TCR 
stimulation (Nagafuku et al., 2011). There is no data has been shown on DOCK2 
deficiency on cytotoxic function of CD8 T cells. From our mix bone marrow 
chimeras’ data, DOCK2 has been shown to have a cell-autonomous role in CD8 T 
cells. The number of circulating naïve CD8 T cells was decreased in Dock2doc/doc 
homozygous mutants. As shown in Chapter III, Dock2doc/doc NP-binding CD8 
cells accumulated at approximately normal percentage of all CD8 cells during 
influenza infection. Since most DOCK2 proliferation studies were done in vitro, 
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the reasonable explanation can be that there might be other costimulatory signals 
were available in vivo to compensates for the DOCK2 deficiency and allow 
relatively normal T cell activation and proliferation (Marchingo et al., 2014) than 
simple in vitro condition.  
 
Unlike naïve CD8 T cells continually recirculating in the lymphoid organs to 
survey antigen, activated lymphocytes retained within the lymphoid organ and 
undergoes clonal expansion and exit with the effector function. It is still obscure 
whether DOCK2 affects the exit of antigen-specific lymphocytes to the infection 
sites. 
 
Recently biallelic mutations in human DOCK2 has been identified as molecular 
cause of combined immunodeficiency found in patients with early-onset, invasive 
bacterial and viral infections (Dobbs et al., 2015). All patients have T-cell 
lymphopenia and impaired in vitro T-cell activation, defective T, B and NK cell 
functions. 3 out of 5 patients have markedly reduced proportion of naïve 
(CD45RA+CCR7+) CD4 and CD8 T cells which were associated with an 
increased proportion of effector memory (CD45RA-CCR7-) CD4 T cell and 
effector memory or CD45RA-CCR7-TEMRA CD8 T cells. 2 out of 5 patients have 
B cell lymphopenia.  And 3 out of 5 patients have defective T-cell dependent 
immunization antibody production. Consist with finding in mouse, RAC1 
activation was impaired in the T cells, the phenotypes shown in DOCK2 deficient 
patients are very similar as we have seen in mouse. It is noted that Patient 4 had a 
F744Cfs*27 mutation truncating DOCK2 at a similar position to the dockland 
E775X nonsense mutation which lacks the DHR-2 domain. Moreover, the study 
of DOCK2 in human also suggested a role in antiviral interferon production in 
nonhematopoietic cells. DOCK2 deficient mice have a severe reduction of pDCs 
in the spleen (Gotoh et al., 2008) Further studies showed that DOCK2 has an 
essential role of mediating interferon-α production in plasmacytoid dendritic cells, 
the major source of type I IFNs for antiviral immunity (Gotoh et al, 2010). When 
Dock2doc/doc homozygous mice were intranasally infected with influenza virus, 
they showed less weight loss and had a trend of better survival compared to 
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heterozygous and wild type mice. It may suggest the existence of a protective 
mechanism in the Dock2doc/doc mice. pDCs are known for contribution to the 
pathogenesis of some autoimmune disease like systemic lupus erythematosus 
(SLE), human psoriasis by production of IFN-α (Blanco et al., 2001; Nestle et al., 
2005; Lande et al., 2007). Together with our immunization experiments, DOCK2 
may serve as a therapeutic target for pDCs/type I IFN-related autoimmune disease. 
 
Another DOCK family member, DOCK8, has been studied extensively in mice 
and humans and shown to play an indispensable role in immune system function. 
DOCK8 is DOCK-C family member that functions as a GEF for Cdc42 via its 
DHR2 domain. DOCK8 mutation has been first discovered to cause a combined 
immunodeficiency syndrome in humans (Zhang, Q., et al., 2009; Engelhardt, K.R., 
et al., 2009). DOCK8 deficient patients also have hyper IgE and severe viral 
infections.  Recently DOCK8 has been shown to have a crucial role in CD8 T 
cells survival and function (Randall, et al., 2011). Dock8pri/pri mutation causes a 
subtle decrease in the primary response but severely compromised the long-term 
persistence of memory T cell and the recall response. T and NK cells from 
DOCK8 deficient mice develop cell shape and nuclear deformation abnormalities 
that result to a new form of cell death named ‘cytothripsis’ (Zhang et al., 2014). 
The defect in DOCK8 prevents the generation of long-lived skin-resident memory 
CD8 T cells and impairs the control of herpesvirus skin infection. DOCK8-
deficient mice have impaired clearance of Herpes simplex virus (HSV) and lead to 
increased disease and decreased CD4 T cell infiltration into HSV-infected skin 
(Flesch, I., et al., 2015). This finding may give a hint for the loss of control of 
HSV in DOCK8-deficient patients.  
 
As two family members that have been studied intensively, DOCK2 and DOCK8 
shared some similarities and also have different properties in T cell IS formation. 
DOCK2 and DOCK8 are indispensible for T cell IS formation but functional 
differently. In DOCK2-deficient T cells, antigen-induced translocation of TCR 
and lipid rafts were severely impaired without affecting PKC-θ and LFA-1. On 
the other hand, DOCK8 affects LFA-1 actin polarization with intact PKC-θ. From 
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our preliminary data of Dock2doc/doc Dock8pri/pri double deficient mice, there is a 
further reduction of spleen T cells number especially CD8 T cell number in the 
double deficient mice. Since DOCK2 and DOCK8 have different role in T cell 
synapse formation, they might have an additive effect on T cell survival, 
activation, and migration. To further address the migration defect in DOCK2 and 
double deficient mice, analysis of thymocytes with mature and egress marker is 
necessary to find out whether there is a further block of recent mature SP 
thymocytes to egress from thymus. Chemotactic assay with the mature SP 
thymocytes is also useful to answer this question. More functional studies can be 
done to understand how the double mutant can affect the activation, survival of 
antigen-specific CD8 T cells.   
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In summary Senp2 is required for: 
 
Persistence of naïve OT-I CD8 T cells in lymphoreplete host 
Persistence of long-term memory OT-I CD8 T cells 
Survival of naïve CD8 T cells  
Attenuate IL-7 induced downregulation of IL7RA 
 
My studies of the duan mouse strain reveal a role for Senp2 in the CD8 T cell 
survival, offering a new insight into a known gene with no previous known 
function in immune system. In particular, my studies show that Senp2 has an 
indispensible role in survival of naïve CD8 T cells and long-term survival of 
antigen-specific memory CD8 T cells. However, the mechanism by which Senp2 
regulates naïve and memory T cell survival is still unknown.  
 
SENP2 is ubiquitously expressed in multiple tissues, increasing the difficulty to 
study its specific role in immune cell subset in vivo. A targeted null mutation in 
Senp2 causes embryonic lethal phenotypes about E10 (Kang et al., 2010). 
Consequently most studies of SENP2 function are in transfected cell lines 
expressing the mutant form of protein in vitro.  
 
Although the SENP2-null homozygous mice are embryonic lethal (Chiu et al., 
2008), the mice carrying the duan mutation in Senp2 gene are physically normal 
and can be bred to propagate the mutation. It is still obscure exactly how the duan 
mutation disrupts the function of SENP2 protein. From our PCR data, the duan 
mutation caused exon 11 skipped in at least 50% of remaining SENP2 mRNA 
transcripts. One possibility is that loss of the exon 11 from the SENP2 protein 
may cause the CD8 T cell phenotype. Western blot has not been done successfully 
to show whether the variant mRNA lacking exon 11 makes protein, either because 
there is no good SENP2 antibody available or there is low expression of SENP2 
in T cells as suggested by the bioGPS microarray data in Chapter 4. If the exon 11 
skipped protein can be made and detected, it is critical to determine the proportion 
of full protein versus truncated protein presented in duan homozygous CD8 T 
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cells. It is also possible that there is reduction of normal mRNA or protein in the 
overall amount of mRNA and protein. The CD8 T cell phenotype in duan mice 
may not be caused by the increased amount of truncated protein (if protein can be 
made). The main effect of the duan mutation is to lower the efficiency of splicing 
so that there is a substantial decrease in the correctly spliced Senp2 mRNA, which 
may be by as much as 90%. As shown in Chapter IV, mice carrying heterozygous 
null allele or heterozygous for duan mutation do not cause the CD8 T cell 
phenotype which implies that a 50% decrease in SENP2 protein is insufficient. In 
order to understand the underlying mechanism, future studies should quantify and 
compare the spliced Senp2 polyA+ mRNA and protein level in dua/dua, +/-, and 
+/+ CD8 T cells. 
 
 
Duan mutation affects the persistence of CD8 T cell 
 
Duan mice have normal thymic development and T cell maturation. However, 
their naive CD8 T cells were markedly reduced in the periphery. When transferred 
into secondary hosts with a full T cell repertoire, the homozygous mutant CD8 T 
cells survived for a much shorter period than co-transferred wild type CD8 T cells. 
Duan CD8 T cells were nevertheless able to survive and compete successfully 
during homeostatic proliferation with wild-type CD8 T cells when the cell 
mixture was co-transferred into lymphopaenic host. Their competitive 
disadvantage was only seen once the T cell compartment began to be repopulated. 
These in vivo experiments suggested that Senp2dua/dua naïve CD8 T cells can 
proliferate normally in response to pMHC and IL-7, but have a specific survival 
defect and cannot persist normally once the repertoire has been repopulated.   
 
IL-7 has been shown to have a critical role in the thymic T cell development and 
in peripheral naïve T cell survival, as reviewed in the introductory chapter. We 
examined IL-7/IL-7R signaling in Senp2dua/dua T cells. We found that Senp2dua/dua 
naïve CD8 T cells had consistently lower IL7RA (CD127) receptor expression on 
the cell surface. Moreover, in mixed bone marrow chimeras experiment, the CD8 
	 208	
T cells derived from Senp2dua/dua bone marrow had lower IL-7RA expression, 
establishing that the lower expression of IL-7R is a cell intrinsic phenotype rather 
than a secondary effect to the altruistic inhibition of excess IL-7. In vitro culture 
with IL-7 showed Senp2dua/dua naïve CD8 T cells had a normal STAT5 
phosphorylation response, but exaggerated downregulation of surface IL7RA 
expression. These results imply that the duan mutation affects naïve CD8 T cell 
survival by exaggerating the downregulation of Il7ra mRNA following IL-7 
signalling.  
 
Although how IL-7 protects cells from death is not fully understood, it may 
involve the regulation of Bcl-2 family members. Bcl-2 is an anti-apoptosis protein 
and can protect T cell against apoptotic signals. Enforced expression of Bcl-2 in 
IL-7Rα-deficient mice improves the survival of T lymphocytes (Akashi et al., 
1997). It has not been tested whether Bcl-2 expression is affected in duan naïve 
CD8 T cells, and this would be a useful future experiment.  
 
A possible clue to the action of SENP2 comes from the finding that the duan 
mutation primarily affects CD8 T cell survival and IL7RA expression, with little 
or no diminution of naïve CD4 T cell numbers or IL7RA expression on these cells. 
In response to IL-7, IL-7R expression is tightly regulated at transcriptional level 
by various nuclear factors and is downregulated by suppressing IL-7Rα 
transcription to allow other cells receive IL-7-mediated survival signal. Different 
molecular mechanism in CD4 and CD8 T cells cytokine-mediated suppression of 
IL-7Ra transcription. The transcriptional repressor Growth Factor Independence-1 
(GFI1) is utilized in CD8 T cells but not CD4 T cells (Park et al., 2004, Ligons et 
al., 2012). IL7Rα expression was dramatically increased on GFI1-deficient CD8 T 
cells but not on CD4 T cells from the same Gfi1-/- mice (Park et al., 2004). When 
a Gfi1 transgene was constitutively expressed in either wild type or Gfi1-/- mice, 
IL7Rα expression was markedly suppressed on CD8 T cells without significantly 
affecting IL7Rα expression on CD4 T cells (Park et al., 2004, Ligons et al., 2012). 
Binding of GFI1 to DNA is insufficient in itself and it needs to specifically 
interact with other nuclear proteins to repress transcription (Grimes et al., 1996).   
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Another Group A member, SENP1, has been shown to play a crucial permissive 
role in STAT5 signalling during early T and B lymphocyte development in the 
thymus and bone marrow (Van Nguyen et al. 2012). The sumo-specific protein 
ligase family, Protein Inhibitor of Activated STAT (PIAS), was discovered as a 
negative regulator of STAT signaling (Schmidt and Muller, 2003). PIAS3 has 
been shown to attach SUMO-2 to phosphorylated STAT5, inhibiting its 
transcriptional activity and preventing further rounds of phosphorylation until the 
SUMO group is removed by SENP1 (Rycyzyn and Clevenger, 2002; Dagvadorj et 
al., 2010 and Van Nguyen et al., 2012). Consequently a homozygous null Senp1 
mutation resulted in greatly diminished IL-7 induced STAT5 phosphorylation in 
immature T cells, and in thymic lymphopenia in fetal liver transplant recipients 
that resembles IL7RA deficiency (Van Nguyen et al., 2012). This mechanism 
does not appear to explain the effects of the Senp2 duan mutation, because I found 
there is normal thymopoiesis and normal STAT5 phosphorylation in response to 
IL-7 in duan homozygous T cells.  
 
Il7ra transcription is specifically inhibited in CD8 T cells in response to IL-7 
STAT5 signalling by the DNA binding protein, growth-factor independent 1 
(GFI-1) (Park et al., 2004). Given CD8-specific downregulation of IL7RA and 
exaggerated downregulation in response to IL-7 caused by the duan mutation, an 
attractive hypothesis is that unchecked sumoylation enhances the inhibitory effect 
of GFI-1 on IL7RA expression. There is no published evidence that GFI-1 itself is 
SUMOylated, but GFI-1 interacts with the STAT3 inhibitor and Sumo-specific 
ligase, PIAS3 (Rodel et al., 2000). In Tarik Moroy’s recent review (Moroy and 
Khandanpour, 2011), he states: “It remains open, whether the activity of PIAS 
proteins as E3 ligases for SUMO residues plays a role in this interaction, but it is 
attractive to speculate that GFI1, which has so far not been shown to be 
sumoylated, may serve as a docking site for other proteins that are to be 
sumoylated. This function although highly speculative may be enabled by an 
interaction with proteins such as PIAS3.” To test this hypothesis, western blotting 
or mass spectrometry could be used to determine the levels of GFI-1 protein and 
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SUMOylation of GFI1 and other proteins in resting and IL-7 stimulated 
Senp2dua/dua cells. A genetic test for a role of GFI1 in mediating the effects of 
Senp2 mutation would be to breed Senp2dua/dua mice with one Gfi1 allele 
inactivated, and measure whether the decreased Gfi1 gene dose could restore 
normal IL7RA expression on Senp2 mutant CD8 T cells. 
 
The loss of naïve CD8 T cells in the Senp2dua/dua mice may not be the result of a 
single gene defect and it could due to the combined effect of multiple genes. 
Besides IL-7 signals, naïve T cells require signals from TCR contact with self-
peptide/MHC complexes for long-term survival (Surh, and Sprent, 2005; Dorfman, 
and Germain, 2002). There is evidence that there could be an interplay between 
TCR signaling and IL-7 signaling pathway in peripheral T cells. It has been 
shown that TCR-mediated activation can up-regulate IL-2R expression but down-
regulate the IL-7R expression (Franchimont et al., 2002) Down-regulated IL-7R 
expression on Senp2dua/dua naïve CD8 T cells has been observed. Although the 
TCR complex signals, co-receptor expression and CD5 expression still need to 
further testing on duan CD8 T cells, it is possible that lower expression of IL7Rα 
in Senp2dua/dua naïve CD8 T cells reflects the increased TCR signaling under 
resting conditions. It is hypothesized that duan mutation may affect downstream 
molecules in TCR signaling pathway that augment TCR signaling and cause the 
resting T cells to become hyper-activation. 
 
 
SENP2 is the downstream target of Hnrpll 
 
SENP2 has been shown as an important functional target of HnRNPLL for 
regulating T-cell survival. The heterogeneous nuclear ribonucleoproteins (hnRNP) 
bind pre-mRNAs in the nucleus to regulate alternative splicing (Dreyfuss et al., 
1993). There are more than 20 hnRNP proteins and hnRNPLL is one member of 
hnRNP proteins that involves in memory T cell RNA rearrangement. hnRNPLL 
has 3 RNA recognition motifs (RRM) and the Hnrpllthu/thu mutation occurs in the 
first RRM of Hnrpll which substitutes a valine residue to a aspartic acid. 
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hnRNPLL is required for normal alternative splicing target genes, therefore the 
mutation affects the alternative splicing of target genes and subsequently affect 
the expression target protein. CD45 (Ptprc) is the most defined mRNA target of 
hnRNPLL, and thunder mice with mutant hnRNPLL constitutively express 
isoform CD45RA, RB and RC and fail to express the lower isoform CD45RO. 
 
The thunder (Hrnpllthu) CD8 T cells showed defect in CD8 T cells survival and 
lower IL-7R expression on naïve CD8 T cells but not in the memory CD8 T cells 
(Wu et al, 2008). Exon assay experiments showed that there was a dramatic 
decrease of IL-7Rα mRNA in naïve Hrnpllthu CD8 T cells compared to their wild-
type counterparts which suggested that the IL-7R expression is decreased in 
Hrnpllthu naïve CD8 T cells at both levels of protein and mRNA (Wu et al, 2008). 
From RNA-sequencing of Hnrpll mutant and wild-type CD8 OT-I T cells, Senp2 
is one of the highly ranked candidate of hnRNPLL targets. By transducing 
normally spliced Senp2, it restored the survival of Hrnpllthu CD8 T cells (Cho et 
al., 2014). Therefore, Senp2 exon 10-exon 11 splicing is an important target for 
Hnrpll-dependent T cell survival. 
 
 
Conclusion 
 
CD8 T cells play a major role in controlling infection by intracellular pathogens. 
Based on the complexity of possible targets of SENP2, it is very hard to identify a 
regulatory pathway that is responsible for the T cell survival defect in duan mice. 
The lower IL-7R expression could contribute to the survival defect seen in mutant 
CD8 T cells. The proliferation of Senp2dua/dua CD8 T cell is normal upon influenza 
virus challenge while long-term memory CD8 T cells fail to persistence.   
 
Dockland mutation has been generated through ENU-mutagenesis screening of 
splenocytes. The DOCK2 mutant strain has T and B cell lymphopenia with 
absence of marginal zone B cells. The phenotypes of Dockland mice match to the 
DOCK2 knockout mice. Dock2doc/doc CD8 T cells have a cell-intrinsic defect in 
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50:50 mix bone marrow experiment. The significance of how the mutation affects 
the CD8 T cell cytotoxic function has not been studied.  
 
Dockland and duan are two different examples of mutations that affect the 
survival or function of CD8 T cells. DOCK2 works downstream of various 
receptors and affect different pathways in different type of cells. On the other 
hand, SENP2 has been shown to have a restricted effect only on CD8 T cells. 
Both mutations could help us to understand the complexity of pathways regulating 
CD8 T cells. 
 
With the help of high-throughput next generation sequencing, more novel genes 
involved in regulating of the immune system could be discovered. Understanding 
of their roles may help us to understand many immune disorders and also to 
generate new therapeutics. 
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